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Summary of thesis
The pathophysiology of the systemic illness seen in patients with acute 
pancreatitis is unknown but there are similarities with the systemic 
complications of sepsis, prompting the suggestion that similar endogenous 
mediators may be responsible. Central to this hypothesis is the role of 
activated mononuclear phagocytes. The long acting somatostatin analogue, 
octreotide (Sandostatin) has been shown to improve hepatic 
reticuloendothelial cell function, an effect which may be beneficial in acute 
pancreatitis by enhancing the clearance of endotoxin from portal blood and 
preventing systemic mononuclear phagocyte activation. This thesis 
addresses two main questions. Firstly the potential role of octreotide in the 
treatment of acute pancreatitis and secondly the role of mononuclear 
phagocyte activation in the pathophysiology of the systemic complications 
o f acute pancreatitis.
Octreotide in acute pancreatitis
58 patients with moderate or severe acute pancreatitis who were admitted 
to hospitals within the West of Scotland over an 18 month period were 
randomised to receive octreotide, 40|Lig/h by continuous intravenous 
infusion, or placebo in addition to standard supportive therapy. Patients 
were comparable in age, sex, aetiology and severity of disease on 
admission. There was no significant difference in the incidence of 
complications (53.6% octreotide group and 43.3% placebo group) or 
mortality (octreotide group 18%; placebo group 20%). The results of this 
study indicate that octreotide is o f little or no benefit in the treatment of 
acute pancreatitis.
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Mononuclear phagocyte activation in acute pancreatitis
Monocytes were isolated from the peripheral blood o f 28 patients with 
moderate or severe acute pancreatitis and the in-vitro secretion o f these 
cytokines measured at intervals during the first week o f illness. Sixteen 
patients (57%) developed systemic complications. Peak TNFa secretion 
was significantly higher in patients who developed systemic complications 
(median = 18.5ng/ml, IQR 5.5-28.5) than in those with an uncomplicated 
course (3.7ng/ml, 2.3-6.4, P<0.01). Similarly, peak EL-6 and peak IL-8 
secretion were significantly higher in the complicated group (EL-6; 
complicated: median = 48.9ng/ml, IQR 12-71, uncomplicated 16.3ng/ml, 
9.9-24.8, P<0.05; IL-8; complicated: median = 754ng/ml, IQR 683-857, 
uncomplicated: median = 602ng/ml, 496-756, P<0.05). No significant 
difference in peak IL-1 secretion was observed between the two groups. 
This study demonstrates that the systemic complications o f acute 
pancreatitis are associated with a significant increase in monocyte secretion 
o f TNFa , EL-6 and IL-8 suggesting that, as in sepsis, these cytokines play 
a central role in the pathophysiology o f the disease.
The role o f IL -ip  and proteolytic degradation of parathyroid hormone 
(PTH) in the pathophysiology o f pancreatitis-associated hypocalcaemia 
was studied. Serum levels of PTH, calcium and albumin were measured 
daily for five days in 41 selected patients with moderate to severe acute 
pancreatitis. PTH was measured by means o f a two-site 
immunoradiometric assay specific for the intact peptide. A rise in PTH 
levels was observed more commonly in patients with a complicated or fatal 
outcome than in those with an uncomplicated course (complicated; 87.5% 
of 16 patients, uncomplicated; 24% of 25 patients, P<0.001, Chi-square 
test). In the presence o f hypocalcaemia, although PTH levels were variable, 
raised levels o f PTH were found more frequently in the complicated group 
(complicated; 7 o f 8, uncomplicated; 2 o f 7, P=0.035, Fisher's exact test).
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This study confirms that an appropriate rise in PTH occurs in response to 
the hypocalcaemic stimulus in patients with acute pancreatitis, with no 
evidence o f significant PTH degradation. There was a significant negative 
correlation between serum calcium levels and the secretion o f IL-1|3 by 
monocytes but this was mainly a consequence o f the results obtained from 
one patient with very low serum calcium associated with high monocyte 
IL -ip  secretion.
Increased production o f pro-inflammatory cytokines by monocytes and 
mononuclear phagocytes would be expected to result in neutrophil 
activation and therefore raised plasma levels o f polymorphonuclear elastase 
(PMNE). Measurement o f PMNE in acute pancreatitis may therefore be a 
simple method o f assessing the degree o f leucocyte activation which would 
allow the early identification o f patients at risk o f developing systemic 
complications. Thirty seven patients entered into the randomised, 
controlled trial o f octreotide had serial measurement o f PMNE carried out. 
The mean age o f these patients was 68 (range 32-88) and gallstones were 
identified as an aetiological factor in 21 (57%). Plasma PMNE levels were 
significantly higher in those patients with systemic complications on each of 
the days on which it was measured (day 1 PMNE complicated 
median=250ug/l, IQR 143-656, uncomplicated median 139, IQR 74.7-254, 
P<0.05; day 3 complicated median=224.1, IQR 139-382, uncomplicated 
median=86.1, IQR 51.4-159.7, P<0.002; day 5 complicated median=178.5, 
IQR 117. Highest levels o f PMNE were observed on day 1 o f the hospital 
admission in all but nine of the 37 cases and o f these, seven subsequently 
developed systemic complications. There was a strong positive correlation 
between IL -lp  secretion on the first day after admission and the plasma 
level o f PMNE (r=0.961, P<0.001). There was no significant correlation 
between the secretion o f TNFa (r=0.061), IL-6 (r=0.282) or IL-8 
(r=0.288) and PMNE levels on day 1.
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Part 1 
Chapter 1
Introduction, hypothesis and aims of the thesis
1.1 General introduction
It is over 100 years since Sir Reginald Fitz described the clinical and 
pathological features o f acute pancreatitis^nd although supportive 
measures have greatly improved since then, there remains no specific 
treatment and many aspects o f the pathophysiology o f the disease are still 
poorly understood.
Patients with severe acute pancreatitis commonly develop a systemic illness 
in the first few days after admission characterised by cardiovascular, 
respiratory and renal impairment. For many years this was thought to be a 
consequence o f the release o f "toxic factors" from the peritoneal exudate, 
produced as a result o f protease activation 2. More recently, however, it 
has been observed that the systemic organ dysfunction seen in acute 
pancreatitis is similar to that seen in patients with sepsis, bums or multiple 
trauma and it has been suggested that similar endogenous mediators may 
be responsible for the systemic illness seen in these conditions3.
There is now strong evidence to suggest that the systemic illness in sepsis 
is mediated by cytokines as a result o f mononuclear cell activation 4 This 
has led to recent attempts to examine mononuclear phagocyte activation in 
acute pancreatitis but results have so far been inconclusive5,6.
In the assessment o f any therapeutic agent in acute pancreatitis, the 
pathophysiology o f the illness must be considered. Somatostatin, and more 
recently its long-acting analogue, octreotide, have been suggested as being 
of possible benefit in the treatment of acute pancreatitis. Not only does 
somatostatin suppress pancreatic secretion, generally thought to be 
beneficial in acute pancreatitis, but it has also been reported to enhance
7
hepatic reticuloendothelial activity 1. This effect would be expected to 
reduce the likelihood o f systemic endotoxaemia and subsequent 
mononuclear phagocyte activation8.
This thesis examines the effect of octreotide in the treatment o f acute 
pancreatitis and also explores the role o f mononuclear phagocyte activation 
and cytokine production in the pathophysiology o f some o f the systemic 
manifestations o f the disease.
1.2 Hypothesis
The systemic complications commonly seen in severe acute pancreatitis are 
the consequence o f unregulated or excessive mononuclear phagocyte 
activation with the subsequent production and release of excessive 
quantities o f pro-inflammatory cytokines.
The function o f the hepatic reticuloendothelial system is important in the 
removal o f toxic factors, particularly bacterial endotoxin, from the portal 
circulation and in patients with severe acute pancreatitis this is impaired or 
its functional capacity is exceeded. The use o f an agent which enhances 
hepatic reticuloendothelial function may therefore reduce the morbidity and 
mortality due to the systemic complications o f acute pancreatitis by 
preventing systemic endotoxaemia and excessive extrahepatic mononuclear 
cell activation.
1.3 Aims of the thesis
1. To examine the therapeutic effect o f the long-acting somatostatin 
analogue, octreotide, in the management o f patients with acute pancreatitis.
2. To determine the role o f mononuclear phagocyte activation in the 
pathophysiology o f the systemic complications o f acute pancreatitis.
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3. To determine the effect o f octreotide on mononuclear cell activation.
4. To examine the role o f cytokines in the pathophysiology of the 
hypocalcaemia of acute pancreatitis.
1.4 Plan of thesis
This thesis is presented in two parts In part 1, the relevant literature is 
reviewed and a clinical trial with octreotide in patients with moderate and 
severe acute pancreatitis is described. In part 2, there is the laboratory 
work concerning the role o f mononuclear phagocyte activation in the 
pathophysiology o f the systemic complications o f pancreatitis.
Part 1 begins with a review o f the relevant literature with regard to the 
pathophysiology o f acute pancreatitis and its treatment following which the 
relevant literature on somatostatin and its analogues in acute pancreatitis is 
reviewed. A clinical trial with octreotide in acute pancreatitis is then 
described.
In part 2, The development o f the methods used in the laboratory study are 
described following which the results o f an experimental study into 
mononuclear phagocyte activation are presented. The role o f 
polymorphonuclear cell activation in acute pancreatitis is explored in 
chapter 6 and a study on the pathophysiology o f hypocalcaemia and its 
relationship to mononuclear phagocyte activation in acute pancreatitis is 
presented in chapter 7.
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Chapter 2
Introduction and review of the literature
2.1. Epidemiology
Acute pancreatitis is a common disorder accounting for some 1234 hospital 
admissions in Scotland in 1985 9.There has been an apparent increase in the 
incidence o f  acute pancreatitis over the last 30 years, rising from around 36 
cases per million in 1969 to 246 cases per million in 1985, the largest 
increase being in young males 9 A smaller increase in incidence o f 26% to 
73 cases per million was reported in a similar study from the Bristol area 
over a similar period o f time 10. In the Scottish study, the case mortality fell 
from 18% to 5.6% 9 although a similar reduction was not seen in the 
Bristol area with case mortality remaining unchanged at 22% for the years 
1968-1969 and 1978-79 10. In as many as 35% 10-42% 11 o f cases, the 
diagnosis o f acute pancreatitis was only made at post-mortem. The 
reduction in case mortality seems likely to be related to improvements in 
diagnosis as the total number o f deaths from acute pancreatitis has changed 
little9.
2.2 Aetiology
The single most common cause o f acute pancreatitis remains gallstones 
which account for approximately 50% o f cases in the West o f Scotland 12. 
The incidence of gallstone pancreatitis varies widely between geographical 
areas, accounting for as many as 57% of cases in the Leicester area 13 but 
only 25% in Germany 14 and 17% in New York 15. Alcohol accounts for 
the majority o f the remainder o f cases accounting for 32-69% of cases with 
miscellaneous causes accounting for around 4-20% 1214There remain a 12- 
15% 12' 15 of patients in whom no cause is identified and these are grouped 
as "idiopathic”. There is growing suspicion that many o f these cases are in
10
fact due to very small gallstones or even biliary sludge 16. Less common 
causes of acute pancreatitis are listed in table 1.1
Obstructive
causes
Choledocholithiasis 
Ampullary carcinoma 
Ascaris infestation 
Pancreas divisum
Toxins Alcohol
Scorpion venom 
Drugs
Infection Coxsackie B 
Mumps
Epstein-Barr virus 
CMV
Hepatitis A, B, non-A
non-B
HIV
M etabolic Hyperlipidaemia
Hypercalcaemia
Miscellaneous Peptic ulcer 
Crohns 
Vasculitis 
Trauma, ERCP 
Hypothermia
Table 1.1 Causes o f acute pancreatitis
2.3 Clinical presentation and diagnosis
The characteristic presentation o f acute pancreatitis is that o f sudden 
abdominal pain. The site o f the pain is usually the epigastric but pain also 
commonly occurs in the right hypochondrium. Rarer sites include the left 
hypochondrium and lower abdomen. The pain commonly radiates to the 
back and this may be the only site o f pain. Vomiting and retching are often 
present and may be the main complaint. Physical examination reveals 
abdominal tenderness and guarding, usually restricted to the upper 
abdomen but occasionally more generalised. Bowel sounds are usually 
absent and, especially in more advanced cases, abdominal distension may 
be a prominent feature. Varying degrees o f dehydration are present
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depending on vomiting and the duration of symptoms prior to presentation. 
Tachycardia and, occasionally, hypotension may also be present. Specific 
clinical signs are rare but body wall ecchymosis, seen as flank staining 
(Grey-Tumer's sign, 17) or periumbilical staining (Cullen's sign, 18) is 
present in around 3% of cases 19 Such signs, since they typically do not 
develop until after the fourth day of hospital admission 19, seldom 
contribute to the initial diagnostic assessment.
With these presenting features, it can readily be appreciated that acute 
pancreatitis can mimic almost any acute intra-abdominal pathology, in 
particular perforated peptic ulcer and acute cholecystitis. The diagnosis 
therefore rests upon the measurement o f serum levels o f pancreatic 
enzymes.
2.3.1 Pancreatic enzymes 
Amylase
Amylase is a starch-splitting enzyme which is specific for the a  1,4 
glucosidic linkage o f the starch molecule. It is secreted mainly by the 
salivary glands and the exocrine pancreas with most o f the amylase 
normally present in the serum originating from these sources. The use o f 
urinary amylase measurements in the diagnosis o f pancreatic disease was 
suggested by Wohlgemuth in 1910 but it was not until 1929 that Elman et 
al described a patient with acute pancreatitis in whom raised levels o f 
serum amylase were found 20 and suggested the usefulness o f serum 
amylase determination for the diagnosis o f pancreatic diseases. Over the 
years this diagnostic test has proven its worth and is now the cornerstone 
o f diagnosis of acute pancreatitis.
The level o f serum amylase required for a diagnosis o f acute pancreatitis 
has been a matter o f some debate. Ranson, in his study o f peritoneal lavage 
for the treatment o f acute pancreatitis, accepted any level above the normal
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range in association with an appropriate clinical history 15 as being 
sufficient for a diagnosis o f acute pancreatitis. Other authors have accepted 
only patients with a threefold 13 or fourfold 12 rise. Few conditions which 
clinically mimic acute pancreatitis are associated with a rise in serum 
amylase o f this magnitude, the exception being acute mesenteric infarction 
which is associated with amylase levels elevated to the diagnostic range in 
8% of patients 21. Difficulty in diagnosis occasionally occurs in patients 
with mild elevations in serum amylase levels in whom perforated duodenal 
ulcer cannot be excluded.
Amylase is excreted in the urine and in such cases o f diagnostic doubt, 
measurement o f urinary amylase has been suggested. However, studies 
have failed to demonstrate any advantage o f urinary amylase levels over 
measurement of serum amylase alone22. Since renal clearance o f amylase 
strongly influences the level o f urinary amylase, the use o f the amylase to 
creatinine ratio has also been suggested as a means o f improving the 
specificity o f urinary amylase measurements. However, studies have failed 
to confirm the usefulness of this approach22.
Lipase
Levels o f serum lipase rise in association with acute pancreatitis and 
parallel the rise o f serum amylase. Several studies have shown that lipase 
levels are more sensitive and specific for the diagnosis o f acute pancreatitis 
23,24than serum amylase. However, like amylase, other conditions such as 
perforated duodenal ulcer and mesenteric infarction may be associated with 
elevated levels25. The availability o f the assay is limited in UK laboratories, 
therefore lipase levels are infrequently measured.
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Trypsin
The majority o f serum immunoreactive trypsin circulates as trypsinogen. 
Although serum levels o f trypsinogen rise in patients with acute 
pancreatitis26, at present, trypsin assays are not generally available on a 
routine basis.
2.3.2 Other Diagnostic Aids 
Plain Abdominal Radiographs
Several abnormalities on plain abdominal radiographs have been described 
in patients with acute pancreatitis. These were studied by Davis et al in 100 
patients with acute pancreatitis and 100 patients undergoing routine 
intravenous urography27. The most commonly observed abnormalities in 
the pancreatitis group were the sentinel loop (26%), thought to represent a 
localised duodenal ileus, colon cut-off sign- due to dilatation o f the 
ascending colon with oedematous swelling in the transverse colon (18%) 
and loss o f definition o f the left psoas shadow (70%). However, while 
these features may be more common in radiographs o f patients with acute 
pancreatitis compared with healthy controls, many o f these features are 
commonly seen in radiographs o f patients with other abdominal 
emergencies such as acute cholecystitis or perforated duodenal ulcer. For 
example, in one study comparing acute pancreatitis patients to those with 
other acute abdominal emergencies28, duodenal abnormalities were 
observed in 21% of patients with perforated duodenal ulcer or acute 
cholecystitis. Plain abdominal radiographs therefore have little to offer in 
the diagnosis o f acute pancreatitis and serve mainly to exclude other 
pathology such as perforated abdominal viscus or intestinal obstruction.
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Ultrasound and CT Scanning
In the early stages o f acute pancreatitis, the presence o f bowel gas 
overlying the pancreas limits the usefulness o f ultrasound in the diagnosis 
o f acute pancreatitis29. In a study from Glasgow29, even in cases o f mild 
pancreatitis, the pancreas was not visualised in almost 60% o f cases. In 
contrast, CT scanning plays an invaluable role in the assessment o f the 
pancreas in acute pancreatitis in demonstrating characteristic pancreatic 
swelling and peripancreatic fluid collections. Although CT may be useful in 
the rare case o f diagnostic doubt, its main role lies in the diagnosis o f local 
pancreatic complications.
2.4 Prediction of Severity
Acute pancreatitis ranges in severity from a rapidly fatal fulminating disease 
to a mild, self-limiting illness which settles within a few days. At either 
extreme the prediction o f severity presents no particular difficulty but in a 
large group o f patients who lie between these two extremes, objective 
grading of severity is difficult and many scoring systems and assays have 
been proposed over the years to improve the accuracy o f clinical 
assessment.
2.4.1 M ultiple Factor Scoring Systems
In 1976, Ranson described the prospective evaluation o f multiple clinical, 
biochemical and haematological indices in the prediction o f severity of 
acute pancreatitis15. Retrospective analysis of 43 factors revealed 11 which 
were o f  prognostic value (table 1.2). In patients with less than 3 positive 
factors, the mortality was 1.2% and the incidence o f major complications 
3.7%. In those with 3 or more positive factors, the major morbidity and 
mortality was 62%. A modified version o f this system was later utilised by 
Imrie and colleagues in the analysis o f patients taking part in a clinical trial
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of intravenous aprotinin (table 1.3)12 Again, three or more positive criteria 
within 48h o f admission were associated with a worse prognosis. This 
modified version was later validated by Blarney et al30, who suggested that 
the transaminase level be excluded. Using the original system, 79% o f 405 
episodes o f acute pancreatitis were correctly classified. Imrie later excluded 
age as a prognostic factor as there was a tendency to overestimate the 
severity o f patients with gallstone pancreatitis, who tended to be older31. 
Despite the apparent accuracy o f these scoring systems, several problems 
remain. Firstly, all multiple factor scoring systems require 48 hours of 
measurement prior to categorisation o f patients. Secondly, the accuracy o f 
these systems in correctly predicting severe disease may have been 
overstated. Using Imrie's modification o f the Ranson criteria, Blarney and 
colleagues found that only 31% of patients with 3 or more positive factors 
had severe pancreatitis30. The system proved more useful in identifying 
those with mild disease with only 8.4% with less than 3 positive factors 
developing severe pancreatitis. Consequently, there have been numerous 
attempts to find an assay which allows accurate prediction o f severity on 
admission to hospital.
On Admission Within 48h
Age >55 Haematocrit fall 
>10%
Glucose >200mg/lml Calcium < 8mg/lml
W B O 16000/mm3 Base deficit >4mEq/l
GOT>250 Sigma Frankel 
units/1ml
Blood urea nitrogen 
increase >5mg/lml
LDH>300IU/1 Fluid sequestration 
>61
PaO7<60mmHg
Table 1.2 Ranson's prognostic criteria in acute pancreatitis.
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Within 48h o f admission________________________
PaO7<60mmHg_______________________________
A1bumin<32g/1________________________________
Calcium <2mmol/l_____________________________
WBC>15x109/1
AST/ALT>1u/l________________________________
LDH>600u/l__________________________________
Glucose >10mmol/l (in the absence of
diabetes)_____________________________________
Urea>16mmol/l (not responding to
therapy)______________________________________
Age >55years_________________________________
Table 1.3 Modified prognostic criteria (Imrie et al, 1978)
APACHE H Score
The APACHE II system uses 12 routinely available physiological and 
biochemical measurements, coupled with a score for age and pre-existing 
health status to give a score which can be used to grade the severity of 
illness in an individual patient32. Although studied most widely in intensive 
care units, the system has been successfully applied to the assessment of 
patients with acute pancreatitis33,34. When the APACHE II score on 
admission is measured, a cut-off score o f 5 allows accurate prediction of 
severity in over 60% of cases34. The positive predictive value, however, is 
only 0.4 although even this is higher than has been reported with multiple 
factor scoring systems30. Increasing the cut-off to 7 slightly improves the 
specificity o f the test without altering the positive predictive value. Peak 
APACHE II score allows even better discrimination between mild and 
severe groups. An APACHE II score o f greater than 7 has been accepted 
as being indicative o f severe acute pancreatitis by the Atlanta Symposium35. 
The advantages of the APACHE II system are that all the criteria for its 
measurement are readily available on admission to hospital, thus for clinical 
trials the cut-off level can be manipulated to improve either the sensitivity
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or the specificity o f the test as is deemed most appropriate. Furthermore, 
the system can be used to monitor the course o f the illness33,34.
2.4.2 Single prognostic indicators 
C-Reactive Protein
C-reactive protein (CRP) is an acute phase protein synthesised by the liver 
in a variety o f disease states. In acute pancreatitis, several studies have 
reported that levels o f CRP may be used to identify those patients with 
severe attacks36-41. Uhl and colleagues37 suggested a cut-off for peak CRP 
of 120mg/l which accurately predicted outcome in excess o f 80% of cases. 
Similar results were reported by Gross et al with a cut-off o f 100mg/l36. In 
a study from Glasgow, Wilson and colleagues found a cut-off peak level o f 
210mg/l to be more accurate34. In all studies, peak levels o f CRP were 
reached between the second and fourth days after admission. Therefore, 
although diagnostic accuracy was similar to that achieved using multiple 
factor scoring systems, measurement o f CRP was unable to give earlier 
prognostic information.
Polymorphonuclear Elastase
Polymorphonuclear elastase (PMNE) is released from activated neutrophils 
in a variety o f conditions and has recently been assessed in patients with 
acute pancreatitis36,37,42. Dominguez-Munoz and colleagues42 found very 
encouraging results in a series o f 182 patients of whom 28 had severe acute 
pancreatitis. Using a cut-off level o f 250ug/l on admission to hospital, the 
authors reported a positive predictive value o f 80% with a negative 
predictive value o f 98%. The positive predictive value o f a level o f greater 
than 300ug/l at 24h rose to over 97%. In a smaller study, Uhl and 
colleagues37 reported similar peak levels of PMNE on day one o f the 
illness, with levels o f greater than 120ug/l accurately predicting necrotising
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pancreatitis in 84% o f cases. However, in all cases, PMNE was measured 
retrospectively on stored plasma samples and the possibility o f observer 
bias cannot be excluded. The use of PMNE has not been evaluated in a 
prospective study.
Trypsinogen activation peptides (TAP)
The activation o f trypsinogen has long been considered the key event in the 
development o f acute pancreatitis The measurement o f trypsinogen 
activation has recently become possible with the development o f an assay 
for the peptides released from the trypsinogen molecule after its activation 
to trypsin. In a series o f 55 patients, workers in Glasgow and London 
measured urinary TAP levels in 55 patients43 with acute pancreatitis o f 
whom 15 were described as having severe attacks. O f these latter patients, 
12 were correctly predicted as severe on the basis o f a cut-off level o f 
2nmol/l o f urinary TAP on admission to hospital (positive predictive value 
0.8). Using the same figure, only 4 o f the remaining 40 patients were 
incorrectly graded as severe (negative predictive value 0.9). However, 
included in those patients with "major complications” are two with ileus, 
one with jaundice, two with duodenal obstruction and three with 
haemorrhage from undefined sources. It is therefore unclear how many of 
these patients genuinely had severe acute pancreatitis by accepted criteria. 
The value o f urinary TAP and other activation peptides such as PLAP 
(phospholipase A2 activation peptide) in the prediction o f severity o f acute 
pancreatitis remains to be determined.
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2.5 Complications of acute pancreatitis
The clinical course o f severe acute pancreatitis is characterised by the 
development o f local complications or systemic organ failure. These have 
recently been defined by an international working party meeting in Atlanta 
in 199235. Their recommendations are summarised below.
2.5.1 Local Complications
Acute fluid collection
This was defined as a collection o f fluid in or near to the pancreas 
occurring early in the course o f the illness (within 4 weeks o f the onset of 
acute pancreatitis) and lacking a defined wall o f fibrous or granulation 
tissue.
Pancreatic necrosis
This is present if, on intravenous contrast-enhanced CT scan, focal or 
diffuse areas o f non-enhancement o f greater than 3 cm or more than 30% of 
the gland are present. This is typically associated with peri-pancreatic fat 
necrosis. The distinction between sterile and infected pancreatic necrosis 
depends culture o f tissue or fluid from percutaneous needle aspiration 
although, in many centres the distinction is made on clinical grounds.
Acute pseudocvst
This is defined as a collection o f pancreatic juice enclosed by a wall o f 
fibrous or granulation tissue 4 or more weeks after an attack o f acute 
pancreatitis. Therefore an acute fluid collection which persists for more 
than 4 weeks and aquires a fibrous wall becomes by definition an acute 
pseudocyst.
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Pancreatic abscess
This is defined as a collection o f pus, usually in proximity to the pancreas 
which is associated with little or no pancreatic necrosis. The presence of 
pancreatic necrosis is associated with a very much worse prognosis and 
would be included in the definition o f "infected pancreatic necrosis".
2.5.2. Systemic complications
Organ failure in acute pancreatitis is defined by the following criteria:
Shock
Systolic blood pressure < 90mmHg
Pulmonary insufficiency 
Pa02 < 60mmHg
Renal failure
Serum creatinine greater than 177umol/l after rehydration
2.5.3 Incidence of complications
The incidence o f the above complications in acute pancreatitis is difficult to 
determine as definitions have varied with time and between authors. In a 
Glasgow study12 pseudocyst occurred in 5.5% of cases but this included 
patients who would now be defined as having acute fluid collections. The 
number o f local complications which are found will also depend on how 
avidly they are sought. In one series the incidence o f fluid collections in 
acute pancreatitis was 53%44. The incidence o f pancreatic necrosis depends 
largely upon how many patients undergo CT scanning. Thus in a study 
from Leicester, the incidence o f pancreatic necrosis was 1.5%13 whereas in 
another study from the same area45 where 45% of patients had early CT
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scanning, at least 23% of patients had pancreatic necrosis. Similarly, the 
incidence o f local complications depends upon the definitions used and the 
frequency o f biochemical sampling. The incidence o f respiratory 
complications varies greatly between studies and was found to be as high 
as 47% when repeated blood gas measurements were made12. Severe renal 
failure is less common at 3-4% 12,13.
2.6 Pathogenesis of Acute Pancreatitis
It is now over 100 years since the first comprehensive account o f acute 
pancreatitis by Sir Reginald Fitz1. Seven years later, Chiari proposed that 
the pancreatic damage was the result o f autodigestion of the gland by 
activated pancreatic enzymes. Since then, our understanding o f the 
pathophysiology of the disease has progressed remarkably little despite 
many years o f intensive research.
2.6.1 Gallstone Pancreatitis
It was Opie who first noted the association between an obstructing 
ampullary stone and fatal acute pancreatitis46. Since then controversy has 
persisted over the exact sequence o f events in gallstone pancreatitis. 
Subsequent large studies cast doubt on the ampullary obstruction theory. In 
a post mortem study of 1 cases o f fatal pancreatitis Shader and Paxton 
found obstructing ampullary calculi in only three cases47. In patients 
undergoing operation for gallstone pancreatitis, Kelly found obstructing 
calculi in only 5%48.
The finding that if the stools o f patients with pancreatitis and proven 
gallstones are screened for stones, they will be found in 85-95% of 
cases48,49 suggests that gallstone migration is the important aetiological 
factor in these cases. Certain features of the biliary tract in patients with 
gallstones and a history of pancreatitis are compatible with an increased
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tendency towards migration. The cystic duct tends to be wider than in 
patients with gallstones and no history o f pancreatitis and the gallstones are 
smaller and more numerous29,50,51.
More recently the concept o f transient ampullary obstruction has been 
introduced. Acosta52 found ampullary obstruction in 63% o f patients 
undergoing early operation for gallstone pancreatitis. The incidence 
dropped from 75% at <48 hours to 25% at >4 days suggesting that 
pancreatitis is associated with transient ductal obstruction. He also found 
that persisting obstruction was associated with fulminating disease and 
suggested that the duration o f obstruction may determine the severity o f 
the disease.
Like Acosta, Armstrong50 found the incidence o f ampullary obstruction 
decreased with time, falling from 66% with operation under 48 hours to 
3.8% at greater than 22 days. In those without obstruction, gallstones are 
usually recovered from the stool, confirming gallstone migration.
It would seem likely that gallstone pancreatitis is related to the migration o f 
a stone with transient obstruction of the ampulla o f Vater. The mechanism 
by which such a stone initiates pancreatitis remains controversial but there 
are three main theories;
• Bile reflux
• Duodenal reflux
• Ductal obstruction.
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Bile reflux
Bile reflux was initially championed by Opie as the pathogenesis o f 
gallstone pancreatitis46. He postulated that, following the obstruction o f the 
ampulla o f Vater by a stone, bile would be allowed to reflux along the 
pancreatic duct via the common channel. There are two main objections to 
this theory;
1 .Bile itself is unlikely to be pathogenic.
It has been assumed that pancreatitis is initiated by the intrapancreatic 
activation o f protease precursors. Bile does not cause trypsin activation53 
and bile introduced into the pancreatic duct at low pressures will not 
initiate pancreatitis54. The entire biliary output o f experimental animals can 
be routed through the pancreatic duct without causing pancreatitis55. 
Infected bile under normal pressure does, however, cause pancreatitis54. In 
experimental models, it is necessary to inject bile at high pressure for 
pancreatitis to occur and the degree o f damage caused is related to the 
pressure used. Such pressures are unlikely to be generated under 
physiological conditions.
2.Reflux is unlikely to occur.
For bile reflux to occur following ampullary obstruction, a functioning 
common channel must exist. This was demonstrated at cholangiography in 
only 23% of cases in a study by Acosta52.
The type of obstruction usually present prevented bile reflux by obstructing 
the pancreatic duct. Although others have claimed to demonstrate bile 
reflux more commonly in patients with pancreatitis, this has been in the 
recovery period where gallstone obstruction was not present and thus a 
functioning common channel more likely. The methods used for 
demonstrating bile reflux involve operative cholangiography which utilises
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high injection pressures unlikely to be obtained under normal physiological 
conditions. The normal pressure gradient between the pancreatic duct and 
common bile duct would also be expected to prevent bile reflux. Pancreatic 
duct pressures have been found to be 2-3 times greater than those in the 
common bile duct, both in normal subjects and in a variety o f pathological 
conditions56. One study57 however, has demonstrated slightly greater 
common bile duct pressures in patients with common bile duct stones. 
Even in these patients, the pancreatic duct sphincter pressure remained 
greater than 3 times the common bile duct pressure at all times. It is 
difficult to explain bile reflux under these conditions.
Duodenal reflux
McCutcheon58 offered his "fresh approach" to the pathogenesis o f 
pancreatitis: as bile alone is unlikely to activate pancreatic proteases, he 
suggested that duodenal contents containing enterokinase may gain access 
to the pancreatic duct, thus initiating pancreatitis. Factors normally 
preventing duodenal reflux include; the oblique course o f the pancreatic 
duct which tends to become compressed as it passes through the duodenal 
muscle, the sphincter o f Oddi and the mucosal folds at the papilla. It was 
proposed that the presence o f a stone in the ampulla caused fixed 
dilatation, overcoming these factors and favouring the reflux o f duodenal 
contents. In experimental animals, the formation o f a closed duodenal loop, 
with the resultant rise in intraduodenal pressure, is associated with the 
onset of haemorrhagic pancreatitis59. This is prevented by the ligation o f 
the pancreatic duct60 suggesting that duodenal contents are responsible. 
McCutcheon and Race61 demonstrated reflux o f barium into the pancreatic 
duct, confirming this as the aetiological factor. Stimulation with 
cholecystokinin has been shown to favour duodenal reflux after the 
formation of a closed loop62. Such conditions are, however, unlikely in
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gallstone pancreatitis. Perfusing the pancreatic duct with bile mixed with 
duodenal content at physiological pressures does not cause pancreatitis55.
It has been suggested that duodenal reflux may explain the occasional 
occurrence o f pancreatitis after a Bilroth II gastrectomy58.
Pancreatic duct obstruction
Although pancreatic duct obstruction is rarely found in post mortem 
studies of acute pancreatitis, being found in only one o f three patients in 
one series47, in patients undergoing early intervention it is found much 
more frequently49. At least transient obstruction o f the ampulla o f Vater is 
a likely step in the pathogenesis o f the disease. Pancreatic duct obstruction 
may occur either as a direct consequence o f an impacted stone or as a 
result o f the subsequent oedema.
In experimental animals, pancreatic duct obstruction alone does not result 
in the development o f haemorrhagic pancreatitis63. Ligation o f the 
pancreatic duct leads to mild pancreatic oedema and hyperamylasaemia 
followed, if the obstruction is prolonged, by acinar cell atrophy and 
fibrosis64,65. I f  ductal ligation is combined with secretagogue stimulation, 
however, more severe pancreatitis develops, accompanied by areas o f fat 
necrosis66. A similar effect is seen if ductal ligation is followed with a 
meal67.The development o f pancreatic necrosis depends upon the 
subsequent reduction o f pancreatic blood flow68. In the clinical situation, 
the common presentation o f pancreatitis is with simple pancreatic oedema 
and hyperamylasaemia accompanied by abdominal pain, all o f which may 
be caused by ductal obstruction alone. It has been observed that the onset 
of pain in gallstone pancreatitis often follows a large meal. It has been 
suggested that the variable course o f the disease and the development o f 
pancreatic necrosis may depend upon the subsequent extent o f pancreatic
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ischaemia. Further support for the ductal obstruction theory comes from 
case reports o f pancreatitis induced by the obstruction o f the pancreatic 
duct by Ascaris Lumbricoides69
One experimental study examined the effects o f biliary and pancreatic 
obstruction, both independently and in combination70. It was found that 
pancreatic duct ligation alone resulted in the development o f pancreatic 
oedema and hyperamylasaemia but the addition o f bile duct ligation 
resulted in pancreatic necrosis. The underlying mechanism was not known 
but biliary obstruction was previously shown to increase pancreatic 
secretion in the same species71 which may have contributed to the 
development of acute pancreatitis.
2.6.2 Alcohol-induced Acute Pancreatitis
Many patients with alcohol-induced acute pancreatitis subsequently 
develop chronic pancreatitis, with recurring attacks o f pain and pancreatic 
insufficiency but acute pancreatitis does not progress to chronic 
pancreatitis in all cases72. Subclinical pancreatic damage has been 
demonstrated in heavy drinkers73 and there is little doubt that in many 
patients presenting with acute alcoholic pancreatitis, pancreatic damage has 
already occurred. In any discussion o f the pathophysiology o f acute 
alcoholic pancreatitis, there is therefore considerable overlap with chronic 
pancreatitis and at the present time it is unclear why some patients present 
with a seemingly isolated attack o f acute pancreatitis and others progress 
to chronic pancreatitis.
The mechanism by which alcohol causes pancreatic damage remains a 
subject o f some debate. Three main theories have been proposed: these are 
the ductal plug hypothesis, the toxic-metabolic hypothesis and the large 
duct flow/reflux hypothesis.
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Ductal plug hypothesis
The ductal plug hypothesis is based on the observation that the 
administration o f alcohol to experimental animals results in changes in the 
composition o f pancreatic juice which favour the development of 
proteinaceous plugs which may obstruct small pancreatic ducts leading to 
the development o f inflammation and consequent degeneration o f the area 
drained by that duct.
In dogs, alcohol administration results in an increase in protein 
concentration in pancreatic juice with associated decreases in secretory 
volume and bicarbonate concentration74. Plugs with a concentric, laminar 
structure were found within the ducts. Other investigators have failed to 
find ductal plugs in similar experiments on rats75,76. Evidence from human 
studies suggests that increased protein concentration o f pancreatic juice is 
found in patients with a high alcohol intake77. Decreased levels o f secretion 
of lithostathine, a protein which attenuates calcium carbonate 
crystallisation78, have also been identified in the pancreatic juice o f chronic 
alcoholics which may be one predisposing factor in the development o f 
chronic calcifying pancreatitis. Increased serum levels o f another family o f 
proteins, known as pancreatitis associated protein (PAP) have been 
demonstrated in acute pancreatitis and have been suggested as a marker o f 
subclinical pancreatic injury79. Their role in the pathophysiology o f acute 
pancreatitis is uncertain and it appears that they are secreted as part o f the 
acute phase response following the initial pancreatic damage80.
As mentioned in the preceding section, experimental models o f simple duct 
obstruction do not lead to the development o f acute pancreatitis but to 
chronic atrophy and this mechanism may therefore be o f more relevance to 
the pathophysiology o f chronic rather than acute pancreatitis. It is also o f 
relevance that in experimental pancreatitis, the administration o f alcohol
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does not worsen the severity o f pancreatitis induced by duct obstruction81, 
whereas it significantly worsens the severity of secretagogue-induced 
pancreatitis.
Toxic-metabolic Hypothesis
Ingested ethanol is metabolised in the liver to ethanaldehyde. Both ethanol 
itself and ethanaldehyde are toxic to cells and the basis o f the toxic- 
metabolic hypothesis is that ethanol and its metabolites are directly 
injurious to pancreatic acinar cells resulting in the development o f 
pancreatitis82. It has been demonstrated that ethanaldehyde combined with 
a short period o f ischaemia can induce acute pancreatitis in an ex-vivo 
model83 and there is evidence that the quantity o f alcohol ingested in the 
week prior to a first attack o f acute pancreatitis is an important determinant 
o f the severity o f the attack83.
Large duct Flow/Reflux Hypothesis
This theory simply suggests that alcohol facilitates the development o f 
acute pancreatitis by either duodeno-pancreatic or biliary-pancreatic reflux. 
The bile of alcohol-fed rats is more toxic to the pancreas than bile from 
control rats when injected into the pancreatic duct84. Intragastric alcohol 
increases the permeability o f the pancreatic duct in cats and allows the 
induction o f acute pancreatitis by activated pancreatic enzymes infused into 
the duct85. Such models may explain cases o f alcohol-induced pancreatitis 
in the absence o f chronic pancreatic damage but the relevance o f the 
complex experimental models employed to the development of pancreatitis 
in humans is uncertain.
It can be readily appreciated that no one theory satisfactorily explains the 
development of alcohol-induced acute pancreatitis in man, and in
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particular, it is unknown which, if any, o f these mechanisms are responsible 
for the development of an acute attack o f pancreatitis in a chronic 
alcoholic.
2.6.3 Cellular events in experimental pancreatitis
Under normal circumstances, pancreatic zymogen enzymes are synthesised 
on the rough endoplasmic reticulum of the acinar cell and transported with 
zymogen enzymes to the Golgi complex. Here, the two classes o f enzyme 
are separated, the lysosomal enzymes into lysosomes and the zymogens 
into secretory granules. This occurs by means o f the recognition o f a 6- 
phosphorylated mannose residue unique to the lysosomal enzymes. 
Cathepsin-B, a lysosomal hydrolase, is capable o f trypsinogen activation 
and this separation prevents intracellular activation o f proteases. In 
addition, a potent trypsin inhibitor is synthesised and transported with the 
zymogen enzymes86.
In three divergent experimental models o f acute pancreatitis, alterations in 
the normal pattern o f enzyme secretion result in the potential for 
intracellular activation o f pancreatic enzymes. In a choline deficient, 
ethionine supplemented diet model, Steer et al87 have demonstrated an 
intracellular accumulation o f zymogen granules, the contents o f which are 
subsequently discharged into lysosomes. In a caerulin hyperstimulation 
model, zymogen accumulation did not occur but large intracellular 
vacuoles appeared which contained both lysosomal and digestive enzymes. 
In a ductal obstruction model o f acute pancreatitis, Ohshio et al63 have 
demonstrated that cathepsin-B, a lisosomal hydrolase capable o f the 
activation o f trypsinogen, is found within zymogen granules and it has 
therefore been suggested that intracellular, rather than extracellular, 
zymogen activation is the first event in the pathogenesis o f acute
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pancreatitis. However, the relevance o f these findings in experimental acute 
pancreatitis to  acute pancreatitis in man is not known.
2.7 Management of Acute Pancreatitis and its Complications
The mainstay o f management o f acute pancreatitis remains supportive and 
although many specific medical therapies have been proposed, none has 
been shown to be better than standard supportive care when assessed in 
clinical trials.
2.7.1 Supportive measures
On presentation, pain, vomiting and dehydration are the main problems. 
Pain is usually controlled with intramuscular morphine derivatives, 
pethidine being commonly used as it is thought to have less potential to 
cause sphincter o f Oddi spasm than morphine itself. Vomiting often 
resolves quickly after admission to hospital but if persistent can be 
alleviated by nasogastric suction. In patients with more severe attacks, 
nasogastric suction is often used routinely, as in these patients prolonged 
ileus is common. Clinical trials, however, have shown no benefit in terms o f 
clinical outcome, duration o f pain, or duration o f hyperamylasaemia with 
the routine use o f nasogastric suction in patients with acute pancreatitis, 
although the number o f patients studied was small and patients with severe 
pancreatitis were not studied88. Intravenous fluids are given to correct 
dehydration and a urinary catheter is passed in order to assess the adequacy 
of resuscitation. In more severe cases and in the elderly, central venous 
pressure monitoring is commonly employed. The choice of fluid used for 
resuscitation varies but in acute pancreatitis, in addition to fluid lost 
through prolonged vomiting, there is loss o f protein-rich fluid into the 
peritoneum and interstitial space therefore a combination o f colloid and 
crystalloid fluid replacement is often recommended. The majority o f
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patients will settle within a few days on this management but a proportion 
will go on to develop either local or systemic complications.
2.7.2 M anagem ent of Local Complications 
Acute Fluid collection
Acute fluid collections are common in acute pancreatitis may occur in more 
than 50% of severe cases44. They are more common in patients with 
alcohol-related pancreatitis and are often asymptomatic89. Many o f these 
will settle spontaneously and require no intervention but if large and 
causing pressure effects or if infection supervenes then intervention is 
required. If  early intervention is necessary, the choice lies between formal 
laparotomy and external drainage or percutaneous drainage under CT or 
ultrasound guidance. There is little doubt that percutaneous drainage can 
be carried out safely90,91 but recurrence is common and formal laparotomy 
with external drainage may be more appropriate in some cases, particularly 
when there is much debris present or the collection is locculated.
Acute pseudocvst
When there is a well-defined wall around the fluid collection, internal 
drainage may be employed if the cyst fails to resolve or if complications 
supersede. A period o f observation by repeated ultrasound or CT is 
warranted if the pseudocyst is small and asymptomatic89. Internal drainage 
may be carried out by cystogastrostomy if the pseudocyst lies in close 
approximation to the posterior wall o f the stomach or by cystojejunostomy 
when the cyst lies in the body or tail o f pancreas89. Success has been 
reported with endoscopic cystogastrostomy,92'94 although at present this 
technique is restricted to specialist centres.
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Infected pancreatic necrosis
Patients with infected pancreatic necrosis have a high mortality if surgery is 
not undertaken89. In contrast, specialist centres have reported mortality 
rates as low as 10-11% 89,95 for patients with infected pancreatic necrosis 
managed surgically. The details o f the type o f surgery undertaken vary 
between centres but the essential principles are laparotomy with wide 
debridement o f devitalised tissue (necrosectomy) with either prolonged 
postoperative lesser sac lavage and drainage95 or open packing89. In both 
cases, re-operation is often required for the removal o f further necrotic 
tissue. It can be readily appreciated that pre-operative CT scanning is 
essential in order to differentiate between pancreatic abscess (which can be 
successfully managed with simple external or internal drainage) and 
infected pancreatic necrosis.
2.7.3 Management of systemic complications
Respiratory impairment
Arterial hypoxaemia is common in acute pancreatitis, with 50% of patients 
developing pC>2 levels o f 8kPa or less during the first three days following 
admission96. Detailed study o f gas exchange patterns in these patients has 
demonstrated right to left shunting as the main cause o f hypoxaemia97, 
which is similar to the findings in patients with adult respiratory distress 
syndrome (ARDS) occurring as a result o f sepsis. In one study, 50% of 
patients with hypoxaemia had radiological abnormalities, the majority being 
pleural effusions, particularly left sided97. Initial management is by the 
administration o f oxygen by facemask but close monitoring is required as 
pulmonary function can deteriorate rapidly97. Early deteriorating 
respiratory function necessitates management within an intensive care unit 
and early assisted ventilation. When respiratory function begins to 
deteriorate later in the course o f the illness, a septic complication (i.e.
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pancreatic abscess or infected pancreatic necrosis) should be suspected and 
appropriate investigations instituted.
Renal impairment
As with pulmonary insufficiency, renal failure may occur early in the course 
o f the illness when it is associated with inadequate fluid resuscitation or 
fulminant acute pancreatitis, or later when it is often the result o f the 
development o f pancreatic sepsis98. The important factor early in the illness 
is prevention o f this complication by adequate fluid resuscitation but once 
established, treatment is supportive with haemofiltration. Dopamine is 
often used to augment renal perfusion in cases o f incipient renal failure98 
but is o f unproven value.
Cardiovascular impairment
Adequate fluid resuscitation is important, particularly in the early stages of 
acute pancreatitis and in the majority o f patients the circulation can be 
sustained with crystalloid, colloid and blood 98. The onset o f refractory 
shock is associated with a grave prognosis in acute pancreatitis, whether 
occurring early or late in the illness. Treatment is supportive with inotropes 
and fluids and in addition, these patients are usually in need o f artificial 
ventilation and renal support. Myocardial infarction may complicate acute 
pancreatitis, particularly in the elderly, and was thought to be a 
contributory factor in 43% of deaths in one study12
Biochemical complications
Mild hyperglycaemia is commonly seen in the early stages o f acute 
pancreatitis and may be a consequence of the stress response and relative 
pancreatic endocrine insufficiency99. It rarely requires specific treatment. 
Hypocalcaemia is also commonly seen and is associated with the more
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severe cases. The majority o f cases o f observed hypocalcaemia are the 
result o f hypoalbuminaemia100 but true hypocalcaemia does occur. This 
subject is discussed in detail in chapter 5.
2.7.4 Role of early ERCP
Two studies have now been carried out which suggest a role for early 
ERCP and sphincterotomy in patients with gallstone pancreatitis. 
Neoptolemos and colleagues in Leicester101 found a significant reduction in 
morbidity in patients with predicted severe, gallstone pancreatitis if  ERCP 
and sphincterotomy was undertaken within 72h o f admission. Although a 
study from Hong Kong102 failed to confirm this reduction in morbidity 
when ERCP was applied to all patients with gallstone pancreatitis, there 
was a significant improvement in outcome in the subgroup with predicted 
severe disease. In neither study was there any morbidity directly related to 
ERCP. Rather than concluding that ERCP is safe under such 
circumstances, it would be prudent to assume that such reductions in 
morbidity can only be achieved if a suitably skilled and experienced 
endoscopist is available.
2.7.5 Medical management of acute pancreatitis
No specific therapy has been found to be successful in the treatment o f 
acute pancreatitis but proposed treatments have fallen into two main 
categories; inhibition o f pancreatic secretion and counteraction of 
pancreatic enzymes.
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Inhibition of pancreatic enzymes
Systemic Antiprotease Therapy
Activation o f pancreatic proteases has been considered to play a central 
role in the development of pancreatic autodigestion and in the development 
o f the early systemic illness in patients with severe pancreatitis103. 
Aprotinin, a polypeptide trypsin-kallikrein inhibitor obtained from the 
bovine parotid, was introduced by Frey in the 1950's12. Many encouraging 
reports appeared in the European literature during the late 1950's and early 
1960's but these were mainly uncontrolled studies with small numbers of 
patients in whom subjective impressions o f clinical improvement were 
observed104. Subsequent controlled clinical trials were conducted but in 
many cases the number o f patients studied was too small to enable 
conclusions to  be drawn on the efficacy o f aprotinin105'107., Experimental 
work suggesting that the original doses used in these early studies was too 
small led to subsequent trials with higher doses o f aprotinin. Trapnell et 
al104 reported a randomised, controlled trial o f high dose aprotinin which 
demonstrated a significant reduction in mortality in the treatment group. 
However, this trial was subsequently criticised as the mortality in the 
control group was 25% which was higher than that commonly reported in 
other UK centres. Subsequent trials with high dose aprotinin failed to 
demonstrate any effect on mortality or the development o f
1 1 0 9  1 n o
complications ’ ’ and it is now generally accepted that intravenous 
aprotinin has no role to play in the management o f acute pancreatitis. 
Gabexate mesilate (Foy) is a synthetic antiproteases which has the 
theoretical advantage o f being able to inhibit intracellular proteases14. A 
multi-centre controlled trial, recruiting 223 patients with moderate and 
severe acute pancreatitis, has reported no evidence o f improvement in 
outcome with 4g/day o f gabexate mesilate intravenously14.
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Fresh frozen plasma is a rich source o f naturally occurring antiproteases, 
particularly alpha-2-macroglobulin but neither low dose13 (2 units daily for 
three days) or high dose45 (8 units daily for three days) made any impact on 
clinical outcome.
Peritoneal Lavage
Toxic factors have been identified in the peritoneal exudate present in 
experimental pancreatitis which cause hypotension when injected into 
healthy dogs2. Peritoneal lavage, aimed at removal o f these factors, 
improved survival in a number o f experimental models o f acute 
pancreatitis110,111. Many uncontrolled series of patients were reported in 
whom therapeutic peritoneal lavage appeared to improve the clinical course 
in acute pancreatitis112'114. The first randomised trial was carried out by 
Stone and Fabian and reported in 1980115. They observed clinical response 
in the majority of patients treated with peritoneal lavage and also in 
patients in the control group who failed to improve and were subsequently 
given peritoneal lavage. The criteria for clinical improvement were rather 
subjective, however, and overall there was no significant difference in 
mortality between the two groups o f patients. This did not prevent the 
authors from claiming that their observations offered "vigorous support" 
for the use o f peritoneal lavage in acute pancreatitis, to Enthusiasm was 
such that many centres were utilising peritoneal lavage as a primary 
treatment in patients with severe pancreatitis until, in 1985, Mayer and 
colleagues reported the results o f a multi-centre trial conducted between 
Leeds, Bristol and Glasgow116 in which 91 patients with prognostically 
severe acute pancreatitis were studied. There was similar mortality and 
morbidity in the treatment and placebo groups and the power o f the study 
was sufficiently high to exclude a therapeutic effect o f peritoneal lavage.
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Intraperitoneal antiprotease therapy
Following the failure o f peritoneal lavage, a controlled trial o f therapeutic 
lavage with the addition o f the protease inhibitor, aprotinin was carried out 
between centres in Leeds and Glasgow. Patients with mild pancreatitis 
were excluded and 203 patients were eventually recruited117. Once again, 
mortality and morbidity were similar in the two groups o f patients, allowing 
confident exclusion o f a beneficial effect with this treatment.
Inhibition of pancreatic secretion.
In 1948, Paxton and Payne reported the high mortality associated with 
surgical management o f patients with acute pancreatitis and suggested a 
conservative management regime consisting o f fasting, intravenous fluids, 
nasogastric suction, analgesia and atropine to "rest the pancreas"118. Forty 
five years later, our management has changed little and, although atropine 
is no longer used, drugs which may suppress pancreatic secretion continue 
to be the subject o f therapeutic trials.
Glucagon
Glucagon reduces pancreatic secretion and was first suggested for use in 
the management o f acute pancreatitis by Knight and colleagues in 1972119. 
Since then there have been five randomised controlled trials conducted o f 
which four119'123 studied too few patients with severe pancreatitis for valid 
conclusions to be drawn. The one large trial108,109 recruiting 257 patients, 
was conducted under the auspices o f the MRC and compared glucagon 
with aprotinin as well as with placebo. No difference in mortality or 
morbidity was observed between either o f the treatment groups and the 
placebo group.
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Cimetidine
Secretin is responsible for the stimulation o f bicarbonate secretion during 
the intestinal phase o f pancreatic secretion. It was suggested that 
cimetidine, by reducing gastric acid output, may cause a reduction in 
pancreatic stimulation by secretin124 and might therefore improve outcome 
in acute pancreatitis. No effect o f cimetidine was observed in two small 
randomised trials124,125 and the availability of more potent suppressers of 
pancreatic secretion precluded the further study o f cimetidine in this 
context.
Somatostatin and somatostatin analogues
Somatostatin is a potent inhibitor o f pancreatic secretion and its use in the 
treatment and prophylaxis of acute pancreatitis is reviewed in chapter 2.
Antibiotics
Septic complications are the single most common cause o f death in patients 
with severe acute pancreatitis and the use o f prophylactic antibiotics has 
been a point o f controversy in the management o f patients since the mid 
1970's. Early trials with ampicillin126'128 failed to demonstrate any reduction 
in the incidence of complications or mortality, although all involved small 
numbers o f patients with mainly alcoholic pancreatitis. Subsequent studies 
showed that the penetration o f ampicillin and many other antibiotics into 
pancreatic tissue is inadequate to reach therapeutic levels129. A recent study 
in 120 patients undergoing pancreatic surgery compared blood levels and 
pancreatic tissue levels obtained with 10 different antibiotics130. Although 
all achieved therapeutic plasma levels, in only a proportion were high levels 
seen in pancreatic tissue. O f these, ciprofloxacillin, ofloxacin and imipenem 
were active against the majority o f organisms present. Following this, a 
multicentre trial was carried out to assess the effect o f imipenem in patients 
with pancreatic necrosis131. There was a statistically significant reduction in
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the incidence o f pancreatic sepsis in those patients treated with imipenem
0.5g tid, although there was no significant reduction in overall mortality. 
The diagnosis o f pancreatic sepsis in this study depended upon positive 
bacterial cultures which may have been influenced by the administration o f 
Imipenem. The number o f patients undergoing surgery for pancreatic 
necrosis associated with a septic clinical picture was not different in the 
two groups of patients and the routine administration o f prophylactic 
antibiotics cannot be supported on the evidence o f this study alone.
2.8 Mediators of the Systemic Illness in Acute Pancreatitis
In consideration of the potential role o f any therapeutic agent in acute 
pancreatitis, it is necessary to examine the pathophysiology, not only o f the 
underlying pancreatic inflammation, but also o f the systemic manifestations 
o f the illness. It is well-recognised that the late, septic complications o f 
acute pancreatitis result in organ failure and it is assumed that this is a 
consequence o f the same mechanisms which are responsible for organ 
failure due to other forms o f sepsis. What is less clearly understood is the 
mechanism of the early systemic illness which still results in considerable 
morbidity and a high proportion o f deaths from acute pancreatitis116.
2.8.1 Activated proteases
For many years the systemic manifestations of acute pancreatitis have been 
attributed to the actions o f activated proteases released from the damaged 
pancreas. Proteases, complexed with the antiprotease molecules alpha-1- 
antitrypsin and alpha-2-macroglobulin, have been demonstrated in the 
peritoneal fluid, lymph and plasma o f animals with experimental acute 
pancreatitis132. Overwhelming o f these antiproteases was associated with 
hypotension and death. In man, however, free trypsin activity has never 
been demonstrated133,134 and it would appear that in man, unlike in
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experimental pancreatitis, overwhelming o f the natural antiproteases is a 
rare event134. This coupled with the universal failure of antiproteases in 
clinical trials has led to the original hypothesis being questioned.
2.8.2 Acute pancreatitis and sepsis
More recently, it has been observed that the multiple organ failure which 
often precedes death in patients with fulminating pancreatitis is similar to 
that seen in patients with sepsis, bums and trauma3. When the 
haemodynamic parameters o f patients with severe acute pancreatitis were 
measured they were found to closely resemble those seen in patients with 
sepsis, a high output, low-resistance state being the typical findings135’136. 
Pancreatic infection is rarely present in the early stages o f acute pancreatitis 
89 but the similarity between acute pancreatitis and sepsis has led to the 
suggestion that similar endogenous mediators may be responsible for the 
systemic manifestations of both conditions3. In sepsis there is now strong 
evidence to suggest that the development o f systemic complications is a 
result o f the activation of mononuclear phagocytes and the subsequent 
release of pro-inflammatory cytokines which acting through interactions 
with other cells result in end organ damage4
2.8.3 Cytokines in Sepsis
1. Tumour Necrosis Factor Alpha fTNFoO
TNFa was initially known also as cachectin as a result o f its independent 
discovery as both a serum factor causing tumour necrosis137 and as an 
agent causing hypertriglyceridaemia and cachexia in experimental 
infection138,139. TNFa is a 17kDa 157 amino acid polypeptide cytokine140 
which is produced predominately by cells o f the monocyte/macrophage 
lineage although its production by NK-cells, antigen-stimulated T cells and
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mast cells has been documented141. It is synthesised as a pro-peptide which 
undergoes proteolytic cleavage to produce the mature polypeptide140. A 
membrane-associated form has also been identified in which the leader 
protein persists142. The main stimulus to its synthesis and release is 
endotoxin143 (bacterial lipopolysaccharide) although other in-vivo stimuli 
are thought to include viruses and fungi144,145.
A wide variety o f physiological effects have now been attributed to TNFa. 
TNFa acts on endothelial cells to enhance procoagulant activity, increase 
permeability and induce the production o f other inflammatory mediators 
including Interleukin-1 and platelet activating factor4. TNFa induces 
neutrophil margination and activation and is therefore an important 
stimulator of the non-specific immune response146'149. TNFa also induces 
the maturation of myeloid cells to monocytes and macrophages and is 
capable of macrophage activation thus stimulating its own production150,151. 
It can readily be appreciated that all o f these effects may be o f benefit to 
the host in the event of a microbial challenge. However, if production is 
excessive or unregulated the balance may swing towards host injury.
The first evidence o f a role for TNFa in the mediation o f endotoxin- 
induced injury followed the discovery by Beutler et al that passive 
immunisation against endogenous TNFa conferred a survival advantage in 
mice presented with an endotoxin challenge. Similarly, endotoxin resistant 
C3H/HeJ mice did not produce TNFa in response to a bacterial 
challenge143. Administration o f high doses o f TNFa to experimental 
animals was subsequently reported to result in haemodynamic collapse and 
death152. Metabolic changes similar to those seen in septic shock were 
observed, namely hyperglycaemia and hyperkalaemia. The histological 
changes in the lungs, kidneys and gastrointestinal tract o f animals dying 
following a lethal dose o f TNFa were strikingly similar to those seen in 
patients dying from septic shock. Prior administration o f anti-TNFa
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antibody to primates given experimental bacteraemia prevented the 
characteristic haemodynamic and metabolic changes and dramatically 
improved survival153. A similar protective effect o f anti-TNFa antibody 
was reported in rabbits presented with a lethal dose o f bacterial 
endotoxin154. Following experimental endotoxaemia in humans, a transient 
rise in plasma TNFa levels was observed155,156 correlating with signs of 
systemic toxicity.
The experimental evidence suggesting a key role for TNFa in the 
pathophysiology of septic shock was subsequently supported by clinical 
studies. Raised levels o f circulating TNFa were detected in patients with 
meningococcal septicaemia which was associated with a fatal 
outcome157,158. Studies in patients with septic shock admitted to intensive 
care units have generally confirmed the association between high 
circulating TNFa levels with the severity of illness and mortality. Damas159 
studied 27 patients and found significantly higher levels o f TNFa but not 
IL -lp  in non-survivors than survivors. Although de Groote160 found no 
relationship between the severity o f sepsis and plasma TNF levels, the 
patients studied were a heterogeneous group o f whom only one died 
suggesting that the patients were less severely unwell than in the study by 
Damas in which mortality was 63%. More recently, Calandra161 have 
reported persistently raised TNFa levels in patients dying from septic 
shock compared with transiently raised levels in survivors and both 
Marks162 and Offher163 reported a correlation between the severity o f sepsis 
and plasma TNFa levels. High levels o f monocyte TN Fa production have 
also been reported in patients with sepsis following bums164 suggesting the 
activated monocyte is the major source of TNFa in sepsis.
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2. Interleukin-1 beta (IL-lp)
Interleukin-1 (IL-1) was first identified as a polypeptide co-stimulator o f T-
cell responses and named "lymphocyte activating factor" but is now
recognised as a major mediator o f the non-specific inflammatory
response165. The range o f activities attributed to IL-1 are reflected in the
variety of names by which this cytokine has been known (table 1.4).
Purification o f  IL-1 identified two distinct polypeptide species, now known
as IL-1 a  and IL -ip  which are actually the products o f two distinct 
166genes
The main source of IL -ip  is the mononuclear phagocyte although 
production by endothelial cells, neutrophils and B-lymphocytes has been 
reported167. As with TNFa, LPS is the main stimulus to its production 
although IL -ip  production is also induced by other stimuli, including 
TNFa4
Many of the effects o f IL-1 P overlap with those o f TNFa and both are 
capable o f stimulating the release of the other, thus acting in a synergistic 
fashion4. It is therefore possible that much o f the overlap in function 
observed could be explained by the subsequent induction o f secretion o f 
the other. Infusion o f IL-1 P and TNFa together results in systemic effects 
at concentrations well below those required when the cytokines are infused 
separately168’169. In addition to its effects in the inflammatory response such 
as induction o f acute phase protein production167 and neutrophil adherence 
and activation170
IL-ip acts centrally to induce fever171 secondary to the release o f 
prostaglandins in the hypothalamus and may be involved in the 
development of anorexia172. It also causes the release o f adrenal 
corticosteroids, both by a direct action and by increasing the release o f 
ACTH173'175. IL -ip  also stimulates the release o f pancreatic insulin and
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glucagon176. A stimulatory effect o f EL-1(3 on myelopoeisis has also been 
described, an effect which is partly due to induction o f release of 
myelopoetic growth factors177.
Unlike TNFa, an increase in IL -lp levels has not been demonstrated 
following endotoxin infusion in experimental animals or human 
volunteers155. During lethal E Coli septicaemia, however, high circulating 
levels o f IL-1 have been reported178*180 and infusion o f IL -lp  receptor 
antagonist significantly improved survival in a primate sepsis model179. In 
clinical studies raised levels o f EL-lp have been demonstrated but the 
prognostic significance has been less than that observed with TNFa. In 
children with meningococcal septicaemia, Girarden et al demonstrated 
higher IL -lp  and TNFa levels in non-survivors than survivors158. Similarly, 
Waage157 found that detectable levels of plasma IL -ip  were associated 
with a poor prognosis. Cannon et al181 detected raised levels o f IL-1 P in 
patients with sepsis compared with healthy controls. In patients with septic 
shock, Calandra161 reported higher levels of DL-lp in non-survivors than 
survivors although this difference did not persist beyond the first day o f 
study.
Lymphocyte activating factor 
Mitogenic protein 
Endogenous pyrogen 
B-cell activating factor 
Catabolin
Leucocyte endogenous mediator
Haemopoetin-1
Proteolysis inducing factor
Helper peak-1
T-cell replacing factor III
B-cell differentiation factor_____________________
Table 1.4: Previous names for interleukin-1
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3. Interleukin-6 I IL-6)
Interleukin-6 (IL-6), like IL -ip  was previously known by a number of 
names, (table 1.5) All o f these molecules have been shown to be an 
identical 22-29kDa protein now known as IL-6. IL-6 is produced by 
mononuclear phagocytes, endothelial cells fibroblasts and T-cells in 
response to cytokines including TNFa and IL -lp 182. The best described 
actions o f IL-6 are those on hepatocytes and B cells. IL-6 plays an 
important role in the change o f priority in hepatocyte protein synthesis in 
response to various injurious stimuli resulting in the increased synthesis of 
acute phase proteins such as C-reactive protein, fibrinogen and a-1- 
antitrypsin and the decreased synthesis o f albumin182,183. These effects are 
generally beneficial to the host182.
B2 interferon
B-cell stimulatory factor 2
26kDa protein
Hybridoma/plasmacytoma growth factor 
Hepatocyte stimulating factor
Monocyte granulocyte inducer type 2_______________
Table 1.5: Previous names for interleukin 6
4. Interleukin-8 (TL-81
IL-8 is one o f a family o f more recently described inflammatory mediators 
which is secreted by mononuclear phagocytes and other cells stimulated by 
endotoxin. TNFa and IL -ip also induce the secretion o f IL-8184. IL-8 
causes neutrophil aggregation and activation and it is believed that the 
activation o f neutrophils induced by TNFa is, at least in part, a 
consequence of its effect on IL-8 secretion184. IL-8 levels have been shown 
to be elevated in patients with sepsis and high levels appear to correlate 
with a poorer prognosis185 In experimental septic shock in primates, levels 
of IL-8 peak later than those o f IL -lp  and TNFa and correlated with the
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severity of the septic insult. Levels of IL-8 also rise after an IL -ip  
infusion186.
2.8.4 Cytokines in acute pancreatitis
TNFa
In 1988, Rinderknecht first proposed the hypothesis that cytokines may 
play an important role in the pathophysiology of acute pancreatitis3. He 
cast doubt on the conventional view that activated pancreatic proteases 
were responsible for the systemic manifestations o f acute pancreatitis and 
suggested that excessive stimulation of neutrophils by phagocytosed cell 
debris may lead to production o f harmful quantities o f free oxygen radicals, 
leukotrienes and the newly described cachectin (tumour necrosis factor) in 
a situation analogous to septic shock. The first attempt to investigate this 
hypothesis was by Banks and colleagues, who measured serial plasma 
levels o f TNFa in 27 patients with acute pancreatitis5. They found raised 
levels o f TNFa in some patients, including two patients who died o f their 
illness, but found no statistically significant difference in TNFa levels 
between patients with mild and those with severe disease. In those with 
raised levels, TNFa levels peaked within the first three days after admission 
but many patients had TNFa levels which were similar to those observed in 
healthy controls. The authors concluded that it was unlikely that TNFa 
played an important pathophysiological role in acute pancreatitis, although 
they did find evidence o f neutrophil activation. Subsequently, Exley and co­
workers6, in 38 patients with prognostically severe acute pancreatitis taking 
part in a therapeutic trial o f fresh frozen plasma, measured serum levels o f 
TNFa during the first week o f admission. They found detectable levels of 
TNFa on admission in 45% of non-survivors compared with 23% of 
survivors and overall, the levels of TNFa were higher than those reported 
by Banks et al. In addition, endotoxin was detected in 91% o f non­
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survivors on admission. These studies demonstrate the problems associated 
with plasma TNFa measurement. TNFa is thought to act primarily at a 
paracrine level and a cell-bound form has even been described142,187. 
Circulating levels therefore represent "spillover” into the circulation o f 
excess TNFa and the absence o f TNFa in the circulation does not imply 
that TNFa is not involved in a disease process. Circulating TNFa inhibitors 
rapidly bind TN Fa188,189 and can interfere with its detection in assays which 
further complicates the interpretation of these studies190. In addition, TNFa 
has a relatively short circulation half-life191 so that transiently raised levels 
may be missed. It is therefore not surprising that these studies have 
inconclusive results. The presence o f high TNFa levels in certain patients 
with some evidence o f an association with the more severe manifestations 
o f the illness provides encouraging evidence to support further study.
Interleukin-6
Several authors have documented raised IL-6 levels in patients with severe 
pancreatitis. Leser and colleagues39 described elevated levels o f IL-6, 
measured by bioassay, in patients with complicated acute pancreatitis, with 
normal or slightly elevated levels o f EL-6 in patients with mild attacks. 
Similar findings were reported by Viedma et al40 who measured IL-6 by 
ELISA and by Heath and colleagues38 who used a bioassay. What is 
unclear from these papers is the time course o f the rise in plasma IL-6 and 
the variation which occurs between individual patients. Leser39 described 
the pattern o f IL-6 activity in two individual patients with severe disease, 
showing peak levels on day 1, falling thereafter in one patient and on day 3 
in the second patient. It is not clear how accurately this reflects the findings 
in the remaining patients or how this relates to the time from onset o f 
symptoms. In the study by Viedma et al40, persistently raised levels o f IL-6 
were found but there was no obvious peak in IL-6 levels during the 7 days
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of study. Heath et al38 corrected their results for the time from onset of 
symptoms and found that IL-6 levels peaked between 24 and 48 hours after 
symptom onset. It is, however, unclear what degree o f variation there was 
between individual patients.
The relationship between C-reactive protein and EL-6 levels has been 
studied since the rise in plasma EL-6 has been proposed as the main 
stimulus to hepatic acute phase protein production. Peak IL-6 levels 
correlated with peak CRP levels in the studies by Heath et al38 and Leser et 
a39 with the peak in IL-6 preceding the peak in CRP by one day. There was 
no correlation between IL-6 and CRP levels in the study be Viedma et al40.
Interleukin-8
Early studies suggest that plasma IL-8 levels are increased in patients with 
complicated attacks of acute pancreatitis192 but, compared with EL-6 and 
TNF, little is known of the role o f this cytokine an acute pancreatitis.
2.8.5 Role of Endotoxin in acute pancreatitis
For activated leukocytes to be responsible for the systemic manifestations 
of acute pancreatitis, then a factor capable o f inducing leucocyte activation 
must be present in these patients. As discussed in the foregoing section, 
bacterial endotoxin is a potent activator o f mononuclear phagocytes and it 
induces the secretion o f cytokines including TNF, EL-6, EL-1 and IL-8. The 
presence o f endotoxaemia in acute pancreatitis was first reported in 1974 in 
three patients193, with disappearance of endotoxin from the circulation 
when the illness resolved. In 1982 Foulis et al reported 24 patients with 
acute pancreatitis in whom serial assays o f serum endotoxin were carried 
out194. Endotoxin was detected on two consecutive days in half o f the 
attacks o f acute pancreatitis and in 6 o f the 7 patients who developed 
systemic complications. The limulus amoebocyte lysate assay for endotoxin
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has certain limitations therefore assays have been developed which measure 
the immunological response to endotoxin, therefore indirectly measuring 
endotoxin exposure. Kivilaakso et al195 measured titres of antibodies to the 
enterobacterial common antigen in a series o f patients with acute 
pancreatitis. The enterobacterial common antigen is spatially related to the 
lipopolysaccharride component o f the bacterial cell wall and it was argued 
that measurement o f antibodies to this antigen were a measurement o f 
exposure to enteric bacteria and thence to endotoxin. The authors reported 
decreased titres on admission in those patients with complicated or fatal 
pancreatitis, with a rise in levels during the course o f the illness in 
survivors, suggesting endotoxin exposure. However, in 5 o f 6 patients with 
fatal pancreatitis no rise in anti-enterobacterial titres was observed, despite 
proven gram negative septicaemia in two cases. This exemplifies the 
difficulty in interpretation o f such indirect methods o f endotoxin 
measurement. More recently, an assay has been developed to detect titres 
o f an antibody to the core glycolipid portion o f the endotoxin molecule. 
Depletion o f the IgM anti-endotoxin antibody has been demonstrated in 
patients with both mild and severe pancreatitis and falling IgG levels have 
been linked with a poor prognosis196. This contradicts the argument that 
raised titres are an indicator o f endotoxin exposure but it has been 
suggested that antibody depletion results in increased exposure to free 
endotoxin At the present time the complex relationship between endotoxin, 
its circulating inhibitors and leucocyte activation has not been clearly 
defined.
2.8.6 Role of the reticuloendothelial system in acute pancreatitis
In health, portal endotoxin is rapidly removed from the circulation by the 
hepatic Kupffer cells, thus preventing systemic endotoxaemia8. The failure 
o f hepatic reticuloendothelial function results in what has been termed
50
"spillover" of endotoxin into the systemic circulation8. In this way, 
suppression o f reticuloendothelial function, increased endotoxin load or a 
combination of both may be associated with the development o f systemic 
endotoxaemia and the subsequent activation of systemic mononuclear 
phagocytes. In experimental sepsis, systemic endotoxaemia was associated 
with decreased hepatic RES phagocytic function197. Similarly, depressed 
RES function associated with systemic endotoxaemia has been 
demonstrated in patients with obstructive jaundice198. As discussed above, 
acute pancreatitis is also associated with systemic endotoxaemia. In 
experimental acute pancreatitis, the suppression o f reticuloendothelial 
function with oleic acid was reported to increase mortality199. In another 
study, stimulation o f the RES with glucan reduced mortality200. There is 
indirect evidence from clinical studies that the RES is either overwhelmed 
or its function is suppressed as raised levels o f complexed a-2- 
macroglobulin, normally removed by the RES, are present in the circulation 
in patients with severe attacks201.
2.9 Effect of somatostatin and octreotide on reticuloendothelial 
function
Somatostatin was demonstrated to enhance hepatic RES activity in rats by 
Szabo in 1983202. The clearance o f colloidal carbon from the circulation 
was increased in a dose-dependent fashion by somatostatin which was 
more effective than the RES stimulant, zymosan. Baxter and colleagues 
later demonstrated similar effects on colloid clearance with both 
somatostatin and octreotide7.
There is therefore evidence that somatostatin and somatostatin analogues 
may have potential for the treatment o f acute pancreatitis by their 
stimulatory action on reticuloendothelial cell function. The use o f these 
agents in acute pancreatitis is reviewed in the following chapter.
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C hapter 3
Somatostatin and somatostatin analogues in acute pancreatitis
Somatostatin, a 14 amino acid peptide was discovered more than 20 years 
ago in the rat hypothalamus203. Since then it has been identified in species 
from protozoa to man and in a wide range o f mammalian tissues204 As our 
knowledge of its physiological role expands, so the list o f conditions for 
which it has been suggested to be o f potential therapeutic benefit grows 
longer.
3.1 Physiological role of somatostatin
Somatostatin was discovered more or less simultaneously by two separate 
groups o f researchers. Krulich and colleagues found a substance which 
inhibited growth hormone release in the rat hypothalamus during studies on 
growth hormone releasing factor203 and one year later, Heilman and 
Lemmark reported the discovery of a factor which inhibited the release o f 
insulin from pancreatic islet cells in-vitro205. Unsurprisingly, no connection 
was made between these two discoveries at that time and it was not until 
1973, when workers in the Salk Institute made similar observations to 
those of Krulich and colleagues that serious attempts were made to isolate 
and sequence the peptide now known as somatostatin206,207. A 14-amino 
acid peptide was described with a cyclic conformation determined by a 
disulphide bond linking two cysteine residues (figure 3.1).
Subsequent work has identified an amino-terminal expanded form208 
(somatostatin-28), larger pro-hormones and a number o f species specific 
variants (such as a 22-amino acid somatostatin found in catfish). Although 
the first descriptions of somatostatin were restricted to its hypothalamic 
functions, since the description of the first radio-immunoassay for
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H-Ala-Gly-Cys-Lys-Asn-Phe-D-Trp
Cys-Ser-Thr-Phr-Thr-Lys
Somatostatin
H-D-Phe-Cys-Phe-D-Trp 
I I
(ol)-Thr-Cys-Thr-Lys
Octreotide
Figure 3.1 : Amino acid sequence of native somatostatin and octreotide
somatostatin209, somatostatin-containing cells have been identified in most 
mammalian organs.
Within the nervous system, somatostatin functions as a neurotransmitter 
and somatostatin-secreting neurones have been identified in the anterior 
and posterior pituitary, the limbic system, brain stem and spinal cord204. 
Elsewhere, cells containing somatostatin are mainly distributed within the 
secretory cells o f the gastrointestinal tract, the pancreatic islets and the 
salivary glands204.
Outside of the nervous system, there is evidence o f both endocrine and 
paracrine functions o f somatostatin. Somatostatin inhibits the release o f 
insulin and glucagon within the pancreatic islets204. The secretion o f a 
variety o f gut hormones is also inhibited as is exocrine pancreatic 
secretion204. Intestinal motility is also inhibited as is gallbladder contraction. 
Somatostatin also reduces mesenteric blood flow204.
This extensive range o f inhibitory effects on gastrointestinal function 
suggests a potential variety of therapeutic uses o f somatostatin but these 
have been limited by its short half-life necessitating administration by 
continuous intravenous infusion, thus making treatment, in anything but the 
short term, impractical.
3.2 Somatostatin Analogues
The discovery o f the wide range o f physiological actions o f somatostatin 
inevitably led to the search for analogues with similar or more potent 
effects and longer duration of action. The first and most widely studied o f 
these analogues is octreotide (SMS 201-995, Sandostatin) manufactured by 
Sandoz Pharma, Basle, Switzerland. Octreotide is an eight-amino acid 
peptide210 which retains the Phe-D-Trp-Lys-Thr sequence in a cyclic 
conformation (figure 3.1) which has been shown to be necessary for the 
endocrine activity o f somatostatins211. Octreotide has a longer circulation
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half-life than somatostatin-14, o f 41-58 minutes after intravenous 
administration and approximately 113 minutes if administered 
subcutaneously compared with 2-3 minutes for somatostatin-14. The 
effects of octreotide were found to be more specific than somatostatin-14 
in that growth hormone secretion is inhibited preferentially over insulin 
secretion212. This combined with its increased potency makes it more 
suitable than somatostatin-14 for treatment o f acromegaly.
Octreotide completely inhibits the secretion o f pancreatic enzymes, 
gallbladder contraction and CCK response after a Lundh meal213. 
Pancreatic polypeptide, gastric inhibitory polypeptide and to a lesser extent 
insulin secretion are also inhibited by even low doses o f octreotide213. 
Octreotide has now been investigated in the management o f a wide range 
of gastrointestinal diseases and more recently, interest has focused on its 
anti-proliferative effects in a variety o f gastrointestinal malignancies.
3.3 Use of somatostatin and its analogues in gastrointestinal disease.
In addition to its use in the management o f acromegaly, somatostatin or 
octreotide has been used in the treatment o f acute pancreatitis, pancreatic
o iv i o i f  'yi/z
and enterocutaneous fistulae ’ , pancreatic pseudocysts variceal 
haemorrhage217 secretory diarrhoea218 and the short bowel syndrome219. It 
has also been used successfully in the palliation o f some endocrine tumours, 
most notably carcinoid220 and is currently under investigation in a variety o f 
other solid tumours.
3.3.1 Gastrointestinal Fistulae
Many small, anecdotal series have been reported on the experience o f the 
use of somatostatin and octreotide in the management o f enterocutaneous 
and pancreatic fistulae. In the largest randomised controlled trial221, 40 
patients were randomised to receive total parenteral nutrition alone or TPN
54
with somatostatin 250ug/h. The overall fistula closure rate was similar at 
81% with TPN alone and 85% with TPN and somatostatin but fistula 
closure occurred about 7 days earlier in the somatostatin group. This effect 
was associated with a reduction in morbidity as may be expected and a 
reduction in the duration of TPN with its attendant problems. It was 
emphasised, however, that somatostatin simply speeded closure o f fistulae 
which would ultimately close on standard conservative management and 
would not allow closure o f fistulae associated with distal obstruction or 
other unfavourable factors.
3.3.2 Somatostatin and octreotide in the prevention of complications 
after pancreatic surgery
In a large, multicentre trial which has provoked much discussion, Buchler 
and colleagues from one Austrian and various German hospitals compared 
the effect of placebo and octreotide 300pg/day in patients undergoing 
resection for periampullary or pancreatic tumours or chronic pancreatitis222. 
There were an impressive 246 evaluable patients, 125 randomised to 
receive octreotide and 121 to placebo. The incidence o f post-operative 
complications was significantly reduced from 55% to 32% with octreotide 
treatment. However, this difference is entirely accounted for by the 
difference in the incidence o f pancreatic fistulae.
The overall incidence o f pancreatic fistulae was 27% but was 38% in the 
placebo group and 17% in the octreotide group. The number o f patients 
who developed complications unrelated to pancreatic fistulae was similar 
(17% octreotide group, 20% placebo group). An important factor to be 
considered is the definition o f pancreatic fistula employed by the authors. 
This was defined as a leakage o f 10ml o f fluid more than 3 days 
postoperatively containing more than 3 times the serum concentration of 
amylase. Therefore, the expected effect o f octreotide on reducing
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pancreatic enzyme secretion would naturally reduce the incidence of 
fistulae using this definition and might be expected to bias the result in 
favour o f the octreotide group regardless o f the clinical relevance of such 
an effect.
This is underscored by the similar length o f hospital stay in the two groups 
of patients. It is not clear how many patients had clinically significant post­
operative fistulae which failed to meet the trial criteria on the basis of 
amylase levels which therefore do not appear in the results.
3.3.3 Somatostatin and octreotide in the management of secretory 
diarrhoea
Somatostatin inhibits the secretion o f intestinal water and electrolytes and 
the secretion o f vasoactive intestinal polypeptide(VIP) and other 
experimental secretagogues218. Octreotide has been successfully used in the 
treatment o f secretory diarrhoea due to VIP secreting tumours, carcinoid 
syndrome and the diarrhoea often associated with AIDS218. However, the 
evidence o f efficacy o f octreotide in this context is restricted to case 
reports and no randomised, controlled trials have been carried out.
3.3.4 Somatostatin and octreotide in the management of pancreatic 
pseudocysts
The majority of pancreatic fluid collections will settle on conservative 
management and although there have been sporadic case reports o f the use 
of octreotide in patients with pancreatic pseudocysts216, no randomised 
trials have been conducted and there is no conclusive evidence that either 
somatostatin or octreotide alters the natural history o f pseudocysts in any 
way.
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3.3.5 Antitumour effects of octreotide
Recent interest has focused on the potential antitumour effects of 
octreotide and other somatostatin analogues. Many tumours display 
somatostatin receptors, a finding which has led to the development of 
radiolabelled somatostatin analogues to enable imaging of tumours, 
particularly those o f neuroendocrine origin223. In-vitro studies have shown 
that octreotide has an antiproliferative effect on somatostatin receptor 
positive tumour cell lines and similar effects have been demonstrated in 
animal models224. So far, however, there are no reports o f similar 
antitumour effects in primary human malignancies.
3.4 Somatostatin and octreotide in the treatment of acute pancreatitis
The use of somatostatin in acute pancreatitis was first suggested in 
1975225,226 but despite much experimental and clinical study since that time, 
its role in the management o f this condition remains unclear.
There are four main properties o f somatostatin or octreotide which may 
influence the course o f acute pancreatitis.
3.4.1 Mechanism of action 
Inhibition of pancreatic secretion.
It is conventional wisdom that "to rest the gland" is beneficial in the 
management of acute pancreatitis118. Although the validity o f this 
assumption has not been established it has led to clinical trials with 
nasogastric suction88 cimetidine124,125 and glucagon119'123 in the treatment of 
acute pancreatitis, none o f which has been shown to be effective.
Somatostatin causes a dose dependent reduction in exocrine pancreatic 
secretion, the effect on enzyme secretion being greater than the effect on 
secretion of bicarbonate and water227. Similar effects have been
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213 228demonstrated with the somatostatin analogue, octreotide ’ In health, 
the doses o f somatostatin used in clinical trials would be expected to cause 
a 70% reduction in exocrine pancreatic secretion227. This action may 
explain the successful use of somatostatin analogues in the treatment of 
pancreatic fistulae221. However, the secretory status o f the pancreas in 
acute pancreatitis is unknown, as is the effect o f somatostatin on the 
diseased gland. In experimental models at least, pancreatic secretion 
appears to remain at basal levels229 and there is evidence that pancreatic 
exocrine secretion is impaired in the majority o f patients following recovery 
from necrotising pancreatitis230.
Haemodynamic effects.
Somatostatin reduces pancreatic blood flow in experimental animals231. The 
development o f pancreatic necrosis has been linked to hypoperfusion o f the 
gland232 and vasoconstrictors have been shown to worsen the histological 
severity o f experimental pancreatitis233. Conversely, dopamine, which 
improves pancreatic blood flow, has been found to improve the outcome 
from experimental pancreatitis234.
Schroder and colleagues found that, following the induction o f pancreatitis, 
pancreatic blood flow decreased to a greater extent in somatostatin treated 
piglets than in untreated controls235. This would be expected to be 
associated with a deleterious effect on outcome although no difference 
between treated and untreated animals was observed in this study.
Cytoprotection/organoprotection.
Cytoprotective properties have been claimed for somatostatin211’236 on the 
basis o f its ability to reduce the effect o f various toxins on gastric mucosal 
cells and hepatocytes. However, cytoprotection towards the pancreas has
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not been demonstrated and experiments have shown that for somatostatin 
to be effective in this context, pre-treatment is necessary. Obviously in 
acute pancreatitis, where organ damage will have occurred prior to 
admission, such pre-treatment would not be possible.
Stimulation of the reticuloendothelial system.
The fourth way in which somatostatin may influence the course o f acute 
pancreatitis is by its stimulatory effect on the phagocytic cells o f the 
reticuloendothelial system. In experimental acute pancreatitis, survival can
  1 0 O  ' ) ‘5 7
be improved by stimulation o f the RES with either zymosan or glucan ’ 
Conversely, depression of the RES results in worsened survival199. There is
also some evidence of RES depression in patients with acute
• •  201 pancreatitis
Both somatostatin and the long acting somatostatin analogue, SMS 201- 
995, have been shown to increase the clearance o f colloidal carbon7,236. 
Somatostatin was found to be more effective in this regard than 
Zymosan236. Somatostatin has also been reported to enhance monocyte 
phagocytic activity in-vitro238. Survival o f rats after intraperitoneal injection 
o f endotoxin was also improved with somatostatin therapy7 which may 
have been a consequence of RES stimulation.
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3.4.2 Somatostatin in experimental pancreatitis
Somatostatin has been examined in most animal models o f acute 
pancreatitis and has met with varying degrees o f success (Table 3.1). In 
the first study to be reported239, Lankisch and colleagues administered 
somatostatin at a dose of 100|ig/100 g body weight for three hours 
immediately after inducing pancreatitis in rats by the retrograde injection o f 
sodium taurocholate into the pancreatic duct. Although the serum amylase 
and lipase were lower in the treatment group, the overall mortality was 
unchanged. The histological changes in the pancreas were also similar in 
the two groups.
Two years later, Schwedes et al240 reported a significant histological benefit 
with cyclic somatostatin, 62.5pg/h in a canine model of haemorrhagic 
pancreatitis. This effect was seen with both somatostatin pre-treatment and 
with somatostatin administered two hours after the induction of 
pancreatitis. The general condition of the animals in the treated group was 
also noted to be improved.
In addition to the different species used in these experiments, there are 
differences in experimental design which may help to explain these 
contradictory results. In inducing acute pancreatitis, Lankisch et al used 
sodium taurocholate whereas Schwedes et al utilised the animals own bile. 
Neither group o f workers standardised the injection pressures used, a 
factor which may influence the severity of pancreatitis produced. There 
was also a difference in the duration of somatostatin treatment between the 
two studies. Whereas Lankisch et al discontinued treatment after three 
hours, Schwedes et al gave somatostatin by continuous infusion for up to 
24 hours. Native somatostatin has a half life in the circulation o f only two 
to three minutes and it is possible that prolonged treatment in the second 
study was responsible for the difference in result.
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Author Model Survival
effect
Histology
effect
Lankisch et al 1977 Rat, RIB No No
Schwedes et al 1979 Dog, RIB N/A Yes
Adler et al 1980 Rat, CH N/A Yes
Baxter et al 1985 Rat, PDL Yes Yes
Degertekin et al 1985 Mouse,CDED No No
Schlarman et al 1987 Dog, RIB N/A No
De Rai et al 1988 Rat, CDL No Yes
Table 3.1: Somatostatin in experimental pancreatitis
RIB: retrograde injection o f bile or taurocholate
CH: ceruelin hypersecretion
PDL: pancreatic duct ligation
CDED: choline deficient, ethionine supplemented diet
CDL: closed duodenal loop
Subsequently, Schlarman et al241 reported no improvement in pancreatic 
histology following the infusion o f native somatostatin 20pg/kg/h for five 
hours immediately after the induction of pancreatitis by retrograde bile 
injection in dogs, although portal and thoracic duct lymph amylase levels 
were reduced in the treatment group. Similarly, Degertekin et al242 using a 
diet-induced model o f acute pancreatitis in mice, failed to demonstrate a 
significant effect on survival or pancreatic histology following the 
subcutaneous administration o f native somatostatin, 30pg every eight 
hours. However, in view of the short circulation half-life of somatostatin it 
is unlikely that such a dosage schedule would achieve therapeutic levels in 
plasma. It is therefore difficult to draw firm conclusions from this study.
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A beneficial effect o f cyclic somatostatin, 5pg/kg/h, on the histological 
severity o f ceruelin-induced pancreatitis was reported by Adler et al243, 
treatment being commenced immediately after the induction o f pancreatitis. 
Similarly, De Rai et al244 demonstrated reduced histological damage with 
somatostatin given intravenously for 9 hours. No information on the timing 
or dose of treatment was given. Baxter et al245, in addition to 
demonstrating a histological benefit with somatostatin treatment, found a 
dramatic improvement in survival in the treatment group. They continued 
somatostatin, 4pg/kg body weight, for up to 24 hours using a duct-ligation 
model in the rat. Similar results were seen even if treatment was 
commenced immediately or delayed for 24 hours after duct ligation. These 
results suggest that differences in duration o f treatment, but not in timing 
of treatment or size o f dose, may explain some o f the differences in results 
obtained.
Differences between the experimental models used may also play a part in 
the contradictory results observed. In the only study to  demonstrate a 
survival deference, Baxter et al induced acute pancreatitis in rats by ligation 
o f the common bile/pancreatic duct. This model is normally associated with 
pancreatic oedema246 although pancreatic necrosis and a high mortality 
were seen in the control group in this study.
3.4.3 Octreotide in experimental pancreatitis
The development o f the long acting somatostatin analogue, octreotide, has 
led to its use in experimental pancreatitis. Its longer half life allows 
subcutaneous administration avoiding the need for continuous intravenous 
infusion. The three experimental studies using octreotide all show some 
benefit from octreotide administration (Table 3.2).
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Author Model Survival
effect
Histology
effect
Baxter et al 1985 Rat, PDL Yes Yes
Augelli et al 1989 Dog, RIB N/A Yes
Davliakos et al 1990 Dog, ex-vivo N/A Yes
Table 3.2: Octreotide in experimental pancreatitis 
PDL: pancreatic duct ligation 
RIB: retrograde injection o f bile or taurocholate 
ex-vivo: ex-vivo, isolated, perfused pancreas
In the one study to assess survival245, a dramatic advantage was 
demonstrated after twice daily subcutaneous octreotide at a dose o f 2pg/kg 
commencing 12 hours after the induction of pancreatitis by pancreatic duct 
ligation. This survival advantage was of a similar magnitude to that 
reported by the same authors using native somatostatin. Augelli et al238 
were able to demonstrate a reduction in histological severity in animals 
given octreotide, 5pg/h, prior to the induction of pancreatitis although no 
effect was seen if treatment was delayed until pancreatitis was established, 
despite continuing treatment for 24 hours. Similarly, Zhu et al247, giving 
octreotide 2pg/kg/h demonstrated a reduction in histological severity in a 
rat bile injection model. Once again, this effect was only seen if treatment 
was commenced prior to the induction o f pancreatitis.
In the study by Davliakos et al248 an ex-vivo model was used and 
histological benefit was seen after only one injection o f octreotide, even if 
treatment was delayed until one hour after the induction o f pancreatitis. 
However, ex-vivo models have been criticised as being unphysiological246
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and their usefulness in evaluating treatment effects remains to be 
established.
In summary, the evidence from experimental studies is inconclusive 
although in those studies which continue treatment over a prolonged period 
there is evidence o f some improvement in the treatment group. Differences 
between studies are not explained by the size o f dose or the timing of 
administration in relation to the induction o f pancreatitis. Only one study to 
date has reported an overall reduction in mortality with somatostatin.
3.4.4. Clinical trials with somatostatin and octreotide in acute 
pancreatitis
The main difficulty in therapeutic trials in acute pancreatitis is that only a 
very small proportion of those with the disease are likely to benefit 
significantly from specific treatment and it is therefore necessary to recruit 
large numbers o f patients to be confident o f demonstrating a reduction in 
mortality. As with other proposed treatments in acute pancreatitis, clinical 
trials with somatostatin have often failed to recruit sufficient patients for 
meaningful conclusions to be drawn.
Following small, uncontrolled reports in the late 1970's suggesting clinical 
improvement with somatostatin in acute pancreatitis a multicentre study 
was carried out249. The APTS study (Acute Pancreatitis Treatment with 
Somatostatin)250 was conducted between centres in Germany, Switzerland 
and Greece and was intended to include only patients with severe disease. 
Severe acute pancreatitis was defined as hyperamylasaemia and abdominal 
pain with three or more o f five severity criteria present; shock, ileus, 
abdominal distension, white cell count greater than 12000cells/dl and 
glucose greater than 150mg/dl. Somatostatin 250pg/h or placebo was
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infused for up to 7 days. A total o f 77 patients were recruited over a two 
year period, 36 in the treatment group and 41 in the control group.
There were 7 deaths in the control group (17%) and 4 in the treatment 
group (11%) a difference which fails to reach statistical significance. This 
led the authors to conclude that somatostatin was o f no benefit in acute 
pancreatitis. However, it is important to realise that this study has 
insufficient numbers o f patients to exclude a survival advantage as large as 
50%. It can be readily calculated from sample size nomograms that more 
than 200 patients would be required in each group to exclude a type II 
error where the mortality in the control group is only 17%251.
The authors found that serum pancreatic enzyme levels returned to normal 
more quickly in the treatment group, but unfortunately no detailed analysis 
was made o f the incidence o f complications in the two groups, perhaps 
reflecting difficulties in collating this information in a multicentre study.
Since 1985 there have been a further three controlled clinical trials reported 
in the English-language literature, all o f which recruited patients with both 
mild and severe acute pancreatitis (Table 3.3).
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No of 
Patients
Mortality
(Placebo)
Mortality
(Treatment)
Complications
(placebo)
Complications
(Treatment)
Usadel et al, 
1985
77 17% 11% N/A
Choi et al, 
1989
71 5.5% 2.9% 36% 14%
D'Amico et al, 
1990
164 8.5% 2.4% NS
Gjorup et al, 
1992 63 3% 3% 70% 58%
Table 3.3: Somatostatin in the treatment o f acute pancreatitis 
N/A: Not assessed
NS: Not statistically significant but exact figures not given
Choi and co-workers in Hong Kong252 conducted a randomised controlled 
trial comparing somatostatin against standard treatment in patients with 
acute pancreatitis. Only 71 patients were recruited o f whom 15 had 
prognostically severe disease based on the presence o f three or more 
positive Glasgow criteria. Patients were randomised on admission to 
standard treatment and somatostatin 100jig/h for two days by continuous 
intravenous infusion or to standard treatment alone. With such small 
numbers o f patients, it is impossible to assess any effect on mortality alone 
and indeed there were only three deaths overall, two in the control group 
and one in the treatment group. There was a statistically significant 
difference in the complication rate between the two groups which was 
mainly accounted for by local complications, in particular "pancreatic 
phlegmon" which the authors defined as inflammatory pancreatic swelling 
on CT scanning with associated fluid collection.
A multi-centre study was reported by D’Amico et al253 in which a total o f 
164 patients were recruited over a two year period. Patients with acute
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pancreatitis o f every grade of severity were included resulting in an overall 
mortality o f 5.5%. No information was given about the randomisation 
procedure. Somewhat unusually, patients were divided into those requiring 
immediate surgery and those needing medical treatment alone based on a 
clinical and radiological assessment o f disease severity. Patients not 
undergoing immediate surgery were then given either total parenteral 
nutrition alone or total parenteral nutrition with somatostatin, 250pg/h for 
five days. Patients who subsequently deteriorated and required surgery 
were excluded from the study. There was a further sub-division o f patients 
into "haemorrhagic" and "oedematous" pancreatitis based upon the 
operative findings and clinical course. Overall, there was a trend towards a 
reduction in mortality in the somatostatin treated group which failed to 
reach statistical significance (2 vs. 7). Again, there were less local 
complications in the treatment group compared with the control group (1 
vs. 5) although observer bias cannot be excluded and the numbers are too 
small to allow meaningful statistical analysis. The hospital stay for the 
group o f patients undergoing surgery was reduced in the somatostatin 
treatment group. Overall, however, the complex design o f this study makes 
interpretation o f the results difficult.
Recently, Gjorup et al254 have reported a small, randomised controlled trial 
in which 63 patients with acute pancreatitis received somatostatin 250pg/h 
or placebo for three days. Once again, patients with mild pancreatitis were 
included and as a result the overall mortality is only 3%. Although no 
significant differences in mortality or complications were observed between 
the treatment and placebo groups similar criticisms regarding patient 
numbers can be applied to this study. It is worth noting, however, that in 
contrast to the studies by Choi and D'Amico the number o f local 
complications in this study were similar in the two groups.
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Several small, controlled studies have been reported in the foreign- 
language literature255'257. However, in all cases, the studies include patients 
with pancreatitis o f every grade o f severity and therefore the mortality rates 
are low. The complication rates are not reported in sufficient detail to allow 
any meaningful analysis o f clinical outcome.
In summary, no sufficiently large trial has yet been performed for firm 
conclusions to be drawn on the efficacy o f somatostatin in acute 
pancreatitis. There is, however, some evidence o f a trend towards a 
reduction in mortality and complication rate with somatostatin and a meta- 
analysis of the studies carried out to date suggests that overall, there is an 
improvement in outcome with somatostatin treatment258.
3.4.5 Somatostatin and octreotide in the prophylaxis of ERCP- 
induced pancreatitis
Acute pancreatitis is the most common complication following endoscopic 
retrograde cholangiopancreatography occurring in up to 11% of cases259 
although asymptomatic hyperamylasaemia occurs in up to 70%260. Both 
somatostatin and octreotide have been evaluated in the prophylaxis o f 
acute pancreatitis following ERCP261'268 but the results o f controlled 
clinical trials are conflicting. The incidence o f acute pancreatitis in these 
studies is low and most studies do not have the statistical power necessary 
to exclude a therapeutic effect.
One exception to this is the study by Guelrud et al264 who studied a 
particularly high risk group o f patients undergoing pancreatic duct 
sphincter dilatation and found an overall incidence o f acute pancreatitis o f 
43%. Infusion o f somatostatin for 12 hours peroperatively resulted in an 
incidence o f acute pancreatitis o f 25% compared to 75% in the placebo 
group. However, another study has reported a significant increase in the
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incidence o f acute pancreatitis from 11% to 34% following the 
prophylactic use o f octreotide269, suggesting that the use of octreotide may 
even be harmful.
Unlike somatostatin, octreotide has not been the subject o f a large, 
controlled clinical trial in the treatment o f acute pancreatitis. The following 
study was conceived as a single-centre pilot study designed to assess the 
therapeutic potential o f octreotide in acute pancreatitis. As discussed 
above, o f the mechanisms o f action by which octreotide may influence the 
outcome from acute pancreatitis it was felt that its action on the hepatic 
reticuloendothelial system was o f most relevance in the prevention o f the 
early systemic complications.
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Chapter 4.
A Randomised, controlled trial of octreotide in the treatment of 
patients with acute pancreatitis
4.1 Patients and Methods
4.1.1 Ethical approval
Consultant surgeons in 9 hospitals within the Glasgow area were 
approached by the author. The details o f the proposed study were 
explained and approval sought for the inclusion of their patients. Ethical 
approval was sought by the author from each individual hospital ethical 
committee and was granted in all cases. Samples o f consent forms and 
patient information sheets were forwarded and approved. The relevant 
exemption certificate for doctors carrying out clinical trials was obtained 
(DDX) as was demanded prior to the granting o f ethical approval
4.1.2 Study Design.
A double-blind, placebo controlled was conducted. There were two study 
arms;
1. Patients with acute pancreatitis receiving full supportive therapy and 
placebo.
2. Patients with acute pancreatitis receiving full supportive therapy and 
octreotide.
Details o f the supportive therapy were necessarily left to the discretion o f 
the medical teams responsible for the individual patients. The use o f early 
ERCP in gallstone pancreatitis was not precluded and there were no 
restrictions on the timing o f surgical intervention. The use o f antibiotics 
was, again, left to the discretion o f local medical staff but in all hospitals 
the use o f antibiotics was not routine, but restricted to specific indications.
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Patients were assessed on a daily basis by the author and thereafter at 
regular intervals until discharge from hospital.
4.1.3 Entry criteria
Acute pancreatitis was defined as the acute onset o f abdominal pain along 
with a rise in serum amylase to at least four times the upper reference limit. 
Patients were eligible for inclusion in the study if they were assessed within 
72 hours o f the onset o f abdominal pain but all efforts were directed at 
assessing patients within 48 hours o f symptom onset.
Patients with mild acute pancreatitis rapidly recover with standard 
supportive therapy and it was considered desirable to concentrate the study 
on those patients most at risk o f developing complications. As discussed in 
chapter 2, no single method o f assessing severity o f the attack is able to 
adequately differentiate between mild and severe pancreatitis on admission 
to hospital but the APACHE II scoring system32 was considered the best 
available method. It utilises measurements which are readily available in all 
hospitals and can be used on admission to hospital. In order to include as 
many o f the potentially severe cases as possible, it was decided to use a 
cut-off admission APACHE II score o f 5. This, it was anticipated from the 
work o f Wilson and colleagues34 in a similar patient population, would give 
a sensitivity for severe pancreatitis o f 95%with a specificity of 54%. It was 
estimated that at least 40% of the patients so included would develop 
significant complications.
Patients under the age o f 18 were excluded as were females in whom 
pregnancy could not be excluded.
Written informed consent was a pre-requisite for inclusion in the study. It 
was anticipated at the outset o f the trial that there would be a proportion of 
patients who would be too ill to be able to give informed consent and a 
small number o f patients in intensive care units for whom this would
71
obviously be impossible. In these cases, consent from a close relative was 
obtained. All patients were informed o f their right to withdraw from the 
study at any time.
4.1.4 Statistical Analysis
This trial was conducted as a single-centre pilot study in order to assess the 
likely magnitude o f any effect o f octreotide on outcome. It was anticipated 
that this information would, if the results were encouraging, lead to a large 
multi-centre study. The information would also allow more accurate 
estimation of the necessary number o f patients required for such a study. 
As it was unlikely that sufficient patients would be recruited to enable 
hypothesis testing to be carried out with sufficient statistical power, it was 
decided to restrict the analysis to the calculation o f confidence limits for 
any difference observed between the two arms o f the study. The true effect 
of octreotide would therefore be expected to lie between these extremes.
4.1.5 Randomisation procedure
Octreotide and placebo were provided in identical glass vials by Sandoz 
pharmaceuticals. The octreotide vials contained lmg o f octreotide in 5ml 
while the placebo vials contained 5ml o f saline. Labels were removed and 
replaced with labels identifying the vial as containing "trial drug", with the 
name o f the study and the name o f the principal investigator. The vials 
were assembled in individually numbered treatment packs, each containing 
either 5 vials o f octreotide or 5 o f placebo. The packs were numbered 
sequentially and the allocation o f octreotide or placebo to a particular 
number was determined by a computer-generated random code. The 
preparation o f these packs was carried out by a third party (Dr W 
Angerson, non-clinical Senior Lecturer, Department o f Surgery, Glasgow 
Royal Infirmary). The randomisation code was kept in a sealed envelope
72
until termination o f the study and all investigators, patients and attending 
medical staff were not aware o f the nature o f the trial infusion.
On entry to the study, patients were simply allocated the appropriate, 
sequentially numbered pack containing 5 days supply of either octreotide or 
placebo.
4.1.6 Drug administration
If  the entry criteria were met and informed consent given, patients were 
randomised to receive either placebo or octreotide, at a dose o f 1 mg/day 
(40mg/h) by continuous intravenous infusion, continuing for 5 days. 
Intravenous infusion was chosen for administration because o f the local 
discomfort often reported following subcutaneous injection of octreotide 
which it was thought might introduce observer bias. It also removed the 
potential problems associated with reliance on ward nursing staff to 
administer the trial drug. The 5ml vial was diluted with saline in a 50ml 
syringe to give a final volume o f 48ml. This was then infused intravenously 
via a syringe pump at 2ml per hour. In this way, one vial was infused over 
24h. Subsequent infusions were prepared either by the author if present or 
by the junior medical staff who were left detailed verbal and written 
instructions. Each day's infusion was prescribed on an intravenous fluid 
prescription sheet and was signed for by the nurse commencing the 
infusion. The infusion was continued for 5 days or until full biochemical 
and clinical resolution if this was earlier.
4.1.7 Patient recruitment
Junior medical staff in each participating hospital were contacted and the 
details o f the study explained. Contact numbers by which the author could 
be reached was provided. The author was available by radiopage, cellular 
telephone and failing these by answering machine. A sheet with the
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appropriate contact numbers was left in the relevant wards o f each 
participating hospital.
In addition, medical and nursing staff were regularly contacted by the 
author and reminded o f the study, particularly when referral numbers 
dropped.
On being contacted about a patient, the author visited the hospital involved 
as soon as other commitments allowed and assessed the patient for 
inclusion in the study. I f  entry criteria were met and informed consent 
granted, the trial infusion was commenced. Patients not meeting the entry 
criteria were excluded from further study.
4.1.8 Study end-points
Clinical endpoints were death or complications, either local or systemic. 
These were defined as follows:
Local complications:
• pancreatic necrosis (sterile or infected) as defined on contrast-enhanced 
CT scan or at laparotomy
• acute fluid collection defined on ultrasound or CT scan.
Systemic complications:
• respiratory insufficiency (p02<8kPa),
• radiologically confirmed pleural effusion,
• renal impairment (serum creatinine >180umol/l despite fluid
resuscitation in the absence o f pre-existing renal impairment),
• shock (systolic BP< 100).
These definitions were arbitrarily defined, as the study was designed prior 
to the Atlanta convention35 where more precise definitions were agreed. 
The definitions chosen, however, are very similar to those arrived at by the 
Atlanta convention, the one exception being pleural effusion. This, it was
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reasoned, simply represented a fluid collection within the lung and as such 
should be included as a systemic complication.
The degree o f systemic illness was assessed by the acute physiology score 
(APS), which is a component o f the APACHE II score.
In order to simplify the study for participating hospitals, no additional tests 
were required o f the local hospitals but junior medical staff were 
encouraged to carry out daily measurement o f the Glasgow criteria (or 
until normal). The daily measurement o f CRP was also encouraged. All 
patients were requested to have an abdominal ultrasound carried out prior 
to discharge in order to identify gallstones if present.
4.2 Results
Between November 1991 and April 1993, 58 patients were recruited to the 
study. Eight o f the nine hospitals who were approached contributed 
patients to the study (Table 4.1).
Hospital No of Patients
Glasgow Royal Infirmary 20
Stobhill Hospital 7
Southern General Hospital 6
Hairmyres Hospital 5
Monklands Hospital 5
Vale of Leven Hospital 5
Law Hospital 5
Victoria Infirmary 4
Table 4.1: Patients recruited from individual hospitals
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4.2.1 Aetiology
In 31 patients (17 octreotide group, 14 placebo group), gallstones were 
present on ultrasound examination or had been previously diagnosed. O f 
the remainder, 11 gave a history o f excessive alcohol consumption. One 
patient had hypercalcaemia due to primary hyperparathyroidism as a 
probable cause and one patient developed acute pancreatitis following 
ERCP. In 14 patients (24%) no definite aetiological factor was identified. 
Ultrasound is known to be less sensitive when carried out during the acute 
attack and it is probable that some o f those with no known aetiological 
factor had gallstone-related pancreatitis. Patients seldom had repeat 
ultrasound carried out during the same hospital admission.
4.2.2 Comparability of groups
The patient groups are compared in table 4.2. Twenty-eight patients were 
randomised to receive octreotide (13 female, 15 male, median age 64, 
range 25-86) and 30 to receive placebo (19 female, 21 male, median age 
73, range 32-92). Patients in the placebo group had a slightly higher 
proportion o f women than the treatment group (63% compared with 46%) 
and tended to be older with a median age o f 73 compared with 64 in the 
treatment group. Aetiology was similar in the two groups with gallstones 
identified in 54% of the treatment group and 53% of the placebo group.
Octreotide Placebo
No 28 30
Age 64 (25-86) 73 (32-92)
Male 15 11
Female 13 19
Gallstones 17 15
Table 4.2: Patient characteristics, placebo and octreotide groups
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All patients were selected on admission on the basis o f the APACHE II 
score but other measurements o f prognostic severity were similar in 
treatment and placebo groups. Glasgow criteria (median 2 positive factors 
in both groups) and peak CRP within 48 hours o f admission (placebo 
group median=150mg/ml (IQR 110-276), treatment group=157 (77-232)) 
were similar in the two groups of patients.
4.2.3 Effect on Mortality
The trial was of insufficient size to exclude a treatment effect on mortality 
but no difference in mortality was seen between the two groups o f patients 
(octreotide group 5/28 (18%); placebo group 6/30 (20%). There were five 
early deaths (within the first week), three in the placebo group and two in 
the treatment group. All had fulminant pancreatitis and failed to respond to 
maximal supportive therapy. Two patients died within 24h o f admission to 
hospital. Both were elderly and with evidence o f multiple organ failure on 
admission and were not considered for ITU. One o f these patients was 
found at post-mortem to have evidence of coexistent ascending cholangitis 
with intra-hepatic abscesses. Two o f the remaining early deaths were 
admitted to intensive care and had full ventilatory and circulatory support. 
One died after 4 days in ITU, the other after only 48h. The remaining early 
death occurred in a 53 year old lady with severe chronic obstructive 
airways disease who deteriorated rapidly after admission but was not felt to 
be a suitable candidate for ventilation in ITU.
Of the late deaths, there were two patients in each group who died from 
causes not directly related to acute pancreatitis. One had a cerebro-vascular 
accident and died on day 10, one had a myocardial infarction which 
contributed to his death on day 9, one elderly lady died of 
bronchopneumonia on day 20 after making an initial recovery from her 
pancreatitis and one patient died from iatrogenic causes following the
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insertion o f a central venous catheter for the purpose o f intravenous 
feeding. However, all four patients had severe acute pancreatitis associated 
with significant systemic complications. The remaining two deaths were in 
two patients who died in the post-operative period. One, a 69 year old 
female died o f uncontrolled haemorrhage following a necrosectomy for 
pancreatic necrosis with fimgal infection. The other, a 75 year old man died 
o f multiple organ failure following operative exploration of the common 
bile duct for ascending cholangitis.
4.2.4 Effect on incidence of complications
The complications which were observed are summarised in table 4.3. 
Complications were recorded in 26 patients, 14 o f whom were in the 
treatment group and 12 in the placebo group. The overall complication rate 
was therefore 45% which was in keeping with the rate expected with an 
admission APACHE II cut-off o f greater than 5.
Multiple organ failure occurred in 4 patients in the placebo group and three 
in the treatment group. All patients in this study who developed multiple 
organ failure died as a consequence. Isolated respiratory insufficiency was 
the single most common systemic complication and was present in 6 
patients in the placebo group compared with 7 in the treatment group. 
Local complications were recorded in three in the placebo group compared 
with 4 in the treatment group. Two patients, one in each group, had acute 
fluid collections on ultrasound. Both settled without surgical or 
radiological intervention. One patient had an infected fluid collection, by 
definition a pancreatic abscess, which settled following operative 
intervention with prolonged external drainage. One patient had pancreatic 
necrosis on contrast-enhanced CT scan and a second had pancreatic 
necrosis discovered at post-mortem only. Two patients had infected
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pancreatic necrosis Both underwent necrosectomy, with one patient 
surviving and the other dying following uncontrolled haemorrhage.
Placebo Treatm ent
Patient
No
Complication Death Patient
No
Complication Death
7 PE, RF 11 MSOF Day 14
10 RF, IPN 13 RF Day 10
18 MSOF Day 4 23 RF
19 RF, Abscess 24 ARF
22 MSOF Day 1 31 RF
29 RF Day 14 33 MSOF Day 2
36 RF, AFC 35 RF
37 IPN, MSOF Day 27 39 ARF
40 RF Day 20 42 RF Day 4
44 MSOF Day 1 43 AFC, PE
51 RF 48 RF
58 PE 52 RF, PN Day 9
55 RF
56 PE, PN
Table 4.3: Complications and deaths in patient groups
PN: Pancreatic necrosis
IPN: Infected pancreatic necrosis
PE: Pleural effusion
RF: Respiratory failure
ARF: Acute renalfailure
MSOF: Multiple systems organ failure
AFC: Acute fluid collection
CVA: Cerebrovascular accident
The overall combined morbidity and mortality rate in the octreotide group 
was 50% and in the placebo group 40%. There was therefore an observed 
adverse effect o f octreotide on outcome of 10% compared with placebo
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(95% Confidence Interval -35 to +15). These results are summarised in 
table 4.4
Treatm ent
(n=28)
Placebo
(n=30)
Difference (95% 
confidence interval)
Complicated 9 (32%) 6 (20%) -12% (-22% to +10%)
Fatal 5 (18%) 6 (20%) +2% (+22% to -18%)
Total 50% 40% -10% (-35% to +15%)
Table 4.4: Summary of outcome in octreotide and placebo groups
4.2.5 Influence of Aetiology on Outcome
Thirteen of the 31 patients (42%) with gallstone pancreatitis developed 
complications o f whom 5 died. O f those with pancreatitis o f other 
aetiologies, the complication rate was 48% with 6 deaths. Seven o f the 11 
(64%) patients with alcohol-related acute pancreatitis developed 
complications two o f whom died. This difference, however, was not 
statistically significant (P>0.2, Chisquare test).
In the sub-group o f patients with gallstone pancreatitis, there was no 
evidence o f a beneficial effect from octreotide. Sixteen patients with 
gallstone pancreatitis received placebo o f whom 7 had complications 
(44%). In those receiving octreotide there were 6 complications in 15 
patients (40%).
4.2.6 Effect on the systemic illness
The degree o f systemic illness on admission to the trial (as assessed by the 
acute physiology score, APS) was similar in the two groups o f patients 
(treatment group; median APS=4, range 1-12, placebo group; median 
APS=4, range 1-14). There was no difference between groups in peak APS 
during the infusion period. The time taken for the systemic illness to settle, 
as measured by the return o f the APS to zero was identical in both groups
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o f patients, occurring at a mean o f 3.4 days in the treatment group and 3.8 
days in the placebo group.
Patients receiving octreotide had similar serum levels o f C-reactive protein 
to those receiving placebo. No significant difference in CRP levels was 
observed on any o f the 5 days o f trial infusion (Figure 4.1).
No beneficial influence o f octreotide was observed on the incidence of 
systemic complications. As all patients who developed local complications 
also had systemic complications, no separate analysis o f the effect on 
systemic complications was necessary.
4.2.7 Effect on plasma enzyme levels
Previous authors have suggested that the administration o f somatostatin to 
patients with acute pancreatitis may be associated with a more rapid return 
o f serum amylase levels to normal. No evidence of this was observed in the 
present study with similar levels o f amylase being observed on each o f the 
days o f study in the two groups o f patients (Figure 4.2).
4.2.8 Effect on hospital stay
In survivors, hospital stay was not influenced by the administration of 
octreotide. Both groups o f patients had a median hospital stay o f 10 days.
4.3 Discussion
Previous studies with somatostatin or octreotide in acute pancreatitis have 
been discussed in section 3.4.
The main difficulty in conducting clinical trials in acute pancreatitis is the 
large number o f patients which must be recruited to give sufficient 
statistical power to confidently exclude a beneficial effect on outcome. It 
has been estimated that in only 3-5% of patients the outcome may be 
influenced by trial therapy270. It is therefore desirable to focus therapeutic
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Figure 4.2: Amylase levels in patient groups
trials on those patients most likely to benefit from treatment, namely those 
with severe pancreatitis. In the present study, although only 58 patients 
were studied, those with mild disease were excluded resulting in a mortality 
and complication rate o f 45% which is higher than that o f previous studies. 
No statistically significant difference was observed between groups and, 
unlike some previous studies ’ , there was no evidence o f a trend 
towards improved outcome in the octreotide group. The confidence 
intervals for the difference in complication rate between the two groups 
indicate that our results are consistent with an influence on outcome 
ranging from a 35% increase to a 15% reduction in complication rate with 
octreotide therapy. This indicates that even if octreotide has a beneficial 
effect in acute pancreatitis, such an effect likely to be small and o f little 
relevance to routine clinical practice. It is equally likely, from the results of 
this study, that octreotide has a deleterious effect on outcome.
It can be readily calculated from sample size nomograms251 that in order to 
demonstrate a beneficial effect o f octreotide o f 15%, the largest effect 
consistent with the results o f the present study, a study would need to 
recruit 175 patients in each limb to give a power o f 0.85. In the event that 
the true effect o f octreotide was a 10% improvement in outcome, then a 
trial recruiting 800 patients with prognostically severe pancreatitis would 
be required. The power o f the present study to demonstrate a difference of 
15% was 0.15 and it is obvious that such an effect cannot be excluded by 
this trial. The power o f the present study to exclude a beneficial effect o f 
octreotide on outcome o f 30% (reducing the complication rate to 10%) 
was 0.75. From these considerations, the present study indicates that a 
large, beneficial effect o f octreotide on outcome is unlikely. It is also 
unlikely that a trial o f sufficient magnitude to exclude a small beneficial 
effect o f octreotide will ever be conducted.
82
The use o f the APACHE II score may be criticised as a means o f grading 
patients for prognostic purposes as it is less specific than other methods 
such as multiple factor scoring systems or C-reactive protein levels34. 
However, it is the only readily available method by which patients can be 
graded for severity on admission to hospital and therefore allows earlier 
selection o f patients for study. The cut-off level o f five was chosen to give 
a high sensitivity and reasonable specificity for severe attacks34. The overall 
mortality rate o f 19% in this study confirms the relative severity o f disease 
in the group o f patients studied and compares favourably with other trials 
in which patients with mild pancreatitis have been excluded.
One problem encountered with the use o f the APACHE II system was the 
relatively heavy weighting placed on age. Any patient over the age o f 75 
automatically qualified for inclusion in the study with an APACHE II score 
o f 6. This may explain the relatively high median age o f patients recruited 
to the present study. Younger patients needed to score more APS points to 
qualify for inclusion in the study and were therefore more unwell on 
admission than many o f their elderly counterparts.
An admission APACHE II score o f greater than 7 has been recommended 
in order to indicate a prognosis o f severe pancreatitis but, while this would 
reduce the number o f mild attacks included in the study, it would also be 
associated with a reduction in sensitivity resulting in some patients with 
severe pancreatitis being missed. The APACHE II score o f 5 was 
considered a reasonable compromise, allowing inclusion o f almost all o f 
those with severe attacks and excluding at least half o f those with mild 
pancreatitis. It is emphasised, however, that no prognostic scoring system 
meets all the needs o f a clinical trial and the APACHE II system was 
chosen as the most appropriate o f the methods available.
83
4.4 Possible factors responsible for the failure of octreotide to improve 
outcome
Notwithstanding the statistical considerations discussed above, the possible 
reasons why the present study has failed to suggest a benefit from the use 
o f octreotide in acute pancreatitis were examined.
4.4.1. Trial Factors 
Drug administration
No studies were carried out to determine the bioavailability o f octreotide 
during the trial infusions. However, the drug was stored and used 
according to the manufacturer's recommendations. It was kept refrigerated 
at 4°C until the trial infusion was prepared following which it was used 
immediately. The drug was diluted 5:48 which is only very slightly more 
than recommended by the manufacturer (1:9 or 5:45). The continuity o f the 
trial infusion was outwith the direct control o f the author but infusions 
were checked on a daily basis. Brief interruptions to the infusion would not 
be expected to influence the results greatly in view o f the prolonged 
circulation half-life o f octreotide. Interactions with syringes or giving sets 
used in the study have not been previously reported.
The dose o f octreotide used in the present study was 1 mg/day (40pg/h) 
which is greatly in excess o f the dose required for maximal suppression of 
pancreatic secretion271. It is higher than that used in previous studies in 
acute pancreatitis272 and higher than the dose used in studies in pancreatic 
surgery222 both o f which demonstrated a therapeutic benefit with octreotide 
treatment. It is therefore unlikely that inadequate dosage was responsible 
for the negative findings of this study.
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Delay in treatment
There is some evidence from previous experimental studies with 
somatostatin that pre-treatment is required for therapeutic benefit to be 
seen in acute pancreatitis238’247,248. This would obviously not be possible in 
the context o f a clinical trial but every effort was made to ensure that the 
trial infusion was commenced as soon as possible after admission. The 
median delay from symptom onset to trial infusion was 24h (mean 29h, 
range 6-72h) and it is unlikely that this could be significantly improved.
4.4.2. Octreotide-related factors
The many actions o f somatostatin and somatostatin analogues have led to 
several proposed mechanisms by which they may influence the outcome 
from acute pancreatitis. Although octreotide has been to be associated with 
inhibition o f pancreatic secretion, reduction in pancreatic blood flow, 
cytoprotection and reticuloendothelial stimulation, there is no conclusive 
evidence that these properties are likely to be useful in the treatment of 
acute pancreatitis. This is discussed in detail in section 3.4.1.
In conclusion this trial has failed to demonstrate any evidence o f a 
beneficial effect o f octreotide in 58 patients with moderate to severe acute 
pancreatitis. The results o f this study indicate that the therapeutic effect of 
octreotide, if present at all, is small and unlikely to  make any impact on the 
management o f patients with acute pancreatitis.
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Chapter 5
Development of methods for the study of mononuclear phagocyte 
function.
5.1 Introduction
Severe acute pancreatitis is commonly associated with a systemic illness 
characterised by a hyperdynamic circulation135,136 with varying degrees o f 
impairment o f respiratory and renal function. At the extreme end o f the 
spectrum, patients develop multiple organ failure with its associated high 
mortality. This systemic illness has many similarities to that seen in patients 
with sepsis and it has been postulated that similar pathophysiological 
mechanisms may underlie the systemic manifestations o f both conditions3. 
In sepsis, there is now considerable evidence that the systemic illness is the 
result o f uncontrolled activation o f mononuclear phagocytes and the 
consequent release o f increased quantities o f inflammatory mediators. O f 
these, tumour necrosis factor alpha (TNFa), interleukin-1 beta (IL-ip), 
interleukin-6 (IL-6) and interleukin-8 (IL-8) are thought to play an 
important role4. In contrast, the pathophysiology o f the systemic illness 
seen in acute pancreatitis is unknown. For many years it was considered to 
be the result o f activated proteases released from the damaged pancreas 
and the consequent local and systemic release o f vasoactive peptides2,132,273 
However, the failure of antiprotease therapy to influence the outcome from 
acute pancreatitis12,13,45,108 has led to reappraisal o f this theory and the 
search for alternative mechanisms.
Little is known o f the role o f mononuclear phagocyte activation in acute 
pancreatitis. Previous studies have been restricted to the measurement o f 
plasma levels o f cytokines, as an indirect measurement o f phagocyte 
function. Previous authors have demonstrated that plasma levels o f IL-6 
are increased in patients with complicated or fatal acute pancreatitis38,40 and 
IL-6 levels have been reported to have prognostic significance early in the
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course o f the disease38. Plasma levels o f TNFa have been measured in two 
studies with inconclusive results5,6. Gross and colleagues measured plasma 
levels of interleukin-8 in 10 patients with acute pancreatitis and found 
higher levels in those with systemic complications192. There have been no 
studies examining IL -ip  in acute pancreatitis. The interpretation of studies 
on plasma cytokine levels is made difficult by the presence o f circulating 
inhibitors189 the short circulation half-life of many cytokines191 and the fact 
that their main physiological action is at a paracrine level274. In order to 
overcome these problems it was decided to study directly the function of 
mononuclear phagocytes in patients with acute pancreatitis.
In man, the only mononuclear phagocyte readily available for study is the 
circulating monocyte. Monocytes are produced in the bone marrow from 
precursor stem cells and enter the bloodstream as 12-20pm cells with 
typically bean-shaped nuclei. Monocytes migrate to various tissues where 
they differentiate according to the tissue site275. In the liver they become 
Kupffer cells, in the lung, alveolar macrophages. Monocytes, like tissue 
macrophages, are activated by endotoxin and can be induced to release 
cytokines including TNFa, IL -1 p, IL-6 and EL-8. By studying the in-vitro 
function of monocytes taken from patients with acute pancreatitis, it was 
reasoned that an indirect measurement could be made o f the activation 
status and secretory function o f mononuclear phagocytes in-vivo.
The first stage in this study was to develop a method o f separation o f 
monocytes from peripheral blood which would allow the study o f 
monocyte function in patients with acute pancreatitis.
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5.2 Monocyte separation - principles
Monocytes comprise less than 5% of peripheral blood leucocytes as 
determined by esterase activity276 and several methods have been described 
for their enrichment. The ideal method would fulfil three main criteria: 
Firstly, a high yield o f cells is required to enable sufficient numbers o f cells 
to be extracted from a small quantity of blood. Only limited amounts o f 
blood can be taken from patients, particularly when repeated measurements 
are required and when further blood samples are required for routine 
biochemistry and haematology.
Secondly, consistent, high levels of purity are required. The levels o f 
cytokine secretion observed in the resulting cell culture would be a function 
not only o f the activation status of the monocytes, but also on the 
proportion of monocytes present. Therefore, if mixed peripheral blood 
mononuclear cells were studied, it would be necessary to  interpret the 
results in the light o f varying monocyte numbers in the cell populations 
studied, a factor which would make the final interpretation o f the results 
difficult.
Thirdly, any method for monocyte separation should have a minimal effect 
on cell function in order that the function o f the monocytes in-vitro should 
be as close as possible to their function in-vivo.
In practice , any method chosen will be a compromise between these three 
ideals as all the available methods have associated drawbacks.
5.2.1 Density Gradient Separation
Monocytes and lymphocytes are less dense than polymorphonuclear 
leucocytes and erythrocytes and can be separated from them by 
centrifugation at low speed over a medium of appropriate density. 
Metrizoic acid, an iodinated non-toxic compound, is commonly used for 
this purpose. Lymphoprep (Nycomed UK) is a solution o f 9.6%(w/v)
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Sodium Metrizoate combined with the erythrocyte aggregating 
polysaccharide, Ficol. Centrifugation of whole blood on this medium 
produces a band o f cells at the interface layer containing mixed 
mononuclear cells from which monocytes can be further purified using a 
variety o f methods. Monocytes generally represent 20-30% of the mixed 
cell population. A variation on this method is the one step separation o f 
monocytes using Nycoprep 1.068. (Nycomed UK). This is a discontinuous 
density gradient which utilises the fact that monocytes and lymphocytes 
expel water at different rates in hyperosmotic media.
5.2.2. Separation by adherence
Monocytes rapidly adhere to various surfaces and this property can be used 
to separate them from other leucocytes. Leucocyte-rich plasma is normally 
incubated in a tissue culture flask, allowing monocytes to adhere to the 
plastic surface. The non-adherent cells are then washed off and adherent 
cells recovered by incubation with a cation chelating agent such as EDTA. 
Certain substrates, such as gelatin or autologous serum, can be used to 
coat the plates in order to achieve better monocyte yields. This method, 
although relatively simple and requiring no specialised equipment, may 
result in contamination with granulocytes and B-lymphocytes, both o f 
which can adhere under these conditions.
5.2.3. Separation by cell size
Counterflow centrifugal elutriation (CCE) utilises the fact that monocytes 
are generally larger than lymphocytes to separate monocytes from mixed 
mononuclear cells. Although this method allows separation with the 
minimum o f interference to the cells it requires relatively large quantities o f 
blood and depends on the availability o f specialised equipment. 
Furthermore, different populations o f monocytes with varying size are now
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recognised277 and CCE may differentially select larger monocytes with 
different functional characteristics from the whole monocyte population.
5.2.4 Separation by immunomagnetic methods.
Monocytes may be selected by methods utilising magnetic microbeads 
(Dynal) covalently bound to monoclonal antibodies raised against various 
cell-surface determinants. Removal o f T and B-lymphocytes as well as NK- 
cells results in a relatively pure population o f monocytes with minimal 
interference with cell function. High bead:cell ratios are needed for 
effective removal o f lymphocytes and enrichment o f cells by this method is 
not possible278. Recently, a new immunomagnetic method has become 
available. MACS (magnetic cell separation system) was developed at 
University o f Cologne and utilises small, superparamagnetic particles in a 
high gradient magnetic field278. The advantage o f MACS over traditional 
magnetic cell sorting is that the small microbeads used (50-100nm) do not 
interfere with cell function or viability279. Furthermore, the small magnetic 
moment o f the microbeads allows positively selected cells to be easily 
removed from a ferromagnetic matrix outside o f the magnetic field and 
therefore enrichment as well as depletion o f cells is possible278.
5.2.5 Fluorescence activated sorting (FACS)
Similar selection o f cells by their cell-surface markers can be achieved by 
labelling with fluorochrome-conjugated antibodies and separation in a flow 
cytometer with cell sorting capabilities. Although this method allows 
separation o f rare cell populations, including monocytes, it requires 
expensive equipment and is time consuming if large numbers o f cells are 
required278.
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5.3 Comparison of two methods of monocyte separation
O f the monocyte separation methods available, the MACS method 
appeared most promising as it could potentially allow high yields o f cells 
from small quantities of blood. There were no reports in the literature on 
the use o f the MACS system for monocyte separation therefore MACS 
separation was compared with adherence which is a long-established 
method o f monocyte separation.
5.3.1 Methods
120 ml o f venous blood was withdrawn from three healthy donors using 
2.4% EDTA as anticoagulant. Immediately after collection, blood was 
mixed 1:1 with phosphate buffered saline (PBS) and layered on Ficol- 
Hypaque (Lymphoprep, Nycomed UK). 10ml of blood/PBS was pipetted 
onto 7.5ml o f Lymphoprep in sterile 25ml universal containers. After 
centrifugation at 400g for 30 min at room temperature, the mononuclear 
cell-rich interface was collected using a sterile pasteur pipette. PBS was 
added and the cells washed by centrifugation at 600g for 20 min at 4°C. 
Two further washes with PBS were performed, with centrifugation at 200g 
to remove platelets. The cell pellet was then resuspended in 1ml o f PBS 
and counted. The cells were then divided into three aliquots and monocyte 
enrichment was carried out by adherence or magnetic separation. Two 
monoclonal antibodies recognising monocyte cell-surface antigens were 
compared, namely anti CD33 and anti-CD14.
MACS SEPARATION (Figure 5.1)
Microbead-conjugated antibody (60ml) was added to each o f two aliquots 
o f PBMC’s, each containing 3x10? cells. To one aliquot was added anti- 
CD33 antibody and to the other anti-CD 14 antibody. Both were obtained 
from Bekton Dickinson. The cell suspensions were then incubated for 20
91

min at 4°C following which cell separation was carried out. Following 
incubation with the microbeads, each aliquot was separated in the MACS, 
also obtained from Bekton Dickinson. A column (3x10^ cell capacity) was 
sterilised by flushing from below with 70% alcohol. Following this the 
column was washed with PBS/5mMol EDTA/0.2% bovine serum albumin 
(BSA) to  remove all traces o f alcohol. Finally the column was cooled by 
the passage o f several column volumes of ice-cold PBS/EDTA/BSA. The 
PBMC's were pipetted from the top o f the column and flow rate was 
controlled using a 22G needle. The column was washed with 3 column 
volumes o f PBS/EDTA/BSA and then was flushed from below to loosen 
weakly adherent cells. The washing and flushing was then repeated. Finally, 
the column was washed at a higher flow rate using a 21G needle. The 
column was then removed from the magnetic field and the retained cells 
were eluted using cold PBS/EDTA/BSA flushed from the top o f the 
column with short, forceful movements. The positively selected cells were 
then collected by centrifugation at 600g for 6min and the cell pellet 
resuspended in AIMV. A viable cell count was then performed by trypan- 
blue exclusion.
ADHERENCE
Of the remaining PBMC, 4x10^ were added to 20ml o f RPMI medium 
supplemented with 10% n
normal human AB serum in a medium sized culture flask. The flask was 
then incubated for 90min at 37°C in a 5% CO2 enriched atmosphere. The 
flask was then carefully washed with warm phosphate buffered saline to 
remove the non-adherent cells. 5mMol EDTA in PBS was then added to 
cover the bottom of the plate and the cells were incubated for 15min 
following which adherent cells were removed using gentle agitation. The 
resultant cells were then collected by centrifugation at 600g for 6min and
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the pellet was resuspended in AIMV medium. A viable cell count was again 
performed by trypan blue exclusion.
Analysis of purity
The purity o f the resultant monocyte-enriched cell suspension was assessed 
by flow cytometry. 5 pi o f fluorochrome (FITC) -conjugated anti-CD 14 
monoclonal antibody was added to 50ml of each cell suspension and 
incubated at 4°C for 20min. The cells were then washed by centrifugation 
and the cell pellet resuspended in 1ml o f PBS. To one aliquot o f the 
original PBMC suspension was added 5 pi o f FITC-conjugated murine 
immunoglobulin to act as a negative control. The cells were then analysed 
in a flow cytometer (EPICS II, Coulter) and the percentage o f CD 14 
positive cells in the enriched cell populations and in the original PBMC 
populations was measured.
5.3.2 Results
Cell viability in all experiments was assessed by trypan blue exclusion and 
was always greater than 95%. The number o f cells obtained following 
separation on Lymphoprep is shown in table 5.1. Blood from subject 1 
yielded the highest absolute number o f cells but the proportion o f 
monocytes as determined by immunofluorescence was the lowest of the 
three volunteers at 18%.
Subject No PBM C % monocytes
1 1.3xl08 18
2 1.1x10s 26
3 1.15xl08 31
Table 5,1: Yield of monocytes from 30ml peripheral blood
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Cell separation by immunomagnetic positive selection consistently yielded 
the highest number o f monocytes, the yields being two to three times 
higher than achieved by adherence. Furthermore, selection using the CD 14 
cell-surface antigen yielded consistently higher numbers o f monocytes than 
the CD33 method (table 5.2) Using selection by anti-CD14 conjugated 
microbeads, over 30% of the available monocytes in the original PBMC 
population could be retrieved. .
Subject ADHERENCE MACS
CD33
MACS
CD14
1 13% 27% 33%
2 19% 23% 36%
3 7% 23% 33%
MEAN 13% 24% 34%
Table 5.2: Final yield of cells after enrichment for monocytes as 
percentage of the original number of CD 14 positive cells.
The proportion o f monocytes in the final cell population was consistently 
higher with CD 14 immunomagnetic separation than with separation by 
adherence (table 5.3). In two o f the three subjects, however, the 
proportion o f monocytes was higher after separation using the CD33 
antigen compared with the CD 14 antigen.
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Subject ADHERENCE MACS
CD33
MACS
CD14
1 84% 94% 89%
2 74% 86% 89%
3 82% 94% 92%
M EAN 80% 91.3% 90.%
Table 5.3: Proportion of cells in final population identified as monocytes 
by CD 14 immunofluorescence
It was concluded that the monocyte yield achieved by magnetic cell 
separation was higher than that achieved by adherence. In addition, 
monocyte purity was higher and the time taken for separation was 
considerably shorter. The average time taken for monocyte separation 
using adherence was 150min and MACS 25min. MACS separation was 
therefore quicker and more efficient than adherence under these conditions.
5.3.3 Discussion
Immunomagnetic selection o f monocytes proved rapid, easy to perform 
and was associated with consistently high yields o f cells. The purity o f the 
final cell population was around 90% or greater which was higher than was 
achieved by separation using adhesion. Methods o f improving the yield and 
purity of adherent cells have been described. Using fibroblast exudate- 
coated culture plates, monocyte yields o f  2 -7 x 10^ cells from 20ml o f blood 
have been achieved, with monocyte purity in excess o f 90%280. This 
technique was not assessed in the present study but the results obtained 
using uncoated plates for adherence were not encouraging.
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The rapidity with which monocytes could be separated from PBMC with 
the immunomagnetic method minimised the time between venepuncture 
and the availability o f cells for culture and in-vitro assessment o f function. 
It was felt that this would help to minimise the unwanted effects on cell 
function. The method was also simple to learn and to use. Repeated 
separations could be carried out sequentially, allowing the study o f several 
blood samples simultaneously.
Neither CD 14 or CD33 is specific to monocytes. CD33 is found on bone 
marrow progenitor cells but in the peripheral blood, it is only expressed by 
monocytes. In contrast, CD 14 is expressed on peripheral blood monocytes 
but also, if to a lesser extent, on granulocytes. CD 14 is expressed on a 
higher proportion of monocytes than CD33, however, which may explain 
the higher yield o f cells which was obtained using the CD 14 as the target 
antigen. The other reason for improved cell yields with the CD 14 method 
may have been the selection o f granulocytes in addition to monocytes as 
both display the CD 14 antigen. However, the vast majority o f granulocytes 
should have been removed during the initial Lymphoprep separation, as 
granulocytes are sedimented out at this stage along with erythrocytes. 
Cellular smears were made o f the monocyte suspensions in order to check 
for the presence o f granulocytes. After staining, the smears were examined 
by light microscopy and only very occasional granulocytes were observed.
It was therefore concluded that optimal monocyte yields could be achieved 
using the CD 14 immunomagnetic method with acceptable levels o f purity.
Experiments were then conducted in order to assess the effect o f monocyte 
separation on cell function.
96
5.4 Analysis of effect of monocyte separation on monocyte function
As outlined above the optimal method of monocyte separation would be 
associated with minimal effects on cell viability and function. It was 
reasoned that all methods o f monocyte separation would be associated with 
functional changes which would influence the results obtained from in-vitro 
studies. However, as all patient samples would be exposed to similar 
influences, the effect o f these influences would be similar for each patient. 
This would therefore allow comparison o f results between individual 
patients and between patients on separate days o f study. It was considered 
necessary to document as far as possible the effect o f the method chosen 
on monocyte function, if only to exclude uniform cellular activation.
5.4.1 M ethods
Four volunteers were chosen from the laboratory staff. 30ml o f venous 
blood was withdrawn into 2.4%EDTA and immediately separated on 
Lymphoprep as described previously. PBMC were then resuspended in 
AIM V and counted. The proportion o f monocytes in the PBMC 
suspension was then assessed by flow cytometry. An aliquot o f PBMC 
containing approximately \Qp cells was taken from each o f the four cell 
suspensions and placed on ice. The remainder o f the cells were incubated 
with anti-CD 14-microbeads (20|il per 10^ cells) for 20 min at 4°C. The 
PBMC suspensions were then split into two aliquots. One aliquot was kept 
on ice and the on the other, magnetic cell separation was carried out as 
previously described. Monocytes were then separated using the MACS and 
CD14-conjugated microbeads. Monocyte purity was assessed by flow 
cytometry. The monocytes and PBMC were then suspended in AIM V 
medium, adjusted to give a final cell density of 5x10^ monocytes per ml. 
The following culture wells were then set up;
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1. Monocytes alone
2. Monocytes with LPS 200ng/ml (lipopolysaccharide E Coli E5 B55, 
Sigma)
3. PBMC alone
4. PBMC with LPS 200ng/ml
5. PBMC with anti-CD 14-microbeads
6. PBMC with anti-CD 14-microbeads with LPS 200ng/ml
The cells were then cultured for 24h at 37°C following which the 
supernatants were removed, clarified by centrifugation and frozen at - 
30°C. TNF was subsequently measured in the supernatants by ELISA.
5.4.2 Results
The results o f this experiment are summarised in table 5.4. In all cases, 
visual inspection o f the culture wells after 24h confirmed the typical 
phenotypic changes associated with "flattening" o f the monocytes onto the 
surface of the culture flasks. There was a consistent increase in secretion o f 
TNFa with the addition o f LPS to the culture medium. Mean TNFa 
secretion in the monocyte alone wells was 1.4ng/ml. After LPS stimulation, 
TNFa levels rose to  a mean o f 3.6ng/ml (range 1.4-7ng/ml). Mean TNFa 
secretion in the PBMC alone wells was similar at 1.2ng/ml, and rose to a 
mean o f 2.8ng/ml after LPS secretion (range l.l-4.1ng/ml). The basal 
secretion when PBMC to which CD14-microbeads were added was 
unchanged at 1.2ng/ml but the mean secretion after stimulation with LPS 
was lower at 1.9ng/ml, although this difference was not statistically 
significant (T=1.8, P=0.17, two sample t-test).
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Culture
well
Control
1
Control
2
Control
3
Control
4
Mean Mean
Difference
1 1.2 1.0 0.9 2.6 1.4
2 2.8 1.4 2.7 7.0 3.6 2.2
3 1.0 0.9 0.8 1.9 1.2
4 3.5 2.5 1.1 4.1 2.8 1.6
5 1.0 0.9 0.9 1.8 1.2
6 2.25 1.5 1.3 2.4 1.9 0.7
Table 5,4; TNFa secretion (ng/ml)
Culture welll: monocytes alone (MACS separated with CD 14-microbeads)
Culture well 2: monocytes + LPS
Culture well 3: PBMC alone
Culture well 4: PBMC+LPS
Culture well 5: PBMC+CD14
Culture well 6: PBMC+CD14+LPS
5.4.3 Discussion
Basal secretion o f TNFa by monocytes, PBMC and PBMC with CD 14- 
microbeads was similar in all four cases. In three o f the four subjects, the 
effect o f LPS on TNFa secretion by PBMC was slightly attenuated by the 
addition o f anti-CD 14-microbeads to the culture medium. Similar, small 
responses were found in the case o f control 3. The secretion o f TNFa by 
the separated monocytes was similar to that observed in the wells 
containing PBMC. From these results, the following were concluded;
1. The use o f CD 14-microbeads does not remove the ability o f monocytes 
to respond to appropriate stimuli in-vitro.
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2. CD 14 microbeads are associated with no reduction in basal levels o f 
cytokine secretion.
3. There was no evidence of significant cellular activation, as measured by 
TNF secretion, by CD 14-microbeads.
Until recently, the CD 14 cell-surface antigen had no known function, 
although anti-CD 14 mAb had previously been shown to induce an 
oxidative burst in human monocytes281. However, in 1990, Wright and 
colleagues282 demonstrated that CD 14 is in fact a cell-surface receptor for 
LPS and LPS complexed with a serum factor, lipopolysaccharide binding 
protein (LBP). Binding o f monocytes with anti-CD 14 mAb has been shown 
to inhibit serum-dependent LPS stimulation by up tol00% 281 a result which 
would make the use of the CD 14 positive selection method unsatisfactory 
for the present study. However, different epitopes on the CD 14 molecule 
are recognised by different anti-CD 14 mAb. In the study by Couturier et 
al281, mAb IOM2 (Immunotech) and My4 (Coultronics) were each 
associated with complete inhibition o f serum-dependent LPS binding. The 
Becton Dickinson monoclonal antibody, LeuM3 which was used in the 
present series o f experiments and which is conjugated with microbeads for 
use in the MACS system, recognises an epitope on the CD14 molecule 
which is not located in the LPS receptor and thus did not inhibit LPS 
binding281.
A further factor to be considered in the present study is the use o f serum- 
free medium (AIM V). This was chosen in order to exclude the possible 
effect o f serum on the detection o f cytokines in the culture medium but it is 
now appreciated that under serum-free conditions, LPS binding occurs via 
CD 14-independent mechanism281 and therefore, binding by CD 14 mAb 
may be irrelevant under these circumstances.
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It was therefore considered that the use of positive selection o f cells by the 
anti-CD 14-microbeads was an appropriate method for the prospective 
study of monocyte function in patient groups.
5.5 LPS Titration
In order to find the optimal concentration o f LPS for future experiments, a 
titration o f LPS concentration against TNF production was carried out in 
two of the above control subjects.
5.5.1 M ethods
From healthy laboratory volunteers (controls 3 and 4, above), 30ml o f 
venous blood was withdrawn and monocyte separation carried out as 
described above by Lymphoprep separation followed by CD-14 
immunomagnetic monocyte separation.
LPS (E Coli 055 B5, Sigma) was diluted to 50ug/ml in AIM V (Gibco). A 
lOOul aliquot o f this solution was then diluted serially 1:5, by taking 20ul 
into 80ul o f AIM V, followed by 20ul of the resulting solution into a 
further 80ul o f AIM V and so on. This gave 4 concentrations o f LPS in 
AIM V; 400, 2000, 10 000 and 50 OOOng/ml. 20ul o f these solutions was 
added to each o f 4 wells containing 1ml of AIMV with monocytes at a 
density o f 5xl0^/ml. This resulted in a final concentration in the wells o f 8, 
40, 200 and 1 OOOng/ml o f LPS.
The cells were cultured for 24h at 37°C following which the supernatants 
were removed and the concentration o f TNF measured by ELISA.
5.5.2 Results
The results o f this experiment are summarised in table 5.5.
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Concentration 
of LPS
8ng/ml 40ng/ml 200ng/ml 1 OOOng/ml
Control 3 2.3 2.1 2.7 3.2
Control 4 3.1 2.6 7.0 7.9
Table 5.5; LPS titration. TNFa concentration in wells in ng/ml
A concentration o f LPS which would induce significant cytokine 
production but which would not cause maximal cellular stimulation was 
considered ideal. In this way, it was thought more likely that small 
differences between cell populations would be identified. A final culture 
well concentration o f 200ng/ml o f LPS was therefore chosen for all future 
experiments (Figure 5.2).
5.6 Development of technique for patient group
Following these preliminary experiments, these methods were assessed in 
patients who presented with acute pancreatitis. In particular, it was 
important to ensure that the proportion o f monocytes in peripheral blood 
from patients with acute pancreatitis was sufficient to give a satisfactory 
yield o f cells. Also, it was not known how the behaviour o f monocytes 
following in-vivo activation might differ from those obtained from healthy 
donors.
5.6.1 Methods
In three successive patients entered into the octreotide study, blood was 
withdrawn within 48h o f admission for monocyte separation. The blood 
was transported to the laboratory at room temperature and separation 
commenced in each case within lh  o f venepuncture. The manufacturer's
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Figure 5.2: LPS titration
recommended methods were used as described above for separation of 
PBMC and subsequent positive selection of monocytes using the MACS 
system. The proportion o f monocytes in PBMC and in the final positively 
selected cell population were assessed using flow cytometry as described 
before.
5.6.2 Results
The results o f this experiment are shown in table 5.6
Patient
No
APACHE
II
PBMC No 
(xlO6)
PBMC
%CD14
Monocyte 
No (xlO6)
Monocyte 
% CD14
%extraction
17 6 21 25 <1 80 <11
18 11 8 20 <1 50 <31
19 6 25 51 <1 78 <6
Table 5.6 MACS separation of monocytes in patients 17, 18 and 19.
5.6.3 Discussion
These results were considerably worse than was achieved in the control 
subjects and the numbers o f monocytes obtained would have been 
insufficient for the purposes o f the present study. Possible reasons for the 
poor results in the patient group were considered as follows:
1. Low proportion o f CD14+ve cells in peripheral blood.
This reason was excluded by the flow cytometric analysis o f the PBMC 
obtained from these patients. In one patient, 51% of peripheral blood 
mononuclear cells were CD 14 positive, but despite this, less than 1x10^ 
monocytes were eventually obtained.
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2. Deterioration in antibody efficacy.
The microbead-conjugated anti-CD 14 antibody had been kept refrigerated 
at 4°C as suggested by the manufacturer. In view o f these results, 
however, a sample o f antibody was sent to the manufacturer in Germany 
for assessment. It was subsequently returned having performed 
satisfactorily in the laboratory.
3. The disease process could have altered the binding characteristics o f the 
CD-14 antigen resulting in poor extraction rates
4. Alteration in monocyte behaviour resulting in cell loss during separation 
procedure.
This was considered the most likely explanation for the results obtained in 
the patient group. As a result, the following conditions were changed;
5.7 A djustm ent to methodology
5.7.1 M ethods
1. The initial separation of peripheral blood on Ficol was carried out at 
room temperature to avoid subjecting the cells to  unnecessary changes in 
temperature. It was necessary to incubate the PBMC with the anti-CD 14 
antibody at 4°C for optimal antibody binding. Following this the MACS 
separation was carried out using washing buffer cooled on ice and a 
column which was cooled by the passage of this cooled washing buffer. 
Following MACS separation the cells were allowed to return to room 
temperature gradually prior to final resuspension in culture medium and 
culture at 37°C.
2. Bovine serum albumin (0.7%) and EDTA (5mmol/l) were added to the 
PBS used for all washes and for the MACS separation. This was in order
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to reduce the "stickiness" o f the monocytes to the various plastic containers 
used in the procedures and so minimise cell loss.
These methods were assessed with blood from a healthy control and Two 
patients with acute pancreatitis.
5.7.2 Results
The results o f this experiment are shown in table 5.7
Patient
No
APACHE
II
PBMC No 
(xlO6)
PBMC
%CD14
Monocyte 
No (xlO6)
Monocyte 
% CD14
%extraction
Control 0 50 38 7.6 97 39
26 6 40 28 3 97 26
30 7 12 35 2.2 96 50
Table 5 .7 : Monocyte extraction using modified methodology
It was therefore decided to use these methods for all subsequent 
separations and to use only these results for analysis. The detailed 
methodology finally used is given below.
5.8 M ethods used in patient study
5.8.1 Blood Collection
Anterior cubital fossa venepuncture was performed using a 19G butterfly 
needle with 1% propanol as skin disinfectant. Patients in an intensive care 
unit with an indwelling arterial cannula had blood withdrawn from it. 35ml 
of blood was taken into previously prepared 50ml centrifuge tubes 
containing 3.5ml of sterile 2.4% ethanoldiaminotetraacetic acid (EDTA) in
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PBS. Remaining blood was collected into blood bottles, 10ml for serum 
and 10ml for plasma/EDTA.
5.8.2 Separation of Peripheral Blood Mononuclear Cells
Blood samples were returned to the laboratory at room temperature 
following which separation o f peripheral blood mononuclear cells was 
carried out using a density gradient method.
Blood was diluted 1:1 with PBS containing EDTA 5mmol/l and bovine 
serum albumin 0.5% (PBS/EDTA/BSA) and layered 2:1 on ficol-hypaque 
density gradient medium (Lymphoprep, Nycomed UK).
Blood layered on Lymphoprep was placed in a centrifuge and spun at 600g 
for 30min at 20°C. Following this, the interface layers were removed using 
sterile pasteur pipettes and collected in universal containers. 
PBS/EDTA/BSA was added and the cells washed by centrifugation at 800g 
for 20min. The cell pellets were then resuspended and collected in one 
container . Cells were then washed twice at 400g for 12min at 20°C in 
order to  remove platelets. Finally the cell pellet was resuspended in 1ml o f 
PBS/EDTA/BSA and a viable cell count carried out by trypan-blue 
exclusion.
Trypan-blue is taken up only by dead cells, viable cells excluding it. 50ul o f 
cell suspension was diluted 1:100 in trypan blue and counted in a 
haemocytometer.
An aliquot o f cells was kept aside for subsequent analysis by flow 
cytometry. To the remainder o f the separated PBMC was added anti-CD 14 
microbeads (Bekton Dickinson), 20ul per 10^ cells. These were incubated 
at 4°C  for 20 min during which time the separation column was prepared
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for use. A column with a cell capacity o f 3x10^ cells was used. This was 
sterilised using 70% ethanol and then washed with a total o f 20ml of ice- 
cold PBS. The cell suspension was then passed through the column which 
was suspended within the MACS magnet and washed with 3 column 
volumes o f PBS/EDTA/BSA. A 22G needle was used to control the flow 
speed. Following this, the column was flushed from below and a further 3 
column volumes o f buffer washed through using a 20G needle. The cells 
washed through were collected in a universal container. The retained cells 
were then collected by removing the column from the magnetic field and 
gently flushing the column with 20ml o f cold PBS/EDTA/BSA. Both cell 
fractions were spun at 600G for 5 min at room temperature. The cell 
pellets were then resuspended in 1ml o f AIM V medium at room 
temperature and a viable cell count carried out using trypan-blue.
The monocyte fraction was diluted to a final cell density o f 5x10^ cells/ml 
and 1ml aliquots added to the wells o f a 24-well plate. To half o f the wells 
was added bacterial lipopolysaccharride (LPS 055 B5, Sigma) 20ul o f a 
lOug/ml suspension resulting in a final well concentration o f approximately 
200ng/ml. The plates were then cultured at 37°C in a 5% C02-enriched 
atmosphere for 24h. Following this the supernatants were removed and 
spun at 600G for 5 min. The clarified supernatants were then removed and 
frozen in Eppendorf containers at -30°C.
5.9 Discussion
Traditional magnetic separation systems use large magnetic particles which 
allow bound cells to be separated using a simple permanent magnet. Large 
particles, however, interfere with cell viability and may cause activation of 
cells by cross-linking o f cell-surface receptors278. Such techniques are 
usually only used for depletion o f cell populations. The use of magnetic
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microparticles (50-100nm) has a number of theoretical advantages; the 
binding reaction is faster, cross-linking o f cell-surface receptors is avoided, 
optical parameters are not affected allowing further analysis by flow 
cytometry and cell viability should be unaffected278. The major 
disadvantage is the lesser magnetic moment associated with such particles 
necessitating longer separation times in conventional magnetic fields. The 
cell separation method used in the present study was based on the use o f 
50-100nm superparamagnetic particles in a high gradient magnetic field as 
developed by Miltenyi and co-workers at University o f Cologne278. 
Monoclonal antibodies conjugated to these microbeads are available for a 
wide range o f cell-surface markers and the methods have been applied to 
positive selection o f NK-cells with no loss o f viability or alteration of 
function 279.
Dead cells will take up antibody in a non-specific fashion and it was 
considered possible that the positive selection method might result in a 
large population o f dead cells. However, the viability o f the final cell 
population was always in excess o f 95%. Every effort was made to 
minimise the trauma to cells during the separation process, including the 
avoidance o f sudden temperature changes, in order to minimise the 
proportion o f dead cells present.
The monocytes which were obtained using these methods retained their 
function with regard to cytokine secretion, and their ability to respond to 
an LPS stimulus was not impaired.
There were obvious differences between subjects in the proportion o f the 
available monocytes which were successfully extracted using these 
methods. Monocytes are not a functionally homogenous group o f cells and 
it is now known that smaller, immature monocytes secrete less cytokines in 
response to an appropriate stimulus than larger, mature cells283. Any 
tendency o f this methodology to select one type o f monocyte over another
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may therefore directly influence the results obtained. However, both 
functionally immature cells and mature cells are normally CD 14 positive283 
and there is no apparent reason why the methodology used in the present 
study should select one type in favour to another. In contrast, selection o f 
monocytes by cell size, as in countercurrent centrifugal elutriation and one- 
step density separation, may tend to  select a functionally distinct group of 
cells. The results o f the above experiment suggested that higher extraction 
rates occurred when a higher proportion of monocytes was present in the 
initial PBMC population. It was therefore assumed that the monocyte 
separation process removed a fraction o f the initial monocyte population 
which was representative o f the monocyte population as a whole and which 
was similar in nature between individual subjects.
5.10 Measurement of Cytokines
Two methods are available for the measurement o f cytokines; bioassay and 
immunoassay.
5.10.1 Bioassays
Bioassays utilise a biological effect o f the substance under test to measure 
the quantity o f the substance present in the test medium. In the case of 
TNF, cytotoxicity towards the murine cell line L-929 has been widely used 
as the basis o f a bioassay284. Although bioassays have the theoretical 
advantage that only bioactive cytokines are measured, there is considerable 
overlap in function between many cytokines and synergistic effects are also 
possible, such as is present between TNFa and IL-1284. Therefore, such an 
assay often lacks specificity for the cytokine under consideration.
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5.10.2 Immunoassays
Immunoassays utilise highly specific monoclonal and polyclonal antibodies 
to cytokines in order to accurately quantify the amount o f cytokine present 
in a test medium. These have the advantage over bioassays o f rapidity and 
specificity for the cytokine under test. Biological activity o f the test 
cytokine is, however, ignored284. Two types o f immunoassay are available 
depending on whether quantification is achieved with radiolabelled 
antibody (radioimmunoassay, RIA) or by enzyme-linked antibody causing a 
quantifiable colour change in the presence o f an appropriate substrate 
(enzyme-linked immunosorbent assay, ELISA).
All cytokines in the present study were measured by ELISA. IL-6, IL -lp  
and IL-8 were measured using commercially available kits. In the case of 
TNFa, an in-house ELISA was developed.
5.11 Development of TNFa ELISA
The principle o f the ELISA technique is outlined below.
5.11.1 Principles
The substance to be tested, in this case a cytokine, is "captured" from the 
test medium by antibody which is coated on the surface o f a plastic plate. 
The "capture antibody" is coated in sufficient density to allow binding o f all 
o f the antigen present. A second antibody is then added which is linked to 
an enzyme, usually phosphatase or peroxidase. It is essential that this 
antibody binds to a different epitope on the appropriate antigen. After the 
excess antibody is washed off, the remaining "bound" antibody can be 
quantified by adding a substrate solution which changes colour at a rate 
determined by the quantity o f enzyme, and thus the quantity o f the second 
antibody, present in the test well.
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A TN Fa ELISA was developed by modification o f a technique described 
by McIntyre et al190.
5.11.2 Antibodies used
A critical factor in the development o f an ELISA system is the availability 
o f two antibodies recognising distinct epitopes on the antigen molecule. 
For this reason, one monoclonal and one polyclonal antibody is often used, 
the polyclonal antibody hopefully recognising several epitopes on the 
antigen molecule. Paired monoclonal antibodies are also occasionally used. 
It was not possible to purchase ant-TNFa antibodies which had been tested 
in an ELISA system and several antibodies were tested before an optimal 
pairing was achieved.
As "capture" antibody, polyclonal rabbit anti-hTNFa (Genzyme 
Corporation, Cambridge, MA, USA, product code IP 300) was used.
As second antibody, monoclonal anti-hTNFa was used (Boeringher- 
Mannheim GmbH, Germany, Cole 195, Cat No. 1141325)
This was based on a double antibody sandwich technique284 utilising 
polyclonal capture antibody and monoclonal anti-TNFa as secondary 
antibody. Bound secondary antibody was then quantified in two stages 
using firstly, biotinylated anti-mouse monoclonal antibody followed by 
streptavidin-conjugated alkaline phosphatase (both Boeringher Mannheim). 
Plates were read at 415nm and results calculated against a standard curve 
which was generated with serial dilutions o f recombinant human TNFa 
(Genzyme).
I l l
5.11.3 Buffers 
Carbonate Buffer
Na2C 0 3 1.59g 
N aH C03 2.93g
Dissolved in distilled, deionised water and made to 1 litre. pH corrected to 
9.6 with 4M HC1.
Wash Buffer
Phosphate buffered saline (Sigma) with 0.1%Tween
Alkaline Buffer
Diethanolamine 100g/l, pH 10
Alkaline Substrate
Phosphatase substrate 2mg/ml
5.11.4 Methods
1. Immulon II assay plates were used. Preliminary experiments were carried 
out to determine the optimal concentrations o f polyclonal and monoclonal 
antibodies. Dilutions o f 1/1000 of each were found to be optimal.
Rabbit polyclonal anti-TNF (Genzyme) was used as capture antibody.
This was diluted in carbonate buffer at a dilution o f 1/1000 with 50ul being 
added to each well.
2. The plates were incubated for 2 hours at 37°C in a humidified box.
3. The plate contents were discarded and lOOul o f PBS with 2.5%BSA 
added to  each well following which the plates were incubated at 4°C 
overnight. This step ensures blocking o f non-specific binding sites in the 
microtitre wells and improves the specificity o f the assay.
4. The plates were washed twice with PBS/Tween.
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5. Serial dilutions o f TNF standard (Genzyme) were added to each well 
with concentrations from 20 to 0.15ng/ml. The plates were incubated for 
lh  at 370C.
7. The plates were washed twice in PBS/Tween.
8. Anti-hTNFa monoclonal antibody (Boeringher Mannheim) was then 
diluted, 1/1000, in PBS and 50ul aliquots added to the wells.
9. The plates were incubated for lh  at 37°C.
10. The plates were washed twice in PBS/Tween.
11. Biotinylated anti-mouse (Boeringher-Mannheim) was diluted 1/4000 
and 50ul added to each well.
12. The plates were incubated for lh  at 37°C.
13. The plates were washed twice in PBS/Tween.
14. Streptavidin alkaline phosphatase (Boeringher-Mannheim) was diluted 
1/4000 and 50ul added to each well.
15. The plates were incubated for 30min at 37°C.
16. The plates were washed twice using PBS/Tween.
17. lOOul of alkaline substrate (Sigma, 2mg/ml) in alkaline buffer was 
added to each well.
18. The absorbence was read at 415nm after 20min and thereafter until 
satisfactory readings were obtained.
5.11.5 Calculation of results
Standard curves were prepared with the data from the standard wells. The 
mean absorbence between the three triplicate wells was calculated and 
plotted against the concentration in ng/ml. The graph was linearised by 
logarithmic transformation o f both X and Y axes and an equation 
calculated for this line (using Microsoft Cricket Graph). Unknown samples 
were then calculated by solution o f this equation for X (concentration).
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5.11.6 Reproducibility of results 
Methods
Two plates were prepared with three concentrations of TNFa (0.15, 1.5 
and 15ng/ml) each plated 15 times per plate. The plates were treated as 
above, standard curves calculated and results obtained to calculate within- 
plate variability.
Eight plates were prepared with single wells containing 0.15, 1.5 and 
15ng/ml o f TNFa. Plates were treated as above, standard curves calculated 
and results for these wells calculated against the standard curves in order to 
calculate between-plate variability.
Results
The results o f these experiments are summarised in tables 5.8, 5.9 and 
5.10.
Plate 1 Mean TNF Standard deviation %CV
0.15ng/ml 0.2 0.02 10
1.5ng/ml 1.34 0.13 9.7
15ng/ml 18.1 3.5 19.4
Table 5.8 Within-plate variability
Plate 2 Mean TNF Standard deviation %CV
0.15ng/ml 0.16 0.015 9.4
1.5ng/ml 1.4 0.19 13.6
15ng/ml 13.2 1.9 14.4
Figure 5.9 Between-plates variability
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Mean TNF Standard deviation %CV
0.15ng/ml 0.16 0.029 18
1.5ng/ml 1.27 0.212 16.5
15ng/ml 17.2 3.48 19.7
Table 5.10 Linearity of standard curve
Two typical standard curves are shown in figure 5.3. The curves were 
consistently straight between 0.5 and lOng of TNF/ml.
5.12 IL-6 , IL-8 and IL-ip ELISA
Initial attempts were made to develop in-house ELISA assays for both IL-6 
and EL-1(3 but no suitable antibody combination was found and these 
attempts were eventually abandoned. All assays o f IL-6, IL -lp  and IL-8 
were carried out using commercially available ELISA kits (Amersham 
UK).
Methods
1. Samples and standards were added to each well o f a pre-coated 96 well 
plate. The ELISA kit was designed for plasma samples and a preliminary 
test run indicated that the appropriate dilution for the monocyte culture 
supernatant samples was 1/100 in the case o f IL-6 and IL-1 and 1/1000 in 
the case o f IL-8.
2. The plates were then incubated for 2 hours at room temperature.
3. The plates were then washed three times following which peroxidase- 
conjugated polyclonal anti-IL-6 or IL-1 P as appropriate was added to each 
well and plates incubated for 2h at room temperature..
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4. The plates were then washed three times and substrate solution 
(stabilised hydrogen peroxide with tetramethylbenzidine) added to each 
well and the plates incubated for 20min at room temperature. Stop solution 
(1M sulphuric acid) was then added to each well and the plates read on a 
spectrophotometer at a wavelength of450nm.
5. Standard curves were then obtained after logarithmic conversion o f the 
optical density readings and standard concentrations. Regression equations 
were then calculated for the linear standard curve and this was used to 
calculate the concentration o f IL-6, IL-8 and EL-ip in the samples.
Reproducibility
IL-6.
The IL-6 assay had a sensitivity o f 0.35pg/ml. The within assay variation 
was between 2.7%CV to 4.2%CV. Between plates variation was between 
2.4%CV and 7%CV depending on sample concentration.
I L - lp
The IL -ip  assay had a sensitivity o f 0.3pg/ml. The within assay variability 
was between 2.3 and 3.1%CV. The between plates variability was 3.4%CV 
to 7.2%CV depending on sample concentration.
IL-8
The IL-8 assay had a sensitivity o f 3.3pg/ml for cell culture samples. The 
within assay variability was <10% and the between assays variability was 
also <10%.
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Chapter 6
Study of peripheral blood monocyte activation in patients with acute 
pancreatitis.
6.1 Introduction
Using the methods developed above, a study was undertaken to examine 
the role o f mononuclear phagocyte activation in the pathophysiology o f the 
systemic illness in acute pancreatitis. The aims o f this study were twofold.
6.2 Aims
1. To assess the degree o f activation o f peripheral blood mononuclear cells 
in patients with acute pancreatitis in relation to the development o f 
systemic complications.
2. To determine if the administration o f octreotide to patients with acute 
pancreatitis was associated with a reduction in monocyte activation, as a 
results o f its putative effect on reticuloendothelial function.
6.3 Patients
Twenty-eight sequential patients entered into the octreotide trial described 
in chapter 3 were studied (patient no.30-58). Patient 44 was not studied as 
she died before blood was obtained.
6.4 Methods
It was intended that blood should be taken on the first, third and fifth days 
after admission for the study o f monocyte function. Where possible this 
was carried out but in patients who died early in the course o f the illness 
this was obviously not possible. In other instances, insufficient monocytes 
were obtained to enable monocyte cultures to be established and complete
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data for all three proposed days o f study were therefore not obtained for 
every patient.
The first blood sample was usually taken on the morning after the trial drug 
infusion was commenced. 30ml o f venous blood was withdrawn and placed 
in a 50ml centrifuge tube containing 3.5ml o f 2.4%EDTA in PBS. These 
tubes were prepared in batches under sterile conditions by myself. The 
blood was then immediately taken to the laboratory at room temperature 
and monocyte separation carried out using the methods described above. 
Monocytes were suspended in AIM V medium at a final cell density of 
5x10^ cells/ml and cultured for 24h at 37°C in a CC>2-enriched, humidified 
incubator. The culture supernatants were then removed using a pasteur 
pipette and clarified by centrifugation. The supernatants were then 
transferred to sterile Eppendorf containers using a pasteur pipette and 
labelled appropriately. The Eppendorf containers were then stored in racks 
at -30°C.
TNFa, IL-6, IL -ip  and IL-8 were measured by ELISA using the methods 
described above. All results were expressed in ng/ml.
Results were compared on each day o f study and, in addition, peak levels 
were compared between patients. Statistical analysis was by Mann-Whitney 
U test for non-parametric data.
The systemic complications which were recorded were as follows.
Respiratory insufficiency; arterial PO2 < 8kPa requiring either prolonged 
facemask oxygen or assisted ventilation.
Renal insufficiency; serum creatinine > 180uml/l despite fluid resuscitation. 
Shock; systolic blood pressure < lOOmmHg.
Pleural effusion; confirmed radiologically.
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6.5 Results
O f the 28 patients studied 14 were male and 14 female with a mean age of 
58 (range 25-92). Gallstones were identified as a cause o f acute 
pancreatitis in 16. O f the remainder, nine gave a history of chronic alcohol 
excess and in three patients the aetiology o f acute pancreatitis was not 
identified. The delay from onset o f symptoms to first blood sample varied 
from 12 to 102 hours (median 36h).
Sixteen patients had evidence o f systemic complications during the first 5 
days of illness (table 6.1 ). A further two patients had evidence of 
coexisting cholangitis, as defined by the presence o f jaundice and fever, 
(patients 46 and 50) and, in view o f the known effects o f sepsis on cytokine 
production, these patients were excluded from further analysis. Both had 
an otherwise uncomplicated clinical course. The remaining ten patients had 
no evidence o f systemic complications during the course o f their stay.
Patient No Complication Death
31 RF
33 MSOF Day 2
34 ARF
35 RF
36 RF
37 MSOF Day 27
39 ARF
40 RF Day 20
42 RF Day 4
43 RF
48 RF
51 RF
52 RF
55 RF
56 RF
58 PE
Table 6.1: Complications
119
Those patients with systemic complications are described below and are 
identical to those with systemic complications described in chapter 2 with 
the exception o f patient 34. For the purposes o f the clinical trial, patient 34 
was considered to have an uncomplicated course as all biochemical and 
clinical signs o f systemic illness had settled within 24h o f starting the trial 
infusion. However, at the time when the blood sample was taken for the 
study of monocyte function the patient had biochemical evidence o f renal 
impairment and clinical evidence o f a significant systemic illness.
Patient 31 was admitted to ITU within 24h o f hospital admission due to 
deteriorating respiratory function. He was ventilated for 9 days during 
which time there was no deterioration in renal function and despite a 
persistent tachycardia, remained haemodynamically stable. He developed a 
pancreatic fluid collection which was defined on CT at day 16 but this 
settled with conservative management. There was no evidence o f 
pancreatic necrosis.
Patient 33, like patient 31, was admitted to ITU soon after admission and 
required full ventilatory and circulatory support. He became anuric 
overnight and died on the following day o f multiple organ failure.
Patient 34 was admitted almost 60h after the onset o f abdominal pain and 
had evidence o f renal impairment at admission. He was grossly acidotic 
with II+ levels o f 78mmol/l. He was treated with fluid resuscitation and his 
renal function improved rapidly. He took his own discharge on day 2 while 
suffering alcohol withdrawal symptoms.
Patient 35 had early respiratory impairment treated by facemask oxygen 
but was admitted to ITU with ARDS on day 7. He required assisted
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ventilation for 5 days and subsequently made an uneventful recovery, being 
discharged on day 22.
Patient 36 had early renal and respiratory impairment. Her serum 
creatinine initially rose but returned to normal after 4 days. She had 
hypoxia requiring facemask oxygen for 5 days and subsequently developed 
an acute fluid collection which settled on conservative management.
Patient 37 had prognostically severe acute pancreatitis and initial hypoxia 
which required facemask oxygen for the duration o f her hospital stay (27 
days). She had clinical evidence o f a right basal consolidation on day 12 
and remained hypoxic. On day 23 she developed acute renal failure and 
underwent laparotomy and necrosectomy for infected pancreatic necrosis 
on day 27. She died several hours postoperatively from uncontrolled 
bleeding.
Patient 39 had a rising urea and creatinine from admission which was 
associated with high volumes o f dilute urine. He also had hypoxia for 4 
days after admission along with a sizeable pleural effusion and required 
facemask oxygen for 5 days. His renal impairment eventually settled 
without the need for haemodialysis.
Patient 40 was an elderly lady who required facemask oxygen for 3 days 
after admission for hypoxia. She initially made a good recovery but 
developed bronchopneumonia and died on day 21. Her family refused 
permission for a post-mortem.
Patient 42 had long-standing chronic obstructive airways disease and was 
severely hypoxic on admission. She was initially managed with facemask
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oxygen but developed a cerebrovascular accident on day 3, dying on day 4. 
Once again, post-mortem was refused.
Patient 43 was hypoxic for 7 days after admission but was managed with 
facemask oxygen. She also developed an acute fluid collection and a large 
pleural effusion.
Patient 48 had a laparotomy because o f diagnostic doubt and was found to 
have acute pancreatitis at operation. He developed respiratory insufficiency 
postoperatively but this had resolved by day 4. He subsequently made an 
uneventful recovery.
Patient 51 was hypoxic for 5 days and treated by prolonged facemask 
oxygen. His recovery, however, was otherwise rapid and he was 
discharged from hospital on day 7.
Patient 52 had a complicated course with early hypoxia and renal 
impairment. He developed Gray-Tumer's sign on day 5 along with 
radiological evidence o f a basal consolidation. He had a staphylococcus 
aureus septicaemia on day 4 and an acute fluid collection on ultrasound. He 
died on day 8 and at post-mortem was found to have necrotising 
pancreatitis with evidence o f a recent myocardial infarction
Patient 55 had respiratory impairment from admission which necessitated 
care in the intensive care unit. She was managed on facemask oxygen 
initially but was ventilated on day 5 for a further 5 days. Her subsequent 
recovery was uneventful.
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Patient 56 had respiratory impairment on days 1 and 2 and had facemask 
oxygen continued for 5 days. He also developed a pleural effusion but was 
discharged on day 14 with no further complications.
Patient 58 had respiratory insufficiency requiring 3 days o f facemask 
oxygen along with a large pleural effusion and tachycardia. Subsequent 
recovery was uneventful and she was discharged on day 14.
TNFa
Complications
Peak cytokine secretion is shown in figure 6.1. Peak lipopolysaccharide- 
stimulated TNFa secretion by monocytes isolated from patients with 
systemic complications was higher (median=18.5ng/ml, IQR=5.5-28.5) 
than by those isolated from patients with an uncomplicated course 
(3.7ng/ml, 2.3-6.4 P<0.01). Highest levels o f monocyte TNFa secretion 
were seen on days one and three affer admission and were significantly 
higher in the complicated group (figure 6.2). There was a significant 
positive correlation between peak monocyte TNFa secretion and the 
degree o f systemic illness as assessed by the maximum Acute Physiology 
Score (APS, component o f the APACHE II score) during the five days o f 
study (r=0.658, PO.OOl) (figure 6.3).
IL-6
Peak IL-6 secretion by monocytes (figure 6.1) was significantly higher in 
patients who developed systemic complications (48.9ng/ml, 12.1-71) than 
in those with an uncomplicated course (16.3ng/ml, 14.2-37.9 P<0.05). 
Highest levels o f monocyte IL-6 secretion were also seen on days one and 
three after admission and on these days were significantly higher in the 
complicated group (figure 6.4). There was a significant correlation
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Figure 6.1;Peak cytokine secretion in complicated and uncomplicated 
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Figure 6.3: Peak TNF levels and peak APS. r=0.658 , P<0.001
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between peak monocyte IL-6 secretion and the peak APS (r=0.587, 
P<0.01) and between peak IL-6 and TNFa secretion (r=0.678, 
P<0.001).(figures 6.5, 6.6)
IL-8
Peak monocyte IL-8 secretion (figure 6.1) was significantly higher in the 
group of patients with systemic complications (748ng/ml, IQR 643-901), 
than in those with an uncomplicated course (608ng/ml, 496-749, P<0.05). 
Once again, highest levels of monocyte IL-8 secretion were observed on 
days one and three (figure 6.7) and there was a positive correlation 
between peak monocyte IL-8 secretion and the peak APS (r=0.492, 
P<0.02) (figure 6.8)
IL-1 (3
In contrast to the findings with TNFa, IL-8 and IL-6, systemic 
complications were not associated with significantly higher peak monocyte 
IL -ip secretion (complicated group 2.9ng/ml, 1.4-3.4; uncomplicated 
group 1.65ng/ml, 1.2-1.9 P=NS) although significantly higher levels of 
monocyte IL-1 p secretion were observed on day five in the complicated 
group (figure 6.9). There was no significant correlation between peak 
monocyte IL-1 P secretion and peak APS or between peak monocyte IL-1 p 
secretion and peak monocyte TNFa or IL-6 secretion.
Influence of aetiology and therapy
Of the 16 patients who developed systemic complications, 8 had evidence 
of gallstones. On each day of study, there was no significant difference 
between levels of secretion of the 4 cytokines in patients with proven 
gallstones and patients with acute pancreatitis o f other aetiologies (figures 
610-6.13). There was no significant difference in peak cytokine secretion
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Figure 6.6: Peak IL-6 and peak TNF secretion. r=0.678, P<0.001.
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Figure 6.10; TNF secretion: effect of aetiology
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Figure 6.12; IL-8 secretion: effect of aetiology
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Figure 6.13; IL-1 secretion: effect of aetiology
between those with gallstone related acute pancreatitis and those with 
acute pancreatitis of other aetiologies (figure 6.14): (peak TNFa, no 
gallstones median 5.95ng/ml, IQR 3.1-20.4, gallstones 8.75ng/ml, 5-26.4; 
peak TL-lp, no gallstones median 1.45ng/ml, IQR 1.1 -1.3, gallstones 
2.25ng/ml, 1.6-4.0; peak IL-6 no gallstones median 17.4ng/ml, IQR 9.7-60, 
gallstones 32.4ng/ml, 14.6-61; peak IL-8 no gallstones median 741ng/ml, 
IQR 582-766, gallstones 735ng/ml, 535-790)
Effect of O ctreotide on Monocyte Activation
The possible effect of octreotide on cytokine secretion was examined. Ten 
of 14 patients in the octreotide group developed complications (71%) 
compared with six of 12 in the placebo group (50%). On each day of study, 
secretion of TNFa, IL-1 (3, 1L6 and IL-8 was not significantly different in 
patients receiving placebo or octreotide (figures 6.15-6.18), There were no 
significant differences between peak levels of cytokine secretion between 
patients in the placebo and octreotide groups (figure 6.19): (peak TNFa 
secretion placebo group median 12.8ng/ml, IQR 2.5-28.1, octreotide group 
6.6ng/ml, 3.94-14.6; IL-6 placebo group median 28.5ng/ml, IQR 14.5- 
55.1, octreotide group 20.7ng/ml, 11.6-62.3; IL-8 placebo group median 
744ng/ml, IQR 594-804, octreotide group 716ng/ml, 549-774; IL -ip 
placebo group median 2.7ng/ml, IQR 1.4-4.2, octreotide group 1.8ng/ml, 
1.3-2.9).
6.6 Discussion
Pro-inflammatory cytokines have been demonstrated to be elevated in 
plasma from patients with acute pancreatitis38'40,192’285 but the source of 
these cytokines and their relevance to the pathophysiology of the disease 
process is unclear. This study has demonstrated for the first time that 
monocyte secretion of the pro-inflammatory cytokines, TNFa, IL-6 and
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Figure 6.19; Effect of octreotide on peak cytokine secretion. ( IL-8 result 
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IL-8 is increased in patients with systemic complications in acute 
pancreatitis. There was also a strong correlation between peak IL-6, IL-8 
and TNFa secretion and the peak acute physiology score. These findings, 
coupled with the known physiological effects o f TNFa, IL-8 and IL-6, 
strongly suggests that these cytokines are early mediators o f the systemic 
illness in acute pancreatitis.
It is recognised from previous reports that raised plasma levels o f IL-6 are 
present in patients with severe acute pancreatitis, with peak levels 
occurring within the first three days after admission38"40. In the present 
study, the highest levels o f monocyte IL-6 secretion were observed during 
the first three days following admission, being similar to the time course of 
the peak in plasma levels observed by previous authors. This provides 
further evidence that IL-6 is involved in the mediation o f the systemic 
illness associated with acute pancreatitis and furthermore, suggests that 
mononuclear phagocytes are a principal source of IL-6 in acute 
pancreatitis. The main target organ o f IL-6 is the liver182 and within the 
liver, it is exclusively taken up by parenchymal cells. After binding to the 
hepatocyte IL-6 receptor, IL-6 induces a shift in hepatocyte protein 
synthesis away from albumin and transferrin towards acute phase reactants 
such as C-reactive protein, fibrinogen and alpha-1-antitrypsin182. This 
response is generally thought to be protective to the host since IL-6 is not 
associated with the vascular damage seen with TNFa and IL-1 (3.
In acute pancreatitis, many o f the circulating factors which have been 
shown to have prognostic significance may be indirectly linked to the 
actions o f IL-6. Low serum albumin levels are commonly seen in acute 
pancreatitis with levels less than 32g/l being included in the multiple factor 
prognostic scoring systems o f both Ranson et al and Imrie et al. Low serum 
albumin levels may be a consequence of loss o f albumin into the peritoneal
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cavity or extravascular space as a result o f capillary leak but may also 
reflect the actions o f IL-6 on hepatocyte function182. Low albumin levels 
are also seen in patients with sepsis where intraperitoneal albumin loss is 
less prominent.
C-reactive protein levels have been shown by several groups to have 
prognostic significance in patients with acute pancreatitis37,39,41’286,287. Peak 
levels of greater than 210mg/ml41 or 150mg/ml39 have been reported to 
indicate severe pancreatitis and this has been attributed to the associated 
rise in plasma IL-6 which has been shown to correlate with and precede the 
rise in serum CRP39. In the present study, there was only a weak 
correlation between peak CRP levels and peak IL-6 production (r=0.33). 
This finding may be a consequence o f the fact that cells other than 
circulating monocytes are capable of secreting IL-6 in-vivo. Fibroblasts, 
endothelial cells and fixed tissue macrophages all produce EL-6182 and may 
contribute more to the circulating pool o f IL-6 than monocytes. In 
addition, Kupffer cells have been shown to be capable o f the production of 
large quantities o f IL-6 and these may be a main source o f circulating IL-6 
in acute pancreatitis288. Polymorphonuclear neutrophils have also been 
shown to express large quantities o f IL-6 following experimental 
endotoxaemia289. However, the functional status o f circulating monocytes 
would be expected to be indicative o f the secretion o f IL-6 by other 
cytokine-producing cells, although quantitatively other cells may play a 
more important role. A further factor influencing the EL-6 results may be 
that IL-6 production by monocytes is induced by TNFa rather than directly 
by endotoxin. In the in-vitro conditions o f this study, IL-6 production may 
be simply a reflection o f TNFa production in response to endotoxin and 
not o f the functional status o f monocytes in relation to IL-6 production. 
However, against this is the weak positive correlation between peak DL-6 
secretion and TNFa secretion (r=0.672).
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Previous studies on TNFa in the peripheral blood o f patients with acute 
pancreatitis have met with inconclusive results5,6. Furthermore, by 
measuring plasma levels o f TNFa, these studies take no account o f 
possible transient rises in TNFa or o f increased TNFa production at a 
cellular level. The presence o f TNFa inhibitors and binding proteins further 
complicates the measurement o f plasma TNFa and makes the 
interpretation of negative results difficult189. By studying monocyte TNFa 
secretion directly, the present study avoids these difficulties and provides a 
measure o f the activation status o f mononuclear phagocytes at each time 
point which it is assumed reflects the likely behaviour o f these cells in-vivo. 
The present study provides the first conclusive evidence o f a role for TNFa 
in the mediation o f the systemic complications o f acute pancreatitis. TNFa 
is produced by monocytes, fixed tissue macrophages and other cell types, 
the main stimulus to its production being endotoxin141,210,290. It is capable of 
reproducing the clinical and histological effects o f sepsis-induced multiple 
organ failure and there is now good evidence that excessive or unregulated 
production o f TNFa is pivotal to the development o f systemic 
complications in sepsis4. There are many clinical and experimental 
similarities between the pattern o f illness in septic patients and those with 
severe acute pancreatitis but whereas the role of TNFa and other cytokines 
is now generally accepted in sepsis, a similar role for TNFa in acute 
pancreatitis has not been established. The main reasons for this are the 
failure o f studies in pancreatitis to reproduce the findings o f similar studies 
in sepsis in demonstrating raised plasma levels of TNFa in association with 
the development o f complications and the absence o f studies examining 
TNFa in experimental pancreatitis. It is worth examining both o f these 
facts in light o f the results o f work presented since the present study was 
commenced.
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In the first study to examine TNFa in acute pancreatitis, Banks and 
colleagues from Leeds5 studied 27 patients with a clinical and biochemical 
diagnosis o f acute pancreatitis, taking daily venous blood samples during 
the first week o f hospitalisation. Receptor-bound elastase was measured by 
ELISA and TNFa by radioimmunoassay. Eight o f their patients were 
graded as severe o f whom 4 died. The exact nature o f the complications 
which occurred is not reported and in two o f the severe group only local 
complications occurred.
Plasma levels o f elastase were significantly higher in the patients graded as 
severe compared with the mild group although there was considerable 
overlap between groups and the highest level was in one patient who had 
an uncomplicated course. Levels o f TNFa were variable and in many 
patients remained normal. The median TNFa levels in the severe group 
were higher than in the mild group but not significantly so. The authors 
concluded that neutrophil activation occurred in severe acute pancreatitis 
but that there was no evidence to suggest macrophage activation.
In a second study, Exley and co-workers from London and Leicester6 
studied 38 patients with prognostically severe acute pancreatitis (as defined 
by the presence o f three or more positive Glasgow criteria). Venous blood 
was withdrawn on the first, third and seventh days after admission and 
serum TNFa measured by ELISA. In this selected group o f patients there 
were 11 deaths and a further 3 patients with significant complications who 
survived. Day 1 serum TNFa was more frequently measurable in the non- 
survivors (45% v 23%) but of the patients who had no detectable TNFa at 
presentation, 4 developed multiple organ failure and one developed adult 
respiratory distress syndrome (ARDS) indicating a poor association 
between TNFa levels and the development o f systemic complications. 
There was a stronger association between TNFa levels and complications 
in those with gallstone pancreatitis.
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In both o f these studies the authors have examined the association between 
TNFa levels and all complications whereas it would be more relevant to 
restrict analysis to those with systemic complications. Many patients have 
evidence o f minor degrees of systemic organ involvement, particularly 
respiratory impairment, who have an otherwise uncomplicated outcome 
and may have been classified as such in both of these studies.
In another study, De Beaux and colleagues291 measured TNFa and plasma 
levels o f soluble TNFa receptors in patients with acute pancreatitis. TNFa 
itself was rarely present in plasma but increased levels o f circulating 
receptors were seen in those patients with complicated attacks., suggesting 
that the levels o f TNFa receptor may be a better indicator o f TNFa release 
than measurement of TNFa itself.
The main criticism of these studies, however, is the use o f plasma or serum 
TNFa levels as indicators o f macrophage TNFa production. As has 
already been discussed, the short circulation half-life o f TNFa and the 
unpredictable effect o f TNFa-binding proteins on ELISA detection make 
conclusions based on such data difficult and it is certainly not possible to 
exclude a pathophysiological role for TNFa on the basis o f such studies. 
The second problem in assessing the role o f TNFa in acute pancreatitis is 
the absence, until recently, of studies in experimental acute pancreatitis. 
The vast majority o f the research which has led to our current 
understanding o f the pathophysiology o f sepsis has come from 
experimental models where TNFa infusions have been used to reproduce 
the effects o f septic shock and where anti-TNFa antibodies have been 
shown to protect against the deleterious effects o f endotoxin infusion. 
There is no model o f acute pancreatitis which is universally accepted as 
being representative o f the human disease with many causing death by 
rapid and overwhelming protease activation, a process which does not 
appear important in man. At a more practical level, most models involve
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the use of rats or dogs where measurement o f cytokines in these species is 
very much more difficult than in mice, for which antibodies and 
commercially available cytokine ELISA kits are available. Recently, 
however, plasma TNFa has been measured in a model of acute pancreatitis 
with some success. In a bile injection model in the rat, workers from 
Belfast have identified two peaks in TNFa plasma levels following the 
induction o f acute pancreatitis292. The same group have recently 
demonstrated raised intraperitoneal TNFa in association with peritoneal 
endotoxin in the bile injection model (S Dolan, personal communication). 
Formela and colleagues in Liverpool have demonstrated apparent TNFa 
production by pancreatic acinar cells in a microvascular ischaemia model of 
acute pancreatitis293. It has been suggested, but is as yet unproven, that the 
early TNFa peak in experimental pancreatitis mat be the result o f local, 
pancreatic TNFa production with a late peak corresponding to the 
activation o f systemic monocytes and macrophages. This work is, however 
at an early stage and the results o f ongoing studies are awaited.
No evidence was found o f a rise in monocyte IL-1 (3 secretion in association 
with systemic complications. It is interesting to note that reports on serum 
levels o f IL-1 (3 in human sepsis are variable and, unlike TNFa and IL-6, 
levels do not appear to correlate with mortality161,181. There are no 
published reports on plasma IL -ip  levels in acute pancreatitis and the role, 
if any, of this cytokine in acute pancreatitis remains unclear.
IL-8 is a potent activator o f neutrophils and may be the key cytokine 
involved in the neutrophil activation associated with acute lung injury294. In 
the present study, increased IL-8 secretion by monocytes was increased in 
association with the development o f systemic complications and reports are 
now beginning to appear suggesting that serum IL-8 levels are increased in
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patients with acute pancreatitis192,285’295. IL-8 is secreted not only by LPS- 
stimulated mononuclear phagocytes but also by other cells, particularly 
endothelial cells, after activation by TN Fa184. In this way IL-8 is thought to 
be the principal secondary mediator o f TNFa-induced neutrophil 
activation. Although monocyte IL-8 production is increased in association 
with the development o f systemic complications, this may not accurately 
represent the in-vivo role o f IL-8, the prime source o f which may be 
endothelial cells and other cell groups activated by TNFa.
Four patients who developed severe systemic complications had 
persistently low levels o f monocyte TNFa secretion. Three o f these 
patients had alcohol-related acute pancreatitis and this raises the possibility 
that cytokine secretion is partly dependent on aetiology. Alcohol has a 
variety o f effects on the immune system and has been shown to 
downregulate TNFa production by human monocytes296. However, raised 
levels of cytokine secretion were found in other patients with alcoholic 
pancreatitis and overall there was no difference in peak cytokine secretion 
in those patients with pancreatitis due to gallstones and those with 
pancreatitis o f other aetiologies.
Another explanation for the findings in these three patients may have been 
delay in presentation, allowing the peak in TNFa secretion to be missed. 
However, the time from onset o f symptoms to first blood sample in this 
group was similar to that in the remainder o f the patients. In three o f these 
patients, however, IL-8 secretion was high by the time o f first blood 
sample. As EL-8 has been found to peak later than TNFa, this is suggestive 
that an earlier rise in TNFa may have been missed. In the remaining 
patient, secretion o f all three cytokines was persistently low the reason for 
this being unclear.
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Octreotide has been reported to stimulate reticuloendothelial function in- 
vivo and monocyte function in-vitro7,238 therefore the possible influence o f 
its administration to the patients in this study was examined. However, 
peak levels o f cytokine secretion were similar in patients receiving 
octreotide with those receiving placebo and a similar systemic complication 
rate being observed in the two groups o f patients. There was therefore no 
evidence in the present study that octreotide administration reduced the 
degree o f monocyte activation in these patients.
The main stimulus to mononuclear phagocyte activation is bacterial 
endotoxin. For many years it has been known that patients with severe 
acute pancreatitis frequently have endotoxaemia6,193-196 and that this is more 
commonly observed in patients with complicated disease. In acute 
pancreatitis, the combination o f a reduction in splanchnic blood flow and 
local peritonitis may result in an increase in transluminal absorption o f 
endotoxin with subsequent passage through the portal circulation. Impaired 
hepatic reticuloendothelial function may facilitate the passage o f endotoxin 
into the systemic circulation. This sequence o f  events may explain the 
activation o f circulating mononuclear phagocytes observed in this study.
A further consideration is the recent finding that monocyte cytokine 
production is not simply determined by the degree o f cellular activation but 
that there are differences between individuals. Molvig et al297 demonstrated 
that, within individuals, the secretion o f TNFa and IL-1 (I were closely 
correlated and suggested that in HLA-DR2 positive individuals, monocyte 
responses to endotoxin are lower than in HLA-DR2 negative individuals. 
Further evidence of a role for HLA haplotype in the determination o f 
monocyte responses to endotoxin came from Santamaria and colleagues298 
who confirmed the influence o f HLA-DR2 haplotype on cytokine secretion 
and found that certain haplotypes in individuals heterozygous for the HLA-
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DR2 haplotype could also be classified as low or high secretors o f TNFa 
and IL-1 p. The explanation for these findings probably lies in the location 
o f the TNFa gene which is situated in the major histocombatibility complex 
on chromosome 6. Allelic polymorphisms within the TNFa gene have been 
identified299 and the association between IILA class II haplotype and TNFa 
secretion may reflect linkage disequilibrium between the TNFa allele and 
the nearby class II locus. In this way TNFa secretion in response to 
endotoxin may be genetically determined and certain individuals may 
therefore be more at risk o f developing the associated systemic 
complications.
In summary, increased monocyte release of the inflammatory cytokines, 
TNFa, IL-8 and IL-6 but not IL -ip, has been demonstrated in association 
with the development o f systemic complications o f acute pancreatitis. This 
provides evidence that the systemic effects o f acute pancreatitis may be 
mediated by activation o f mononuclear phagocytes and increased cytokine 
release which, if confirmed by further study, may lead to trials o f new 
therapeutic agents designed to modulate this aberrant host response.
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Chapter 7
Polymorphonuclear elastase in acute pancreatitis as a marker of 
neutrophil activation
7.1 Introduction
Many of the effects o f the cytokines released from mononuclear 
phagocytes are mediated by neutrophils300, which release free oxygen
301 302species and proteolytic enzymes causing endothelial damage ’ 
Neutrophil aggregation and superoxide production have been demonstrated 
in experimental models o f pancreatitis and antibodies to neutrophils
O A O  O A  J
attenuate the severity o f lung injury in experimental pancreatitis ’ 
Increased neutrophil superoxide production has also been demonstrated in 
patients with acute pancreatitis305. Polymorphonuclear elastase (PMNE) is 
an enzyme released by neutrophils and increased plasma levels o f PMNE 
are though to reflect neutrophil activation. Raised levels o f PMNE have 
been demonstrated in the plasma and bronchoalveolar lavage fluid o f 
patients with septic shock306 and also in the plasma o f patients with acute 
pancreatitis36,37,42.
In the preceding chapter, monocyte activation w as demonstrated in 
patients with acute pancreatitis. Increased production o f pro-inflammatory 
cytokines by monocytes and mononuclear phagocytes would be expected 
to result in neutrophil activation and therefore raised plasma levels of 
PMNE. Measurement o f PMNE in acute pancreatitis may therefore be a 
simple method o f assessing the degree o f leucocyte activation which would 
allow the early identification o f patients at risk o f developing systemic 
complications.
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7.2 Aims
Levels o f PMNE were compared with the degree o f monocyte cytokine 
production in individual patients to assess the relationship between PMNE 
and the cytokine response. The potential o f plasma PMNE as a prognostic 
marker in acute pancreatitis was also assessed.
7.3 Patients
Thirty seven patients entered into the randomised, controlled trial o f 
octreotide described in chapter 4 had serial measurement o f PMNE carried 
out. All patients were therefore pre-selected on the basis o f an admission 
APACHE II score o f greater than 5. The mean age o f these patients was 68 
(range 32-88) and gallstones were identified as an aetiological factor in 21 
(57%).
7.4 M ethods
Patients had venous blood withdrawn on days 1,3 and 5 after admission. 
Blood was transported to the laboratory on ice where it was spun in a 
refrigerated centrifuge and plasma immediately withdrawn with a pasteur 
pipette. Care was taken not to include cells at the interface layer which may 
contain neutrophils. The plasma was then frozen at -70°C prior to 
measurement o f PMNE by ELISA. PMNE was measured in one batch after 
slow thawing o f the plasma samples.
Systemic complications which occurred in these patients were defined as in 
chapter 1:
Respiratory insufficiency; arterial P02<8kPa 
Pleural effusion
Renal insufficiency; serum creatinine>180ug/l after fluid resuscitation 
Shock; systolic BP<100mmHg.
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MSOF; combination of any two of the above.
Polym orphonuclear Elastase M easurem ent
PMNE was measured using a commercially available ELISA (Merck ).
The principle o f this assay is as follows;
Antibody fragments (Fab') against human granulocyte elastase are 
covalently bound to horseradish peroxidase to form antibody-peroxidase 
conjugates. In these conjugates, the peroxidase activity is inhibited by the 
high local H2O2 concentrations in the substrate solution. In the presence o f 
PMNE, immune aggregates form which allows peroxidase to catalyse the 
reaction;
H2O2 + phenol + 4-aminophenazone —> quinonimine dye.
The quantity o f quinonimine dye formed is proportional to the degree of 
peroxidase activity and thus to the quantity o f PMNE present in the 
sample.
The assay was adapted for use in an auto analyser in the Department o f 
Biochemistry, Glasgow Royal Infirmary.
Results were expressed in pg/1 and statistical analysis was by the Mann 
Whitney U test.
7.5 Results
7.5.1 Relationship between PM NE levels and cytokine secretion
Highest levels o f PMNE were observed on day 1 after admission. Day 1 
monocyte cytokine production was therefore compared with PMNE levels 
in 11 patients with acute pancreatitis (patients 30-40).
There was a strong positive correlation between IL -ip  secretion on the 
first day after admission and the plasma level o f PMNE (Figure 7.1) 
(r=0.961, P<0.001). However, when the very high result for patient 37 was 
omitted, this was no longer statistically significant. There was no significant
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Figure 7.1: Relationship between IL-1 secretion and PMNE levels on day 1. 
r=0.961, P<0.001)
correlation between the secretion o f TNFa (r=0.061), IL-6 (r=0.282) or 
IL-8 (r=0.288) and PMNE levels on day 1.
7.5.2 Neutrophil activation and systemic complications
O f the 37 patients studied, 15 developed systemic complications o f whom 8 
died as a result o f their illness.
Plasma PMNE levels were significantly higher in those patients with 
systemic complications on each of the days on which it was measured 
(Figure 7.2)(day 1 PMNE complicated median=250pg/l, IQR 143-656, 
uncomplicated median 139, IQR 74.7-254, P<0.05; day 3 complicated 
median=224.1, IQR 139-382, uncomplicated median=86.1, IQR 51.4- 
159.7, P<0.002; day 5 complicated median=178.5, IQR 117. Highest levels 
of PMNE were observed on day 1 o f the hospital admission in all but nine 
of the 37 cases and o f these, seven subsequently developed systemic 
complications.
7.5.3 Use of PMNE as a prognostic iiidicator
For prognostic purposes, a cut-off level o f PMNE on admission to hospital 
of 250pg/l has been suggested42. Using this cut-off, 6 o f the 15 p&tients 
with complications were correctly predicted to have severe disease and 
only 3 o f the patients with an uncomplicated outcome incorrectly assigned 
to the severe group. Five o f the seven patients who died had PMNE levels 
o f more than 300ug/l on admission. The sensitivity,-specificity, positive and 
negative predictive values are given in table 7.1 Lowering the cut-off was 
associated with an improvement in sensitivity but an associated reduction in 
specificity with an overall reduction in accuracy.
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Figure 7.2 Granulocyte elastase in 37 patients with 
acute pancreatitis 
* P<0.05, **P<0.02, ***P<0.002
300pg/l 200pg/l 100p.g/l
Sensitivity% 37.5 56.3 81.3
Specif!city% 85.7 61.9 33.3
Positive predictive value% 66.7 52.9 48.1
Negative predictive value% 64.3 65 70
Correctly predicted% 64.9 59.5 54
Table 7.1: PMNE as prognostic indicator in acute pancreatitis.
These results were compared with peak C-reactive protein levels within 
48h o f admission and prognostic scoring by the Glasgow criteria. CRP 
levels were less accurate than day 1 PMNE levels and had the added 
disadvantage o f requiring 48h before prognostic scoring could be carried 
out. Glasgow criteria, while still requiring 48h to elapse, were associated 
with similar overall accuracy as day 1 PMNE levels, using a 300ug/l cut-off 
(Table 7.2)
Peak CRP>150mg/l Glasgow Score>3
Sensitivity% 68.8 43.8
Specificity% 38.1 76.2
Positive predictive value% 45.8 58.3
Negative predictive value% 61.5 64
Correctly predicted% 51.4 62.2
Table 7.2: CRP and Glasgow prognostic score in acute pancreatitis
7.6 Discussion
The early, high levels o f PMNE in patients with systemic complications 
suggest that granulocyte activation is an early event in these patients. The 
very strong correlation between EL-lp secretion by monocytes and day 1 
PMNE levels was an unexpected finding given the poor association which 
was found between IL-1J3 levels and the development o f systemic 
complications reported in chapter 6. In addition there was a poor 
association between PMNE levels and the secretion o f TNFa, IL-6 and IL-
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8. IL-1 [3 has not been shown to activate neutrophils and, with the small 
number of patients studied, it may be a chance finding. Indeed, much o f the 
association between IL-1 (3 secretion and PMNE levels is due to one very 
high result for patient 37.
The absence o f an association between monocyte production o f 
granulocyte-stimulating cytokines such as TNFa and IL-8 and plasma 
PMNE levels early in the course o f the illness suggests that, if neutrophil 
activation is the source o f PMNE, then systemic mononuclear cell 
activation is not responsible for this. One explanation may be that early 
PMNE is the result o f local, pancreatic neutrophil activation as a result o f 
local inflammation at a stage in the disease when systemic mononuclear cell 
activation has not occurred.
PMNE, measured on the first day o f hospital admission, has been reported 
to accurately discriminate between patients with complicated acute 
pancreatitis and those with mild attacks36,42. Gross and colleagues36 studied 
75 patients with pancreatitis o f all grades o f severity. O f these, 41 were 
graded as "severe” by the authors on the basis o f the development o f two 
or more complications. Patients with one complication or an uncomplicated 
outcome were graded as "mild". A level o f PMNE o f greater than 400pg/l 
was associated with a positive and negative predictive value for severe or 
lethal pancreatitis o f 82% and 81% respectively. This was more accurate 
than multiple factor scoring systems or C-reactive protein (CRP) levels. 
The proportion o f patients defined as having severe pancreatitis was 
unusually high at nearly 55% and the reason for this may lie in the rather 
arbitrary definitions for complicated disease employed in this study.
In a study by Dominguez-Munoz and colleagues42 182 patients had serial 
measurement o f PMNE levels. O f these, 28 were considered to have severe 
pancreatitis on the basis o f the development o f either local or systemic
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complications. Once again the complications which were recorded are 
poorly defined and, for example, severe hypoxia was only recorded as a 
complication if associated with radiological changes. "Pancreatic 
phlegmon" is included in the list o f local complications but is not defined 
and this term has been abandoned35. Remarkable results were reported in 
this study with admission PMNE levels o f more than 300ug/l associated 
with a positive predictive value o f 79.4% and negative predictive value o f 
98.1%. In a third study, Uhl and colleagues37 reported 84% overall 
accuracy for PMNE in predicting necrotising pancreatitis with a cut-off 
level o f 120ug/l within 5 days o f admission which was similar to that 
achieved with CRP. No information on the accuracy in predicting 
complicated pancreatitis was given.
These results were not matched by the present, smaller study which had a 
PPV and NPV of 66.7% and 64.3% respectively. However, as was found 
in the study by Gross, day 1 PMNE levels were marginally more accurate 
than multiple factor scoring or peak CRP levels. The reason for the lesser 
accuracy achieved in the present study may he in the fact that patients had 
already been selected on the basis o f an admission APACHE EL score o f 
greater than 5 and the study population was therefore biased towards a 
more severe attack o f pancreatitis. The definitions o f complications were 
also different from those employed in previous studies although the 
definitions in the present study are closest to those suggested by the 
Atlanta symposium. Even allowing for these factors, day 1 PMNE levels 
provided better discrimination than the 48h Glasgow score or CRP level. 
There was, however, considerable overlap between PMNE levels in those 
with complicated and uncomplicated attacks.
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In conclusion, the results o f this study provide evidence o f early neutrophil 
activation in acute pancreatitis, particularly in those patients who 
subsequently develop systemic complications. No evidence was found o f an 
association between monocyte cytokine production and neutrophil 
activation as measured by plasma PMNE levels.
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Chapter 8
Cytokine secretion, parathyroid hormone and the pathophysiology of 
hypocalcaemia in acute pancreatitis
8.1 Introduction
In chapter 6, the similarities between acute pancreatitis and sepsis have 
been discussed in terms o f the alterations in mononuclear phagocyte 
function which are present in both groups o f patients. Hypocalcaemia was 
thought to be a systemic complication unique to  acute pancreatitis as a 
result o f proteolytic cleavage o f parathyroid hormone or saponification in 
areas o f fat necrosis307. However, it has been demonstrated that similar 
biochemical disturbances are also a feature o f severe sepsis308,309. The 
nature o f the hypocalcaemic stimulus in both sepsis and acute pancreatitis 
remains unknown but o f interest is the finding that bolus injections o f IL- 
1(3 are capable o f causing reductions in serum ionised calcium in an 
experimental model310. In this way, mononuclear phagocyte activation may 
play a role in the development o f hypocalcaemia just as it is proposed to 
play a role in the pathophysiology o f other systemic manifestations o f acute 
pancreatitis.
In patients with sepsis, high levels o f PTH are seen in association with 
hypocalcaemia in non-survivors309 but for more than 15 years, there has 
been debate about the nature o f the parathyroid response to the 
hypocalcaemia seen in acute pancreatitis. Although variable or low levels o f 
parathyroid hormone (PTH) in the presence o f hypocalcaemia have been 
reported by some authors, 307’311'314 others have found high levels o f 
circulating PTH in the presence o f low serum calcium.315,316 
Biologically active PTH is an 84 amino acid polypeptide which, both within 
the parathyroid gland and at peripheral sites, undergoes proteolytic
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modification resulting in the formation o f biologically inactive peptide 
fragments317. All o f the published studies to date on PTH levels in acute 
pancreatitis have utilised radio immunoassays based on antisera recognising 
either unspecified or carboxy-terminal amino acid sequences which detect 
variable proportions o f PTH fragments in addition to the intact peptide318. 
Since accelerated proteolytic degradation o f intact PTH has been 
demonstrated in sera from patients with severe acute pancreatitis319,320 it is 
possible that the conflicting results o f previous studies are the result o f the 
molecular heterogeneity o f circulating PTH in this condition. The 
development o f two-site immunoradiometric assays for PTH allows 
measurement o f intact PTH without interference from PTH fragments318 In 
this study circulating levels o f intact PTH were measured in order to assess 
the true nature o f the parathyroid response in acute pancreatitis. In a 
number o f patients, PTH fragments were also measured in order to assess 
whether proteolytic cleavage o f PTH was involved in the pathophysiology 
o f pancreatitis-associated hypocalcaemia.
Calcium homeostasis was therefore examined in patients with acute 
pancreatitis in order to determine the role o f IL -lp  secretion and 
proteolytic cleavage o f parathyroid hormone (PTH) in the pathophysiology 
o f hypocalcaemia.
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8.2 Patients and methods 
Patients
Forty three patients entered into the randomised, controlled trial o f 
octreotide described in chapter 4 had serial measurement o f PTH, calcium 
and albumin carried out. All patients were therefore pre-selected on the 
basis o f an admission APACHE II score o f greater than 5.
Assays
Venous blood was withdrawn into glass tubes and allowed to clot on ice 
prior to centrifugation at 600g (4°C) for lOmin. Serum was removed and 
frozen immediately at -30°C prior to assay. Serum calcium, albumin and 
intact PTH were measured on the same sample. Calcium and albumin were 
measured on a routine auto analyser. Calcium was adjusted for albumin 
using the formula Ca(adj)=(47-alb)x0.02+Ca (where Ca(adj) = adjusted 
calcium, alb = albumin and Ca = total calcium) 321. Intact PTH was 
measured by immunoradiometric assay (Nichols Institute Diagnostics, San 
Juan Capistrano, USA). This utilised two affinity purified polyclonal 
antibodies to PTH, one specific for the mid-molecule region and C-terminal 
end and the other for the N-terminal portion. The mid-molecule/C-terminal 
antibody was bound to plastic beads and the N-terminal antibody was 
supplied radio labelled with Samples and standards were incubated 
for 24h with antibody-coated beads and ^^I-labelled antibody following 
which the beads were washed to remove unbound antibody then bound 
125i_iabelled antibody quantified by counting for one minute in a gamma 
counter. Results were expressed in pmol/1. The normal range o f intact PTH 
in our laboratory is less than 5pmol/l. After determining calcium and intact 
PTH levels, hypocalcaemic samples were assayed for the presence o f PTH 
mid-molecule/C-terminal fragments using a specific radio immunoassay 
(Nichols Institute Diagnostics, San Juan Capistrano, USA). This is a
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competitive protein binding assay in which samples and standards were first 
incubated with goat anti-hPTH(44-68) followed by ^^I-PT H . Antibody 
bound PTH(44-68) was then precipitated using anti-goat precipitant and 
125j_p t h  quantified in the resulting pellet by counting in a gamma 
counter. The quantity o f PTH(44-68) in the original sample, being inversely 
proportional to the amount o f bound 125i _p t h (44-68) was then calculated 
by reading against a standard curve.
8.3 Results
Patients
O f 43 patients studied, two were excluded, one with primary 
hyperparathyroidism and one with chronic renal failure, both conditions 
which are normally associated with high levels o f circulating intact PTH. 
The 41 remaining patients consisted o f 19 males and 22 females, mean age 
70 (range 35-92). The aetiology o f acute pancreatitis was gallstones in 23, 
alcohol in 7 and undetermined in 11. There were 16 patients who 
developed complications o f whom 6 died (Table 8.1).
Hypocalcaemia
Calcium levels < 2.2mmol/l were detected in 62% of all samples. After 
correction for serum albumin, only 19% o f all samples had calcium levels < 
2.2mmol/l, consisting o f 29 samples taken from 15 patients. 50% of 
patients who developed complications and 28% of the uncomplicated 
group developed hypocalcaemia during the 5 days o f the study (P>0.1, chi 
square test). Two patients with fatal acute pancreatitis received intravenous 
calcium gluconate as treatment for hypocalcaemia although neither 
exhibited tetany. No significant difference in serum adjusted calcium levels
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Patient No Complication Death
11 MSOF Day 14
13 CVA, RF Day 10
18 MSOF Day 4
19 RF, Infected fluid collection
22 MSOF Day 1
24 ARF
27 ARF, Ml
31 RF
33 MSOF
35 RF
36 ARF, RF, Fluid collection
37 ARF. Infected pancreatic necrosis
39 ARF, RF
40 RF Day 21
42 CVA, RF Day 4
43 RF, Fluid collection
MSOF =  multiple systems organ failure, RF =  respiratory failure (defined as p02<8kPa 
for >24h requiring high flow oxygen therapy or assisted ventilation), ARF =  acute renal 
failure (defined as serum creatinine >200mmol/l for >24h), Ml =  myocardial infarction, 
CVA =  cerebrovascular accident.
Table 8.1: Complications in patients entered into study
was seen between the uncomplicated and complicated groups on any o f the 
first five days after admission (Figure 8.1).
Parathyroid hormone
Intact PTH levels were significantly higher in patients with a complicated 
outcome on four o f the five days studied (Figure 8.2). There was, 
however, no significant correlation between adjusted calcium levels and 
intact PTH on individual days. Peak PTH levels o f more than 6pmol/l were 
observed more frequently in the complicated than the uncomplicated group 
(14 o f 16 patients, complicated group; 6 o f 25 patients, uncomplicated 
group (P<0.001, Chi-square test). In the complicated group, individual and 
mean PTH levels peaked around the second day o f admission. Intact PTH 
levels in the patients who developed hypocalcaemia were variable but a rise 
in PTH (>6pmol/l) was observed more frequently in the complicated group 
(7 o f 8, complicated group; 2 o f 7, uncomplicated group; P=0.035, Fisher's 
exact test).
PTH  fragments
Serum samples from hypocalcaemic patients were analysed for PTH mid- 
molecule/C-terminal fragments. Low levels o f PTH fragments were found 
associated with low intact PTH levels. Intact PTH levels correlated with 
the levels of PTH fragments (Figure 8.3, rs = 0.743, P<0.002, Spearman 
rank correlation ).
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Figure 8.1: Calcium levels in patients with acute pancreatitis
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Figure 8.2: PTH levels in patients with acute pancreatitis
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Figure 8.3: PTH and PTH Fragments in hypocalcaemic patients
IL-ip secretion and hypocalcaemia
In 14 patients (patients 30-43), monocyte EL-1J3 production was measured 
as described in chapter 6. Peak levels o f monocyte IL -ip  production were 
compared with plasma levels o f PTH and calcium. There was no 
correlation between peak PTH levels and IL -lp  secretion by monocytes 
(r=0.007). There was, however a significant correlation between the lowest 
serum adjusted calcium level and peak IL -ip  secretion (r=0.698, P<0.01) 
although this result is a consequence o f the high IL -ip  result for patient 37. 
If  this result is omitted, no significant correlation was demonstrated.
8.4 Discussion
The majority o f cases o f hypocalcaemia observed in acute pancreatitis are 
the result o f hypoalbuminaemia, with a reduction in total but not ionised 
calcium322. However, despite correction for albumin, hypocalcaemia may 
still occur314,315,322 a finding which has been confirmed by direct 
measurement o f ionised calcium316,323’324. The failure o f homeostatic 
mechanisms to maintain normal levels o f serum ionised calcium has led to 
studies investigating the nature o f the parathyroid response in acute 
pancreatitis but reports in the literature are conflicting. Condon et al307 
studied PTH levels in 12 patients with hypocalcaemia and found 
undetectable levels o f PTH in plasma from 8 o f these although no 
correction for serum albumin was made and therefore the true incidence o f 
hypocalcaemia may have been lower. Similarly, in 9 patients with 
hypocalcaemia, Robertson et al311 found normal levels o f PTH with calcium 
levels returning to normal following administration o f bovine PTH. Weir et 
al312 reported low ionised calcium in 8 o f 11 patients with acute 
pancreatitis. PTH levels in these patients were variable, with high levels in 
5 o f the 8 patients and undetectable levels in the remaining three. 
McMahon et al313 found lower levels o f PTH in patients with severe
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pancreatitis when compared to those with mild disease, despite lower levels 
of serum calcium in the severe group. In contrast, Imrie et al325 studied 
more than 90 patients with serial blood sampling and reported high levels 
of PTH in both normocalcaemic and hypocalcaemic subjects. The highest 
levels o f PTH were observed on the day o f admission which fell over the 
next two days in association with a rise in serum calcium. Similar findings 
were reported in a series o f 6 patients with acute pancreatitis admitted to 
an intensive care unit316 although in this study PTH levels peaked later, 
around the second day. McMahon et al314, in a second study o f 18 patients 
of whom 6 developed hypocalcaemia, reported low levels o f plasma PTH 
despite urinary calcium and phosphate levels suggestive o f a renal response 
to PTH.
In all o f these studies, assays for PTH were based on polyclonal antisera to 
PTH which, in addition to the intact molecule, would detect varying 
quantities o f PTH fragments depending on the concentration and nature o f 
fragments present and the affinity o f the antisera. In the present study, an 
assay was used which was specific for the intact PTH molecule and did not 
detect PTH fragments even in high concentration. The present results 
indicate that high levels o f circulating intact PTH are present in patients 
with acute pancreatitis, in the presence o f both normal and low serum 
calcium. However, the correlation observed between PTH fragments and 
intact PTH in the present study suggests that the use o f PTH fragment 
assays is not sufficient to explain the discrepancies between the present 
findings and those o f some previous reports.
A rise in PTH was observed more frequently in those patients who 
developed complications, with peak levels occurring towards the second 
day after admission. This is in contrast to the findings o f Imrie et al315 
where the highest levels were seen in the first sample taken after admission. 
The reason for this discrepancy may be the result o f differences in timing o f
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blood samples between the two studies or in handling o f samples prior to 
assay.
In uncomplicated acute pancreatitis, intact PTH levels seldom rose beyond 
the normal range, even in the presence o f hypocalcaemia. There are several 
possible explanations which may explain this finding. Firstly, the calculated 
ionised calcium levels may not reflect true ionised calcium levels in this 
group of patients. All 6 patients with hypocalcaemia and low PTH levels 
had a serum albumin o f less than 32g/dl and the results may reflect 
inaccuracies in correcting total calcium for such low albumin levels. 
Although close correlation between corrected and ionised calcium in acute 
pancreatitis has been reported, 324 Croton et al found no correlation during 
the first 36h o f illness323. Nomograms for the correction o f calcium for 
albumin levels have been shown to be unreliable in patients with sepsis310 
and it is possible that a similar situation may exist in acute pancreatitis, 
perhaps as a result o f a varying affinity o f calcium for albumin in 
pathological states. Secondly, it may be the result o f proteolytic 
degradation o f intact PTH in-vivo or in-vitro, although increased levels o f 
PTH fragments were not observed in these samples as might be expected if 
this were the case.
Hypocalcaemia is not unique to acute pancreatitis but occurs in other 
critically ill surgical patients. 309 Such patients have been reported to exhibit 
changes in serum PTH similar to those observed in this study, with a rise in 
PTH accompanied by low ionised calcium occurring in non-survivors309. 
Similarly, patients who survived had normal levels o f PTH despite 
hypocalcaemia suggesting that both in critical surgical illness and acute 
pancreatitis, the magnitude o f the parathyroid response, rather than the 
level o f serum calcium, correlates with outcome. Whether a rise in PTH 
may be detrimental under such circumstances by allowing further 
intracellular accumulation o f calcium, remains a matter o f speculation.
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One possible explanation for the hypocalcaemia which occurs in both sepsis 
and in patients with acute pancreatitis is the action o f IL -ip  which is 
capable o f inducing experimental hypocalcaemia. In the present study, one 
patient with a serum calcium level o f less than 2mmol/l had greatly 
increased monocyte IL -lp  secretion but in the remainder o f the patients, all 
o f whom had serum calcium levels o f greater than 2mmol/l, there was no 
correlation between IL -lp  secretion and serum calcium. It remains possible 
that IL -ip  or other cytokines play a key role in the development o f 
hypocalcaemia but further study is obviously required.
Recent work by Ward and colleagues326 has suggested a role for calcium in 
the initial acinar cell insult during the development o f acute pancreatitis but 
it is unlikely that this mechanism explains the development o f 
hypocalcaemia during the course o f the illness.
In conclusion, this study has shown that raised levels o f intact PTH occur 
in patients with complicated or fatal acute pancreatitis. Normal levels o f 
PTH are present in the majority o f patients with uncomplicated acute 
pancreatitis, even in the presence o f hypocalcaemia. No evidence o f 
proteolytic degradation o f PTH was found and, in fact, higher levels o f 
PTH were more common in patients who developed complications o f acute 
pancreatitis. No convincing evidence was demonstrated o f a relationship 
between monocyte IL -lp  secretion and hypocalcaemia. The nature o f the 
hypocalcaemic stimulus in acute pancreatitis remains unclear.
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Chapter 9.
General discussion, conclusions and suggestions for further work
9.1 Conclusions
The principal aims o f this thesis were to investigate the role o f 
mononuclear phagocyte activation in acute pancreatitis and the possible 
effect o f octreotide on outcome, by virtue o f its suggested effect on 
reticuloendothelial function. The main findings were as follows;
1. Monocyte activation occurs in acute pancreatitis, and there was evidence 
to  support the hypothesis that they are involved in the pathophysiology o f 
the development o f systemic complications..
2. Octreotide has little or no effect on outcome in acute pancreatitis and 
did not demonstrably reduce the degree o f mononuclear phagocyte 
activation.
9.2 Discussion
In acute pancreatitis, improvements in supportive care and resuscitation 
have led to a reduction in the mortality associated with the early systemic 
illness. Patients continue to suffer significant morbidity and early deaths do 
still occur. In the clinical trial described in chapter 4, there were 5 early 
deaths due to systemic organ complications which was, in fact, the biggest 
single cause o f death. Much attention has been focused on the potential 
role o f surgery in the later stages o f pancreatitis, particularly with regard to 
the treatment o f infected pancreatic necrosis. In the present study, 
however, there was only one death directly attributable to this 
complication. These results would suggest that much could still be 
achieved by focusing any new treatment on the early systemic illness.
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Previous attempts at treatment based on antiprotease therapy or peritoneal 
lavage have proved unsuccessful and the results presented in chapter 6 o f 
this thesis provide evidence that any future treatment should be directed 
towards the prevention o f mononuclear phagocyte activation or the 
antagonism of mononuclear phagocyte products.
The main stimulus to mononuclear phagocyte activation is bacterial 
endotoxin and as discussed in chapter 2, there is some evidence that 
endotoxaemia occurs in patients with acute pancreatitis.
The effects o f TNFa and IL-8 are mainly mediated by neutrophils and in 
chapter 7, raised levels o f neutrophil elastase confirmed the presence o f 
neutrophil activation early in the course o f acute pancreatitis. Previous 
authors have demonstrated neutrophil activation by similar methods. The 
present study was, however, unable to demonstrate a link between 
monocyte cytokine secretion and neutrophil activation, as measured by 
PMNE levels.
There is therefore evidence in support o f the individual components the 
proposed hypothesis, with endotoxaemia, mononuclear phagocyte 
activation and neutrophil activation each having been demonstrated in 
patients with acute pancreatitis.
9.3 Further study required
There is now evidence that endotoxaemia, monocyte/macrophage 
activation, cytokines and neutrophil activation are involved in the 
development o f the systemic effects o f acute pancreatitis. However, all 
studies have been restricted to the study o f isolated components o f the 
complex cascade o f events. In this thesis, evidence has been presented that
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monocyte activation occurs in acute pancreatitis but no relationship 
between this and neutrophil activation was demonstrated. Endotoxaemia 
was not assessed and it is not known whether this would have shown a 
correlation with monocyte activation. Before the hypothesis as outlined 
above can be generally accepted, there is a need for a study which seeks to 
determine whether the separate components o f this proposed mechanism 
can be demonstrated simultaneously. Measurement o f anti-endotoxin core 
antibody together with mononuclear phagocyte activation measured by 
both in-vitro cytokine secretion and cell surface activation markers, could 
be combined with direct and indirect measurement o f neutrophil function. 
In addition, further research is needed in order to explain the reasons for 
differing reactions to endotoxin between individuals. As outlined above, 
this may have a genetic basis or it may be a consequence o f the degree o f 
endotoxaemia present. Assessment o f TNFa allelic polymorphism 
associated with measurement o f monocyte TNFa secretion in patients with 
acute pancreatitis may help to explain this further.
Indirect measurement o f gut perfusion can be easily carried out using 
gastric tonometry and such a study would help to explain the mechanism 
behind the appearance o f endotoxin in acute pancreatitis. Other studies o f 
intestinal barrier function could be combined with this.
Little is known o f the role o f T-cells in the immune disturbances seen in 
acute pancreatitis. Curley et al provided some evidence o f diminished T- 
helper cell numbers327 but further study is required. In particular, the role o f 
monocyte regulatory cytokines such as IL-10 and IL-4 awaits investigation. 
EL-4 has been shown to suppress monocyte TNFa, IL-1J3 and EL-8 
secretion328'331 and more recently, IL-10 has been identified as a factor 
which inhibits monocyte IL-1(3 and TNFa secretion332. IL-10 is also 
produced by LPS-stimulated monocytes and may therefore have a role in 
autoregulation o f monocyte function332. IL-4 is produced by T-helper cells
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and the reduction in T-helper cells seen in some patients with acute 
pancreatitis may therefore be important in the determination o f monocyte 
responses to endotoxin.
9.4 Future treatm ent options
Confirmation o f the proposed hypothesis by such studies could lead to new 
therapeutic strategies in acute pancreatitis.
Prevention o f endotoxaemia
Initial resuscitation o f patients with acute pancreatitis could be improved in 
order to prevent the splanchnic hypoperfusion associated with the 
development o f endotoxaemia. Additional agents such as dopamine may 
selectively improve splanchnic perfusion and there are reports that 
dopamine may improve the outcome from experimental pancreatitis. 
Improvement o f gut barrier function by enteral nutrition may also be 
beneficial. Selective gut decontamination was suggested by Foulis and 
colleagues as long ago as 1982 194 and there has recently been a study o f 
selective gut decontamination in patients with severe pancreatitis carried 
out in the Netherlands333, the results o f which are promising. Prevention o f 
endotoxaemia by enhancement o f hepatic RES activity is another option 
but, as was reported in chapter 4 o f the present thesis, it is unlikely that 
octreotide will prove useful in this regard.
Anti-endotoxin antibody
Human polyclonal antibodies to the polysaccharide side chain and core 
regions o f the endotoxin molecule was used in patients with gram negative 
sepsis by Ziegler et al334with a reported reduction in mortality from 39 to 
22%. However, the use o f pooled antisera carries with it the risk o f 
transmission o f blood-borne viral infection and more recently, monoclonal
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antibody to the lipid-A moiety on the endotoxin molecule has become 
available. In a study o f over 500 patients, Ziegler et al335 reported no 
overall effect o f anti-endotoxin although there was a reduction in mortality 
in the sub-set o f patients with culture-positive gram-negative septicaemia. 
Two subsequent studies with a different monoclonal antibody has 
conflicting results in patients with gram negative sepsis336,337. Despite these 
results, anti-endotoxin antibody may be worth considering as a therapeutic 
trial in acute pancreatitis.
Cytokine Inhibitors
Antibodies to TNFa are under investigation in patients with sepsis. The 
association between high monocyte TNFa production and the systemic 
manifestations o f acute pancreatitis provides a rationale for similar clinical 
trials in acute pancreatitis. Antibody to IL-8 prevents experimental lung 
injury294 and such antibodies may in the future be developed for clinical 
trials.
Prevention o f neutrophil activation
Clinical trials are currently underway with a platelet activating factor 
antagonist inhibitor. PAF is a cytokine released from endothelial cells, 
activated leukocytes and platelets which has potent effects on neutrophil 
activation and which has been implicated in the pathophysiology o f acute 
pancreatitis338,339. Its place in the complex cascade o f events has yet to be 
elucidated but with the development o f a non-toxic peptide inhibitor, 
studies in experimental pancreatitis have given encouraging results.
A large, multi-centre clinical trial with a PAF antagonist in patients with 
acute pancreatitis is currently underway.
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Appendix 1
Abbreviations used in thesis
ACTH: adrenocorticotrophic hormone 
AIMV: adoptive immunotherapy medium five 
AFC: acute fluid collection
APACHE: acute physiology and chronic health evaluation
APS: acute physiology score
ARDS: adult respiratory distress syndrome
ARF: acute renal failure
BSA: bovine serum albumin
CCE: countercurrent centrifugal elutriation
CDED: choline deficient ethionine supplemented diet
CDL: closed duodenal loop
CH: ceruelin hyperstimulation
CRP: C-reactive protein
CT: computerised tomography
CVA: cerebrovascular accident
DDX: doctors and dentists exemption (certificate)
EDTA: ethyl-diamino tetra-acetic acid
ELISA: enzyme-linked immunosorbent assay
ERCP: endoscopic retrograde cholangiopancreatography
FACS: fluorescence-activated cell sorting
IL -la : interleukin 1 alpha
IL-1 p. interleukin 1 beta
IL-6: interleukin 6
IL-8: interleukin 8
IPN: infected pancreatic necrosis
IQR: interquartile range
ITU: intensive therapy unit
LPS: lipopolysacharride
MACS: magnetic cell separation system
MSOF: multiple systems organ failure
N/A: not assessed
NPV: negative predictive value
NS: not significant
PAF: platelet activating factor
PBMC: peripheral blood mononuclear cells
PBS: phosphate buffered saline
PDL: pancreatic duct ligation
PE: pleural effusion
PLAP: phospholipase A2activation peptide 
PMNE: polymorphonuclear elastase 
PN: pancreatic necrosis 
PPV: positive predictive value 
PTH: parathyroid hormone 
RES: reticuloendothelial system 
RF: respiratory failure 
RIA: radioimmunoassay
185
RIB: retrograde injection o f bile 
TAP: trypsinogen activation peptide 
TNFa: tumour necrosis factor alpha
Appendix 2
Publications and presentations
At the present time, two papers have been published from work presented 
in this thesis.
McKay CJ, Imrie CW, Baxter JN; Somatostatin and somatostatin 
analogues - are they indicated in the management o f acute pancreatitis? Gut 
1993 ;34; 1622-1626.
McKay C, Beastall GH, Imrie CW, Baxter JN. Circulating intact 
parathyroid hormone levels in acute pancreatitis. Br J Surg 1994;81:357-
60.
Two further papers have been accepted for publication
McKay C, Gallagher G, Brookes B, Imrie CW, Baxter JN. Monocyte 
activation is associated with the systemic complications o f acute 
pancreatitis. Br J Surg, 1996 (in press).
McKay C, Baxter JN, Imrie CW. Mononuclear phagocyte function in acute 
pancreatitis. Scand J Gastroenterol 1996 (in press).
The work described in this thesis has been widely presented at meetings in 
the UK, Europe and the USA, including the Surgical Research Society, 
Pancreatic society o f Great Britain and Ireland, European Pancreatic Club, 
International Hepatopancreaticobiliary Association and the American 
Gastroenterology Association.
Abstracts from these presentations have been published as follows;
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activation in acute pancreatitis is related to the degree o f systemic illness. 
Digestion 1992;52:104-105.
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production o f tumour necrosis factor in acute pancreatitis is related to 
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McKay C, Gallagher G, Imrie CW, Baxter JN. Monocyte production o f 
tumour necrosis factor in acute pancreatitis is related to outcome. B r J 
Surg 1993;80:649
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McKay C, Baxter JN, Imrie CW. A randomised, controlled trial o f 
octreotide in moderate to severe acute pancreatitis. Digestion 1994;55:316
McKay C, Baxter JN, Imrie CW. Systemic complications in acute 
pancreatitis are associated with increased cytokine release by monocytes. 
Digestion 1994;55:316-7
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McKay C, Imrie CW, Baxter JN. Systemic complications in acute 
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